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1 
ACTIVATABLE PROBES AND METHODS 
FOR IN VIVO GENE DETECTION 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
2 
bright states allows for differentiation between bound and 
unbound probes and transduces target recognition into a 
fluorescence signal. 
Linear fluorescent probes, as are used in fluorescence 
in-situ hybridization (FISH), are "bright" in both the bound 
and unbound state. To detect positive signal after hybrid-
ization, unbound probe must be removed by washing, which 
prevents the application of this method to gene detection in 
living cells. In theory, molecular beacons do not require a 
This application is a continuation-in-part of U.S. Utility 
patent application Ser. No. 10/179, 730 filed on Jun. 25, 
2002, now U.S. Pat. No. 7,081,336 which claims the priority 
benefit of U.S. Provisional Patent Application Ser. No. 
60/300,672 filed Jun. 25, 2001 and U.S. Provisional Patent 
Application Ser. No. 60/303,258 filed Jul. 3, 2001, and 
further claims the priority benefit of U.S. Provisional Patent 
Application Ser. No. 60/538,381 filed Jan. 21, 2004, and 
U.S. Provisional Patent Application Ser. No. 60/538,382 
filed Jan. 21, 2004, the entire contents of each application is 
hereby incorporated by reference in their entireties 
10 washing step and so should be directly usable in living cells. 
However, interaction between molecular beacons and cer-
tain intracellular factors can cause fluorescence in the 
absence of target hybridization and lead to false-positive 
signals. Using conventional molecular-beacon-based meth-
15 ods, the fluorescent signal that results from target hybrid-
ization carmot be distinguished from any other event that 
spatially separates reporter from quencher, such as probe 
degradation by intracellular nucleases or interaction with 
STATEMENT REGARDING FEDERAL 
SUPPORT OR DEVELOPMENT 20 
DNA binding proteins that unwind the hairpin stem structure 
Two linear oligonucleotide probes labeled respectively 
with donor and acceptor fluorophores have been used in 
FRET-based studies of DNA hybridization, DNA secondary 
structure and RNA synthesis, however, the sensitivity of 
intracellular gene detection using such probes suffers from 
This work was supported in part by Grant No. BSE-
0222211 awarded by the National Science Foundation. 
Accordingly, the U.S. government may have certain rights in 
the claimed subject matter. 25 strong background signal due to unbound probes and cell 
autofluorescence. 
BACKGROUND 
1. Technical Field 
The unique target recognition and signal transduction 
capabilities of molecular beacons have led to their applica-
tion in many biochemical and biological assays including 
This application relates generally to the detection of target 
polynucleotides, such as mRNA. More specifically, the 
present disclosure relates to a dual molecular beacons 
approach that uses energy transfer. 
2. Related Art 
30 quantitative PCR, protein-DNA interactions, multiplex 
genetic analysis, and the detection of mRNA in living cells. 
However, false-positive signals due to protein-beacon inter-
action and nuclease-induced beacon degradation signifi-
cantly limit the sensitivity of the in vivo applications. The 
35 thermodynamic and kinetic properties of molecular beacons 
are dependent on its structure and sequence in complex 
ways. Moreover, the signal-to-background ratio in target 
detection is dependent not only on design (length and 
sequence of the stem and probe) but also on the quality of 
The ability to monitor and quantify the level of gene 
expression in living cells in real time can provide important 
information concerning the production, temporal and spatial 
processing, localization, and transport of specific mRNA in 
different conditions. This new type of information could 
potentially revolutionize biological studies and may also 
have applications in medical diagnostics and therapeutics. 
Technologies currently available for analysis and quantifi-
cation of gene expression such as real-time PCR, Northern 
blotting, expressed sequence tag (EST), serial analysis of 
gene expression (SAGE) and DNA microarrays are powerful 45 
tools for in vitro studies; however, they are not capable of 
quantifying gene expression in living cells. There is a clear 
need to develop molecular probes that can recognize target 
mRNA in living cells with high specificity and instanta-
neously convert such recognition into a measurable signal 50 
with a high signal-to-background ratio. 
40 oligonucleotide synthesis and purification and the assay 
conditions employed. 
Molecular beacons are a class of fluorescence-quenched 
nucleic acid probes that can be used in a quantitative 
fashion; these probes fluoresce upon target recognition (i.e., 
hybridization) with potential signal enhancement of >200 55 
under ideal conditions. Structurally, they are dual-labeled 
oligonucleotides with a reporter fluorophore at one end and 
a dark quencher at the opposite end. They are designed to 
have a target-specific probe sequence positioned centrally 
between two short self-complementary segments which, in 60 
the absence of target, anneal to form a stem-loop hairpin 
structure that brings the fluorophore in close proximity with 
the quencher. In this configuration the molecular beacon is 
in the "dark" state. The hairpin opens upon hybridization 
with a complementary target, physically separating the fluo- 65 
rophore and quencher. In this configuration the molecular 
beacon is in the "bright" state. Transition between dark and 
SUMMARY 
The present disclosure provides compositions and meth-
ods for the detection of a target polynucleotide. One aspect, 
among others, provides a probe set comprising a donor 
polymer comprising a first polynucleotide binding domain 
complementary to a first region of a target polynucleotide. 
The polynucleotide binding domain is flanked by first and 
second stem regions which hybridize in the absence of the 
target polynucleotide to form a stem-loop structure. In some 
aspects, the stem regions or a portion of at least one stem 
region is also a portion of the polynucleotide binding 
domain. The donor polymer also comprises at least one 
quantum dot. Typically, at least one end of the donor 
polymer comprises at least one quantum dot. In some 
aspects, the donor polymer comprises one quantum dot at 
one end and another moiety (including but not limited to, 
metals, biomolecules, organic and inorganic moieties) on the 
other end. 
The probe set further comprises an acceptor polymer 
comprising a second polynucleotide binding domain 
complementary to a second region of the target polynucle-
otide flanked by first and second stem regions which hybrid-
ize in the absence of the target polynucleotide to form a 
stem-loop structure. As noted above, the stem regions or a 
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portion of the stem regions can be a portion of the poly-
nucleotide binding domain. The acceptor polymer also com-
prises at least one reporter on at least one end of the acceptor 
polymer. In some aspects, the acceptor polymer has at least 
one reporter on both ends of the acceptor polymer. Energy 
transfer occurs between the donor and the at least one 
reporter when the donor polymer and the acceptor polymer 
hybridize to the target polynucleotide and the quantum dot 
is exposed to an exciting amount of energy. Representative 
donor and acceptor polymers include, but are not limited to 10 
molecular beacons. 
Thus, another embodiment provides molecular beacon 
probes comprising fluorescent or luminescent energy trans-
4 
FIGS. 4a-4c show signal-to-noise ratios for dual FRET 
molecular beacons with (4a) a Fam-Cy3 FRET pair, (4b) a 
Fam-ROX FRET pair and (4c) a Fam-Texas Red FRET pair. 
The error bars display the minimum and maximum ratios 
calculated for dual FRET molecular beacons separated by 3, 
4, 5, or 6 bases. 
FIG. 5 shows emission spectra for dual FRET molecular 
beacons with a Fam-Texas Red FRET pair. The samples 
described in the figure were excited at a wavelength of 475 
nm. 
FIG. 6 shows normalized peak emission of the acceptor 
due to FRET for molecular beacon pairs with a Fam donor 
and a Cy3, ROX, or Texas Red acceptor. All the intensities 
were normalized relative to the peak intensity of the Fam-fer moieties. The molecular beacons contain polynucleotide 
binding domains that enable the molecular beacons to 
hybridize sufficiently near each other on a target polynucle-
otide, e.g. mRNA, for energy transfer to occur and a 
detectable signal to be generated. 
15 labeled donor beacon bound to target. 
Other aspects provide probes comprising at least one 
protein transduction domain (PTD), at least one targeting 
signal, fragments thereof, or combinations thereof, operably 
linked to the probe. PTDs and targeting signals enable the 
probes to be non-invasively delivered to specific intracellu-
FIG. 7 shows the effect of spacing between donor and 
acceptor beacons on the fluorescence emission of acceptor 
dye for dual FRET molecular beacons with a Fam donor and 
a Texas Red acceptor. Four different targets were tested, 
20 
separating the donor and acceptor beacons by 3, 4, 5, or 6 
bases. 
lar regions. 
FIGS. Sa and Sb show time resolved emission spectra 
obtained in a two-probe detection assay using Terbium 
25 chelate as a donor and (Sa) Cy3 as an acceptor and (Sb) ROX 
as an acceptor. All samples were excited at a wavelength of 
325 nm. 
Still another aspect provides methods for using the dis-
closed probes to detect in vivo gene expression. In some 
aspects, the expression of more than one gene can be 
detected in vivo. Generally, the disclosed probes are deliv-
ered to at least one living cell, and the quantum dot is 
exposed to an exciting amount of energy. The presence of a 30 
target polynucleotide is correlated with a detectable signal 
produced by the reporter in response to energy transfer from 
the quantum dot donor. The amount of detectable signal can 
also be used to quantitate the levels of target nucleotide in 
the cell. 35 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 9 shows time resolved emission spectra generated by 
a two-probe detection assay utilizing a Europium-labeled 
oligonucleotide as a donor probe and a Cy5-labeled oligo-
nucleotide as an acceptor probe. 
FIGS. lOa and lOb show one-photon (lOa) and two-
photon (lOb) excitation spectra of 6-Fam labeled and Cy3 
labeled oligonucleotides. 
FIGS. lla and llb shows alternative molecular beacon 
designs. FIG. lla shows Conventional molecular beacons 
have stem sequences that are independent of the target 
sequence. FIG. llb shows shared-stem molecular beacons 
are designed such that one arm of the stem participates in The patent or application file contains at least one drawing 
executed in color. Copies of this patent or patent application 
publication with color drawing(s) will be provided by the 
Office upon request and payment of the necessary fee. 
40 both hairpin formation and target hybridization. 
FIG. 1 shows hybridization of the donor and acceptor 
molecular beacons to adjacent regions on the same mRNA 45 
target results in FRET. By detecting FRET, fluorescence 
signals due to probe/target binding can be distinguished 
from that due to beacon degradation and non-specific inter-
actions. In the figure, letters Q, D and A represent respec-
tively quencher, donor dye and acceptor dye molecules. 50 
FIG. 2 shows a schematic of the assay system with 4-base 
spacing between donor and acceptor molecular beacons 
when hybridized to the synthetic target. In this example both 
beacons have a probe length of 19 bases and a stem length 
of 5 bases. The underscores indicate the 38-base sequence of 55 
the target complementary to the beacons. Note that for each 
beacon one arm of the stem is part of the probe sequence so 
that the movement of the dye molecules is restricted after 
hybridization. 
FIG. 3 shows typical emission spectra of dual FRET 60 
molecular beacons. Three signal-to-background ratios are 
defined: S:BdA-fB represents the enhancement in fluorescence 
of a conventional molecular beacon in the presence of target. 
S:BaMB indicates the increase in fluorescence resulting from 
the sensitized emission of the acceptor. S:Ndeg is the ratio of 65 
the signal from sensitized emission of the acceptor to the 
false-positive signal. 
FIGS. 12a and 12b show examples of the design con-
straint of shared-stem molecular beacons with certain stem/ 
probe combinations. FIG. 12a shows the design of a molecu-
lar beacon with a probe length of 19 bases and a stem length 
of 6 bases inadvertently resulted in additional bases partici-
pating in stem formation (circles). FIG. 12a shows the 
design of a molecular beacon with a probe length of 18 bases 
and a stem length of 4 bases inadvertently resulted in an 
additional base participating in target hybridization (circle). 
FIG. 13 shows a comparison of the milting temperature of 
shared-stem and conventional molecular beacons as deter-
mined by the initial concentrations of probe and target. By 
fitting the data with a straight line, changes in enthalpy 
(slope of the fitted line) and entropy (y-intercept) charac-
terizing the phase transition between bound-to-target and 
stem-loop conformations of a molecular beacon were 
obtained. 
FIG. 14 shows determination of the changes in enthalpy 
(slope of the fitted line) and entropy (y-intercept) charac-
terizing the phase transition between bound-to-target and 
stem-loop conformations for conventional molecular bea-
cons. Similar trend was found for shared-stem molecular 
beacons. 
FIGS. 15a and 15b show determination of the changes in 
enthalpy (slope of the fitted line) and entropy (y-intercept) 
characterizing the phase transition between bound-to-target 
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and stem-loop conformations for FIG. 15a shared-stem and 
FIG. 15b conventional molecular beacons interacting with 
wild-type and mutant targets. 
FIG. 16 shows a comparison of melting temperatures as 
a function of stem length for conventional and hared-stem 
molecular beacons in the presence of wild-type target. 
FIGS. 17a and 17b show melting behavior of conven-
tional and shared-stem molecular beacons with a 19-base 
probe and a 5-base stem. FIG. 17a shows melting curves for 
conventional and shared-stem molecular beacons in the 
presence of wild-type (solid line) and mutant (dashed line) 
target. FIG. 17b shows the difference in the fraction of 
conventional or shared-stem molecular beacons bound to 
wild-type and mutant targets. 
FIG. 18 shows the difference in the fraction of beacons 
bound to wild-type and mutant targets for shared-stem 
molecular beacons with stem lengths of 4, 5, and 6 bases. 
The same trend is true for conventional molecular beacons. 
FIGS. 19a and 19b show a comparison between conven-
tional and shared-stem molecular beacons on FIG. l9a the 
on-rate of hybridization with target and FIG. l9b the disso-
ciation constant without target (i.e., the transition between 
stem-loop hairpin and random-coiled beacons) for molecu-
6 
DETAILED DESCRIPTION 
The present disclosure may be understood more readily 
by reference to the following detailed description of the 
multiple embodiments of the disclosure and the Examples 
included therein. Before the present probes, probe sets, 
compositions, and methods are disclosed and described, it is 
to be understood that this disclosure is not limited to any 
specific probes, polynucleotide probes, nucleic acid probes, 
10 specific polynucleotide targets, specific nucleic acid targets, 
specific cell types, specific conditions, or specific methods, 
etc., as such may, of course, vary, and the numerous modi-
fications and variations therein will be apparent to those 
skilled in the art. It is also to be understood that the 
15 terminology used herein is for the purpose of describing 
particular embodiments only and is not intended to be 
limiting. As used in the specification and in the claims, "a" 
or "an" can mean one or more, depending upon the context 
in which it is used. Thus, for example, reference to "a 
20 nucleic acid probe" can mean that one or more than one 
nucleic acid probe can be utilized. 
Definitions 
lar beacons with a 19-base probe length and various stem 25 
lengths. 
In describing and claiming the disclosed subject matter, 
the following terminology will be used in accordance with 
the definitions set forth below, unless indicated otherwise. 
FIGS. 20a and 20b show an exemplary embodiment of the 
disclosed probes and the excitation and emission spectra of 
an exemplary quantum dot and reporter. 
FIG. 21 shows an exemplary embodiment of a split 30 
protein probe. 
FIGS. 22A-C are line graphs showing results of solution 
studies of probe-target hybridization of exemplary dual 
FRET molecular beacons. (a) Fluorescence emission spectra 
of K-ras targeting molecular beacons under Cy3 excitation 35 
(545 nm). (b) Emission spectra for survivin-targeting 
molecular beacons. ( c) Emission spectra for 'random 
sequence' molecular beacons (RBs) with respectively 
complementary targets (blue curve), survivin targets (red 
curve), K-ras targets (green curve) and no target (light blue 40 
curve), indicating very high hybridization specificity. 
FIGS. 23A-H are fluorescence micrographs showing the 
detection of K-ras mRNA expression in normally-growing 
and stimulated HDF cells using single donor molecular 
beacons only (a-d), or dual FRET molecular beacons (e-h). 45 
"Localization Signal", "Localization Sequence", "Local-
ization Domain", "Targeting Signal", "Targeting Sequence" 
or "Targeting Domain" are used interchangeably and refer to 
a signal that directs a molecule to a specific cell, tissue, 
organelle, or intracellular region. The signal can be poly-
nucleotide, polypeptide, or carbohydrate moiety or can be an 
organic or inorganic compound sufficient to direct an 
attached molecule to a desired location. Exemplary 
organelle localization signals include nuclear localization 
signals known in the art and other organelle localization 
signals known in the art and described in Emanuelson et al., 
Predicting Subcellular Localization of Proteins Based on 
Their N-terminal Amino Acid Sequence. Journal of Molecu-
lar Biology. 300(4):1005-16, 2000 Jul. 21, and in Cline and 
Henry, Import and Routing of Nucleus-encoded Chloroplast 
Proteins. Annual Review of Cell & Developmental Biology. 
12:1-26, 1996, the disclosures of which are incorporated 
herein by reference in their entirety. In some embodiments 
the organelle localization signals include signals having or 
conferring a net charge, for example a positive charge. 
Positively charged signals can be used to target negatively 
charged organelles such as the mitochondria. Negatively 
charged signals can be used to target positively charged 
FIG. 23I shows a bar graph indicating dual FRET molecu-
lar beacons give a much better signal-to-background ratio, 
and a more quantitative measure of mRNA expression level 
than single beacons. 
FIGS. 24A-H are fluorescence micrographs showing 
detection of survivin mRNA expression in MIApaCa-2 and 
normal HDF cells using single donor molecular beacons 
only (a-d), or dual FRET molecular beacons (e-h). 
50 organelles or regions. 
FIGS. 25A-C are fluorescence micrographs showing 
mRNAlocalization in HDF and MIAPaCa-2 cells. (a) & (b): 
Fluorescence images of K-ras mRNA in stimulated HDF 
cells. Note the filamentous K-ras mRNA localization pat-
tern. (c) A fluorescence image of survivin mRNA localiza-
tion in MIAPaCa-2 cells. 
FIGS. 26A-C are fluorescence micrographs showing fluo-
rescence in situ hybridization (FISH) studies. (a) Detection 
of K-ras mRNA in fixed HDF cells using fluorescently 
labeled linear probes. Note the filamentous localization 
pattern near the cell peripheral region. (b) A negative control 
study of the FISH assay using fluorescently labeled linear 
Poly-A probes resulted in very low background 
"Protein Transduction Domain" or PTD refers to a 
polypeptide, polynucleotide, carbohydrate, or organic or 
inorganic compounds that facilitates traversing a lipid 
bilayer, micelle, cell membrane, organelle membrane, or 
55 vesicle membrane. A PTD attached to another molecule 
facilitates the molecule traversing membranes, for example 
going from extracellular space to intracellular space, or 
cytosol to within an organelle. Exemplary PTDs include but 
are not limited to HIV TAT YGRKKRRQRRR (SEQ ID NO. 
60 38) or RKKRRQRRR (SEQ ID NO. 39); 11 Arginine 
residues, or positively charged polypeptides or polynucle-
otides having 8-15 residues, preferably 9-11 residues. 
As used herein, the term "polynucleotide" generally refers 
to any polyribonucleotide or polydeoxribonucleotide, which 
65 may be unmodified RNA or DNA or modified RNA or DNA. 
Thus, for instance, polynucleotides as used herein refers to, 
among others, single- and double-stranded DNA, DNA that 
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is a mixture of single- and double-stranded regions, single-
and double-stranded RNA, and RNA that is mixture of 
single- and double-stranded regions, hybrid molecules com-
prising DNA and RNA that may be single-stranded or, more 
typically, double-stranded or a mixture of single- and 
double-stranded regions. The terms "nucleic acid," "nucleic 
acid sequence," or "oligonucleotide" also encompass a poly-
nucleotide as defined above. 
In addition, polynucleotide as used herein refers to triple-
stranded regions comprising RNA or DNA or both RNA and 
DNA. The strands in such regions may be from the same 
molecule or from different molecules. The regions may 
include all of one or more of the molecules, but more 
typically involve only a region of some of the molecules. 
One of the molecules of a triple-helical region often is an 
oligonucleotide. 
The term "molecular beacon" generally means labeled, 
for example dual-labeled polynucleotide probes comprising 
a polynucleotide binding domain and stem regions. The stem 
regions hybridize in the absence of a target polynucleotide 
and form a stem-loop structure. In particular, the term 
molecular beacon includes hairpin polynucleotide probes 
labeled with a quantum dot that form a stem-loop structure 
in the absence of a target polynucleotide. 
Probes 
One embodiment of disclosure provides probes, in par-
ticular a set of probes for detecting the presence of absence 
of at least one target polynucleotide. An exemplary probe set 
comprises at least two probes. The first probe is a donor 
polymer comprising a first polynucleotide binding domain 
complementary to a first region of a target polynucleotide. 
The polynucleotide binding domain is flanked by first and 
second stem regions which hybridize in the absence of the 
target polynucleotide to form a stem-loop structure. The 
donor polymer also includes at least one quantum dot. 
Typically the quantum dot is attached to one end of the probe 
and serves as a donor during energy transfer. In other 
embodiments, the donor polymer comprises quantum dots 
attached to opposite ends of the donor polymer. 
8 
hybridize to the target polynucleotide and the donor of the 
donor polymer and the reporter of the acceptor polymer are 
positioned to permit energy transfer between the donor and 
the reporter. 
Labeling of the probes can be accomplished, for example, 
during oligonucleotide synthesis, by adding amino-modifier 
dC and amino-modifier dT in place of a 2'-deoxycytidine 
and thymidine base, respectively. In certain cases, fluores-
cently labeled nucleotides can be directly incorporated into 
10 the polymer chain-at desired places. After deprotection, the 
primary amine on the C6 analogues can be separated from 
the oligonucleotide by a spacer arm with a total of about 
1-10 atoms, which can then be labeled with fluorophores. 
Alternatively, customized internal Cy3 labeling of oligo-
15 nucleotides can be performed at specific companies (e.g., 
Glen Research). The length of the modified oligonucleotide 
on the acceptor probe can be adjusted so the self-quenching 
of the reporter, for example Cy3, is minimized. 
Another embodiment of the present disclosure provides 
20 donor and acceptor polymer probes that can non-invasively 
report the presence or absence of a target polynucleotide 
either in vivo or in vitro. Non-invasive delivery refers to 
delivery without significant physical damage to a cell or 
tissue using for example, a mechanical device such as needle 
25 or other mechanical or physical means such as poration that 
may cause significant cellular or tissue damage. Embodi-
ments of the disclosure provide polymer probes modified 
with a protein transduction domain (or cell penetrating 
peptide) to facilitate translocation of the probe from the 
30 extracellular space to intracellular space. The polymer 
probes can translocate to any region of the interior of a cell 
including the interior of membrane bound organelles such as 
the nucleus, mitochondrion, or chloroplast. It will be appre-
ciated by those of skill in the art that any membrane 
35 organelle is included within the scope of the disclosure. It 
will be further appreciated that any cell having a membrane 
or cell wall is within the scope of this disclosure including, 
but not limited to animal cells such as human cells, and plant 
cells. Microbial cells and bacterial cells are also within the 
40 scope of this disclosure. 
The second probe is an acceptor polymer comprising a 
second polynucleotide binding domain complementary to a 
second region of the target polynucleotide flanked by first 
and second stem regions which hybridize in the absence of 
the target polynucleotide to form a stem-loop structure. The 45 
acceptor polymer also comprises at least one reporter or 
label, and optionally, at least one quencher. One embodiment 
provides an acceptor probe comprising a reporter that does 
not emit a detectable signal when exposed to an exciting 
amount of energy for donor excitation. Another embodiment 50 
provides an acceptor probe comprising a reporter that emits 
Another embodiment provides polymer probes that can be 
delivered into biological cells, tissues and animals using, for 
example, microinjection, electroporation, toxin-based deliv-
ery methods (for example, using streptolysin 0), and trans-
fection agents (including liposome-based and dendrimer-
based transfection). 
Other embodiments provide polymer probes that are 
further modified to include targeting signals such as intra-
cellular targeting signals, organelle targeting signals, cellu-
lar targeting signals, tissue targeting signals, or organ tar-
geting signals. Generally, such targeting signals are known 
a detectable signal when exposed to energy transferred from 
the donor. Still another embodiment provides an acceptor 
probe comprising at least one quencher so that in the absence 
of a target polynucleotide the reporter is quenched. Yet 55 
another embodiment provides an acceptor polymer compris-
ing at least one reporter attached to both ends of the polymer. 
Energy transfer occurs between the donor of the donor 
polymer and the at least one reporter of the acceptor polymer 
when the donor polymer and the acceptor polymer hybridize 60 
to the target polynucleotide and the quantum dot is exposed 
to an exciting amount of energy. An exciting amount of 
energy refers to an amount of energy that results in the 
emission of energy by the quantum dot. The emissions of the 
quantum dot excite the reporter which generates a detectable 65 
signal. The polynucleotide binding domains of the donor and 
acceptor polymers are designed so that the two probes 
in the art. Targeting signals include, but are not limited to, 
amino acid or nucleic acid sequences, as well as lipids or 
carbohydrates that target the probe to a specific cell, tissue, 
organ or intracellular region of a cell. Such targeting can be 
accomplished through receptor:ligand interactions or by 
using a targeting signal that modifies the polarity, hydro-
phobicity, hydrophilicity, or any combination thereof, of the 
disclosed probes. Thus, the targeting signal can confer a 
positive or negative charge to the probe as needed. Exem-
plary targeting signals include, but are not limited to, growth 
factors, growth factor receptors, antibodies or fragments 
thereof specific for extracellular epitopes, carbohydrates, 
lipids, peptides, nucleic acids, nuclear localization signals, 
mitochondria localization signals, chloroplast localization 
signals, polar or non-polar small molecules, co-factors and 
vitamins. 
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It will be appreciated by those of skill in the art that the 
disclosed probes can include a PTD, a targeting signal, or a 
combination thereof. The PTD, the targeting signal, or both 
can be releaseably linked to the probe, for example through 
cleavable bonds, so that the probe is released from the PTD 
10 
or targeting signal when the probe arrives at a desired 
location. In one aspect, the PTD is cleaved when the probe 
enters the cytosol and the targeting signal remains linked to 
the probe. In another aspect, the targeting signal is removed 
from the probe when the probe reaches the desired location. 10 
gold, silver, copper, titanium, nickel, platinum, palladium, 
oxides thereof (e.g., Cr2 0 3 , C030 4 , NiO, MnO, CoFe20 4 , 
and MnFe04 ), and alloys thereof), metalloid and metalloid 
oxide nanoparticles, the lanthanide series metal nanopar-
ticles, and combinations thereof. In particular, semiconduc-
tor quantum dots are described in more detail below and in 
U.S. Pat. No. 6,468,808 and International Patent Application 
WO 03/003015, which are incorporated herein by reference. 
Suitable quantum dots include, but are not limited to, 
luminescent semiconductor quantum dots. In general, quan-
tum dots include a core and a cap, however, uncapped 
quantum dots can be used as well. The "core" is a nanom-
eter-sized semiconductor. While any core of the IIA-VIA, 
IIIA-VA or IVA-IVA, IVA-VIA semiconductors can be used 
The disclosed probes include, but are not limited to, 
labeled oligonucleotides or polynucleotides such as molecu-
lar beacons. Some molecular beacons are labeled with a 
reporter and a quencher, for example the acceptor polymer 
can be labeled with a reporter and a quencher so that the 
reporter is quenched in the absence of a target polynucle-
otide. As used herein, molecular beacons also include poly-
nucleotides labeled with a quantum dot. Generally, molecu-
lar beacons include a sequence that is complementary to a 
target polynucleotide (target recognition sequence or poly-
nucleotide binding domain). The degree of complementarity 
is sufficient to enable sequence specific interactions between 
the probe and the target polynucleotide. Some embodiments 
can detect single base differences or single nucleotide poly-
morphisms in a target polynucleotide. The disclosed probes 
may have target recognition sequences or polynucleotide 
binding domains 7-140 nucleotides, but it will be appreci-
ated that the target recognition sequence can be of any length 
that permits sequence specific association with the target 
polynucleotide. In some embodiments, the sequences flank-
ing the target recognition sequences form a stem hybrid, or 
"stem duplex" 3-25 nucleotides in length. Modified nucle-
otides and modified nucleotide linkages may be used to 
produce the disclosed probes and are described more fully 
below. Such modifications are known in the art and include 
modifications to increase resistance to the enzymatic deg-
radation. In non-limiting embodiments, labile phosphodi-
ester or phosphoester linkages may be replaced with more 
stable linkages, such as phosphorothioate or thioester link-
ages. For example the disclosed probes may include, for 
example, peptide nucleic acid ("PNA") linkages. The dis-
closed compositions and target polynucleotides can be 
DNA, RNA including rRNA, nuclear RNA, mRNA, cDNA, 
genomic DNA, or combinations thereof. 
Quantum Dots 
Another embodiment provides dual FRET hairpin probes 
with quantum dots as the donor. In some embodiments, 
signal intensity is increased and photobleaching is overcome 
by using quantum dot based probes. Quantum dots are 
semiconductor nanocrystals about 1 to about 20 nm in size. 
In comparison with organic dyes and fluorescent proteins, 
quantum dots represent a new class of fluorescent labels 
with unique advantages. For example, the fluorescence 
emission spectra of quantum dots can be continuously tuned 
by changing the particle size, and a single wavelength 
(typically in the blue or UV spectrum) can be used for 
simultaneous excitation of all different-sized quantum dots. 
Surface-passivated quantum dots are highly stable against 
photobleaching and have narrow, symmetric emission peaks 
(25-30 nm wide at half maximum intensity). Quantum dots 
also have high quantum yield: it has been estimated that 
CdSe quantum dots are about 20 times brighter and 100 
times more stable than single rhodamine-6G molecules 
The quantum dots of the present disclosure include a 
number of types of quantum dots such as, but not limited to, 
semiconductor, metal, and metal oxide nanoparticles (e.g., 
15 in the context of the present disclosure, the core must be 
such that, upon combination with a cap, a luminescent 
quantum dot results. A IIA-VIA semiconductor is a com-
pound that contains at least one element from Group IIB and 
at least one element from Group VIA of the periodic table, 
20 and so on. The core can include two or more elements. In 
one embodiment, the core is a IIA-VIA, IIIA-VA or IVA-
IVA semiconductor that ranges in size from about 1 nm to 
about 20 nm. In another embodiment, the core is more 
preferably a IIA-VIA semiconductor and ranges in size from 
25 about 2 nm to about 10 nm. For example, the core can be 
CdS, CdSe, CdTe, ZnSe, ZnS, PbS, PbSe or an alloy. 
The "cap" is a semiconductor that differs from the semi-
conductor of the core and binds to the core, thereby forming 
a surface layer on the core. The cap can be such that, upon 
30 combination with a given semiconductor core a luminescent 
quantum dot results. The cap should passivate the core by 
having a higher band gap than the core. In one embodiment, 
the cap is a IIA-VIA semiconductor of high band gap. For 
example, the cap can be ZnS or CdS. Combinations of the 
35 core and cap can include, but are not limited to, the cap is 
ZnS when the core is CdSe or CdS, and the cap is CdS when 
the core is CdSe. Other exemplary quantum does include, 
but are not limited to, CdS, ZnSe, CdSe, CdTe, CdSexTe1_x, 
InAs, InP, Pb Te, PbSe, PbS, HgS, HgSe, HgTe, CdHgTe, and 
40 GaAs. 
The wavelength emitted (i.e., color) by the quantum dots 
can be selected according to the physical properties of the 
quantum dots, such as the size and the material of the 
nanocrystal. Quantum dots are known to emit light from 
45 about 300 nanometers (nm) to 1700 nm (e.g., UV, near IR, 
and IR). The colors of the quantum dots include, but are not 
limited to, red, blue, green, and combinations thereof. The 
color or the fluorescence emission wavelength can be tuned 
continuously. The wavelength band of light emitted by the 
50 quantum dot is determined by either the size of the core or 
the size of the core and cap, depending on the materials 
which make up the core and cap. The emission wavelength 
band can be tuned by varying the composition and the size 
of the QD and/or adding one or more caps around the core 
55 in the form of concentric shells. 
The intensity of the color of the quantum dots can be 
controlled. For each color, the use of 10 intensity levels (0, 
1, 2, ... 9) gives 9 unique codes (101 -1), because level "O" 
cannot be differentiated from the background. The number 
60 of codes increase exponentially for each intensity and each 
color used. For example, a three color and 10 intensity 
scheme yields 999 (103 -1) codes, while a six color and 10 
intensity scheme has a theoretical coding capacity of about 
1 million (106 -1). In general, n intensity levels with m 
65 colors generate (nm-1) unique codes. Use of the intensity of 
the quantum dots has applications in quantum dots including 
a plurality of different types of quantum dots having differ-
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ent intensity levels and also in quantum dots including a 
plurality of different types of quantum dots having different 
intensity levels that are included in a porous material. The 
quantum dots are capable of absorbing energy from, for 
example, an electromagnetic radiation source (of either 
broad or narrow bandwidth), and are capable of emitting 
detectable electromagnetic radiation at a narrow wavelength 
band when excited. The quantum dots can emit radiation 
within a narrow wavelength band (FWHM, full width at half 
maximum) of about 40 nm or less, thus permitting the 10 
simultaneous use of a plurality of differently colored quan-
tum dots with little or no spectral overlap. 
12 
polymer, lipid, phospholipid, or a phospholipid 
monomethoxy PEG micelle. The hydrophobic core of a 
DSPE-PEG micelle provides a cavity to encapsulate indi-
vidual QDs, while the dense PEG polymer layer on the outer 
surface facilitates conjugation of the hairpin probe. Many 
functionalized PEG-lipid derivatives, such as DSPE-PEG-
maleimide and DSPE-PEG-amine, are commercially avail-
able (Avanti Polar Lipid). In some embodiments, the dis-
closed probes have one QD. 
In one embodiment, the organic soluble quantum dots 
may be coated with amphiphilic polymers such as octy-
lamine-modified polyacrylic acid, which can be further cross 
linked to increase the stability of coatings or chemically 
modified to introduce functional groups for conjugation of 
The synthesis of quantum dots is well known and is 
described in U.S. Pat. Nos. 5,906,670; 5,888,885; 5,229, 
320; 5,482,890; 6,468,808; 6,306,736; 6,225,198, etc., Inter-
national Patent Application WO 03/003015, (all of which are 
incorporated herein by reference) and in many research 
articles. The wavelengths emitted by quantum dots and other 
physical and chemical characteristics have been described in 
U.S. Pat. No. 6,468,808 and International Patent Application 
WO 03/003015 and will not be described in any further 
detail. In addition, methods of preparation of quantum dots 
are described in U.S. Pat. No. 6,468,808 and International 
Patent Application WO 03/003015 and will not be described 
any further detail. 
15 biopolymer probes. Further these coatings may have func-
tional groups for conjugation of linker proteins such as 
streptavidin, which may provide further possibilities to 
chemically conjugate other moieties to the probe. 
In another embodiment, the amphiphilic polymers may be 
20 biological polymers such as peptides which may provide 
water-solubility and functionalization to quantum dots. 
These peptides may contain modified amino acids for vari-
ous functions such as bioconjugation. 
In another embodiment, the coatings may be of the type 
The hydrophobic protection structure can include a cap-
ping ligand and/or a block copolymer. In particular, the 
hydrophobic protection layer includes the capping ligand 
and the block copolymer, where the capping ligand and the 
block copolymer interact with one another to form the 
hydrophobic protection structure. As such, the capping 
ligand and the block copolymer are selected to form an 
appropriate hydrophobic protection structure. For example, 
the block copolymer and the quantum dot can interact 
through interactions such as, but not limited to, hydrophobic 
interactions, hydrophilic interactions, pi-stacking, etc., 
depending on the surface coating of the quantum dot and the 
molecular structure of polymers. 
25 of DHLA (Lipoic Acid) or Mercaptoacetic Acid-coated in 
which the Thiol group of the coatings form a bond with the 
capping layer (e.g., ZnS) of the quantum dots. In such 
bi-functional coatings, one part of the molecule forms a 
bond with the quantum dot surface and other functional 
30 molecule provides the chemistry for bioconjugation of 
probes. 
In still another embodiment, silica based coatings such as 
silanes may be used to produce water-soluble quantum dots. 
These silanes are chemically linked to the surface of the 
35 quantum dot. Further, these coatings may be modified with 
molecules such as PEG to provide increased water solubility. 
As illustrated in FIG. 20a, an exemplary donor hairpin 
probe is conjugated to the surface of a quantum dot (QD), 40 
which is optionally coated with phospholipid-PEG. The 
acceptor stem-loop hairpin probe is labeled with at least one, 
typically 2-3 reporters or acceptor dyes attached to one arm 
of the stem. Hybridization of both donor and acceptor probes 
to adjacent regions of the same target polynucleotide, for 45 
example mRNA, will bring the acceptor dyes in close 
proximity of the quantum dot, resulting in FRET and fluo-
rescence emission characteristic of the acceptor dye when 
the quantum dot is exposed to an exciting amount of energy, 
for example excited with a wavelength less than about 450 50 
nm. A suitable quantum dot includes, but is not limited to 
CdSe/ZnS quantum dot (Evident Technologies) as a donor, 
which has a broad excitation spectrum (FIG. 20b), and Cy3 
as the acceptor. Generally, the quantum dot has a diameter 
Methods of Detection 
Probes and probes pairs of the present disclosure can be 
used to detect, localize, or quantify a target polynucleotide 
in a cell, in particular a living cell, tissue, or organ. Repre-
sentative cells include plant and animal cells. Target poly-
nucleotides can be any polymer of nucleotides, DNA, RNA 
or combinations thereof, genomic, mRNA, nuclear RNA, 
enzymatic RNA, enzymatic DNA, or ribosomal RNA. 
Embodiments of the disclosed methods provide real-time 
visualization of specific endogenous mRNA expression in 
VIVO. 
One embodiment of the disclosure provides a method of 
detecting at least one target polynucleotide using the dis-
closed probes and probe sets. An exemplary method of 
detecting a target polynucleotide comprises delivering at 
least one probe, probe set, or molecular beacon pair to the 
interior of a cell or organelle. The at least one probe set or 
molecular beacon pair comprises a donor molecular beacon 
and an acceptor molecular beacon. The donor molecular 
beacon comprises a quantum dot and forms a stem-loop 
structure in the absence of a target polynucleotide. The 
acceptor molecular beacon comprises at least one reporter 
and forms a stem-loop structure in the absence of the target 
polynucleotide. The acceptor molecular beacon optionally 
includes at least one quencher opposite the reporter so that 
the reporter is quenched in the absence of the target poly-
nucleotide. The method further comprises exposing the 
of about 2.4 nm. As shown in FIG. 20b, Cy3 has some 55 
overlap between its excitation spectrum (maximum at 548 
nm) and the emission spectrum of the QD (with an emission 
peak at 520 nm). When a FRET assay is performed with 400 
nm excitation and 570 nm emission detection, there is no 
direct excitation ofCy3, and very low signal of the QD (FIG. 60 
20B). Therefore, no quenching is necessary for the QD and 
Cy3 dye. It will be appreciated that other QD and organic 
dye pairs can be used to achieve the maximum signal-to-
background ratio based on their excitation and emission 
spectra. 65 quantum dot to an exciting amount of energy so that energy 
transfer occurs between the quantum dot of the donor 
molecular beacon and the reporter of the acceptor molecular 
Another embodiment provides a donor polymer probe 
wherein the quantum dot is encapsulated, for exarriple in a 
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beacon when the donor molecular beacon and the acceptor 
molecular beacon hybridize to the target polynucleotide. The 
energy transfer enables the reporter to produce a detectable 
signal. The detectable signal can indicate the presence or 
location of the target polynucleotide in cell as well as the 
amount of target polynucleotide in the cell. 
Another embodiment provides a method for sorting living 
cells that express a target polynucleotide or a predetermined 
level of a target polynucleotide. In this embodiment, a 
plurality of cells are loaded with the disclosed probes or 
probe sets. The cells are exposed to an exciting amount of 
radiation sufficient to allow energy transfer to occur between 
the donor of the donor probe and the reporter of the acceptor 
probe when the donor and acceptor probes hybridize to the 
target polynucleotide. Cells having a detectable signal from 
the reporter can be selected and separated from cells that do 
not have a detectable signal from the reporter. Separating the 
cells can be performed using automated devices which 
include, but are not limted to fluorescence-activated cell 
sorters. Representative cells include, but are not limited to 
eukaryotic cells, animal cells, human cells, stem cells, germ 
cells, pluripotent cells, totipotent cells, undifferentiated 
cells, endodermal cells, mesenchymal cells, ectodermal 
cells, brain cells, skin cells, heart cells, bone marrow cells, 
blood cells, lymphocytes, adipose cells, smooth muscle 
cells, muscle cells, osteoclasts, osteoblasts, macrophage, 
T-cells, helper T-cells, among others. 
The presence of the detectable signal in the cells is 
indicative of the expression of the target polynucleotide by 
the cell. The expression of the target polynucleotide can also 
be correlated to the presence or predisposition to a pathology 
including, but not limted to cancer, viral infection, genetic 
disease, Alzheimer's Disease, muscular dystrophy, diabetes, 
obesity, heart disease, atherosclerosis, inflammatory 
pathologies, autoimmune diseases, among others. 
In other embodiments, a detectable signal is indicative of 
14 
amount of energy. A detectable signal observed from the 
reporter indicates the presence of the target polynucleotide 
in the sample. 
It will be appreciated by those of skill in the art that the 
disclosed probes can be used with single- or multiple-photon 
microscopy, time-resolved fluorescence microscopy or fluo-
rescence endoscopy, among others. 
One embodiment provides a method for detecting cells 
expressing a target polynucleotide including contacting a 
10 
cell suspected of expressing the target polynucleotide with 
the disclosed probes or probe pairs which are individually 
operably linked to a protein transduction domain, The 
probes include a region complementary to the target poly-
nucleotide. The probes can be added to a cell culture of 
15 immortalized cells, primary culture cells, transfected cells, 
or administered to a organism or tissue. Preferred tissues are 
those tissues with optical characteristics that enable the 
detection of the probes or it may involve the use of endo-
scopic instruments in combination with appropriate optical 
20 instrumentation for excitation and detection of electromag-
netic emission in vivo. Preferred organisms include humans 
and zebra fish. When used with tissues, near-infrared labels 
are preferred. 
25 Once the cell is contacted with the probe, the PTD on the 
probe facilitates translocation of cell membranes including, 
but not limited to, lipid bilayers, micelles, vesicles, and 
organelles such as the nucleus, mitochondria or chloroplast. 
The PTD enables the probe to travel from extracellular space 
30 to intracellular space including the interior of organelles. 
The probes can be irradiated with an exciting amount of 
electromagnetic radiation. An exciting amount of radiation 
is that amount of radiation sufficient to enable the probe to 
emit electromagnet radiation. The electromagnetic energy 
35 emitted by the probe indicates that probe has bound its 
complement and that the cell expresses the target polynucle-
otide. 
a point mutation, deletion or insertion in the target poly-
nucleotide relative to a control polynucleotide. Exemplary 
target polynucleotides include, but are not limited to poly- 40 
nucleotides encoding an oncogene, transgene, signal trans-
duction protein, growth factor, viral protein, K-ras, survivin, 
p53, p16, DPC4, or BRCA2. 
Another embodiment provides a method for sorting cells 
expressing a target polynucleotide. A plurality of cells 
suspected of expressing the target polynucleotide is con-
tacted with at least one probe or at least one probe pair, for 
example a quantum dot probe, optionally, operably linked to 
a protein transduction domain, wherein the protein trans-
duction domain facilitates translocation of the at least one In some embodiments, in vivo or in vitro detection of 
more than one target polynucleotide (multiplexing) is 
accomplished by using at least two probe sets specific for 
different target polynucleotides. In one embodiment, the 
reporter for the acceptor pro be specific for a first target 
polynucleotide provides a different detectable signal than the 
reporter for the acceptor probe specific for the second target 
polynucleotide. For example, one reporter can have a detect-
able signal at one wavelength, and the other reporter can 
have a detectable signal at a different wavelength. The 
presence of a detectable signal from either reporter or the 
combined detectable signal of both reporters is indicative of 
the presence and optionally the location of the respective 
target polynucleotides. The movement of target polynucle-
otides over a period of time can also be tracked and 
visualized using the disclosed probes and probe sets. 
Other embodiments provide methods for detecting at least 
one target polynucleotide in vitro, for example in an array, 
solution, test tube, gel, matrix, or the like. The disclosed 
probes can be fixed or attached to a solid support. Alterna-
tively, the target polynucleotide can be fixed or attached to 
a solid support. The disclosed probes can be combined in 
vitro with a sample suspected of containing a target poly-
nucleotide. The combination is exposed to an exciting 
45 probe to at least one of the plurality of cells' interior. The 
probe includes a region complementary to the target poly-
nucleotide. The plurality of cells are irradiated with an 
exciting amount of electromagnetic energy and electromag-
netic energy emitted in response to the exciting amount of 
50 electromagnetic radiation by the molecular beacon in the 
interior of at least of the plurality of cells can be detected. 
Cells emitting a detectable amount of electromagnetic radia-
tion can then be separated from cells, which are not emitting 
a detectable amount of electromagnetic radiation. Methods 
55 for separating cells are known in the art, for example, by 
using a fluorescence-activated cell sorter, which are com-
mercially available. 
Another embodiment provides a method for detecting a 
target polynucleotide in a host. This embodiment includes 
60 administering to the host the disclosed probes which are 
optionally, operably linked to a protein transduction domain, 
and optionally linked to a targeting signal. Generally, the 
probes are in the form of a pharmaceutical composition. The 
probes are irradiated with an exciting amount of electro-
65 magnetic radiation, and the electromagnetic radiation emit-
ted by the probes in response to the exciting amount of 
electromagnetic radiation is detected. The detected electro-
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magnetic radiation can be correlated with the presence, 
location, and quantity of the target polynucleotide in the 
host, cell, or tissue. 
Still another embodiment provides an approach to study 
the transport of RNA in living cells and model organisms 
such as oocytes using the disclosed probes which are option-
ally, operably linked to a protein transduction domain as 
well as a targeting signal such as a nuclear localization 
signal (NLS) whenever necessary. For these studies, the 
disclosed probes may be delivered specifically to the nuclear 10 
compartment, where they hybridize with the target RNA 
molecules which may be subsequently transported to the 
cytoplasm. This real time imaging of RNA transport may be 
used to gain a better understanding of RNA biology and 
developmental biology. Further, the disclosed probes may be 15 
linked to a targeting sequence such as NLS and modified 
using a caged fluorophore. In the native state the modified 
probe does not emit much signal. Using controlled excita-
tion in the nuclear compartment, the caged molecule may be 
released, emitting a signal that can be imaged for studying 20 
transport of RNA molecules from nucleus to cytoplasm. 
Another embodiment provides an approach in which 
co-localization of RNA with subcellular organelles and the 
dynamics of RNA or DNA molecules interacting with pro-
teins and can be studied. For this approach, the disclosed 25 
probes, optionally, operably linked to a protein transduction 
domain optionally linked to a targeting signal is used in 
conjugation with fusion protein of interest (GFP-protein) or 
any fluorescently labeled protein (fluorescent labeled anti-
body targeted protein) or subcellular organelle. The molecu- 30 
lar beacons target the nucleic acid molecules of interest 
(RNA or DNA) and, upon hybridization with the target, 
provide electromagnetic emission in particular wavelength 
range, while the fusion protein or any fluorescently labeled 
protein or organelle provides the non-overlapping wave- 35 
length upon excitation. This allows one to study the RNA-
protein interactions and its dynamics in living cells. 
Yet another embodiment provides a method for identify-
ing compounds that interfere with the expression of a target 
polynucleotide, for example a nucleic acid suspected to be 40 
involved with a pathological condition, for example cancer 
or other disease states. The method includes contacting a 
living cell or a plurality of living cells with a compound 
suspected of modulating the expression of a gene, for 
example a small organic molecule or antisense drug, con- 45 
tacting the cell with a probe having a region complementary 
to a transcript of the gene, irradiating the probe or the cell 
with an exciting amount of electromagnetic radiation, and 
detecting the emission of electromagnetic radiation from the 
probe, wherein detectable emission from the probe is indica- 50 
tive of expression or the location of the gene. The cell can 
be a primary culture, immortalized cell, or transfected cell. 
Typically, a cell is transfected with a gene of interest and the 
probe is specific for transcripts of the gene of interest. A test 
compound can be selected based on its ability to decrease the 55 
expression of a gene or increase the expression of a gene 
when compared to a control sample. A control sample 
includes a cell contacted with the probe in the absence of the 
test compound. Decreased expression of a gene is indicated 
by little to no detectable emissions from the probe; whereas, 60 
increased gene expression is indicated by detectable emis-
sions from the probe which are greater from cells treated 
with the test compound compared to cells not treated with 
the test compound. This screening method is adaptable to 
high-throughput screening and imaging, for example using 65 
a fluorescence activated cell sorter, cell arrays, tissue arrays, 
or other microfluidic devices, which allow for high through-
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put detection and imaging. Combinatorial libraries can be 
used with this method to identify compounds that modulate 
gene expression in vivo. 
Another embodiment provides a method for determining 
the effectiveness of a therapeutic, for example a therapeutic 
that modulates gene expression of a host or suspected of 
modulating gene expression. The disclosed probes can be 
used to obtain in vivo gene expression data from a individual 
or cell specific gene expression data of an individual or host. 
Such data can be used to determine whether the therapeutic 
is effective in the individual based on the level of specific 
gene expression in a host. One embodiment provides a 
method including the steps of administering a therapeutic to 
a host, obtaining cells from the host, contacting the cells 
with a probe operably linked to a PTD and optionally to a 
targeting signal, wherein the probe includes a target recog-
nition sequence complementary to a predetermined target 
polynucleotide, irradiating the cells with an exciting amount 
of radiation, and detecting electromagnetic emission from 
the cells in response to the exciting amount of radiation, and 
correlating the amount of detectable electromagnetic emis-
sion from the cells with amount of target polynucleotide in 
the cells. A therapeutic includes compounds, molecules, 
drugs or combinations thereof, administered to a host to 
treat, alleviated, mitigate; a pathology of the host or a 
symptom of a pathology. 
Alternatively, one or more cells from a host can be 
contacted in vitro with an agent, for example a therapeutic 
agent, suspected of modulating expression of a target poly-
nucleotide. Typically, the cells can be incubated for a period 
of time to allow the therapeutic agent to have a biological 
effect. The cells can then be contacted with the disclosed 
probes operably linked to a protein transduction domain, 
wherein the probes include a target recognition sequence 
complementary to the target polynucleotide. The cells con-
taining the probes are irradiated with an exciting amount of 
radiation and electromagnetic emission from the cells emit-
ted in response to the exciting mount of radiation can be 
detected. Emission from the cells exposed to the therapeutic 
agent and containing the probes can be compared with 
emissions from a control sample of cells containing the 
probes but which were not exposed to the therapeutic agent. 
A difference in emission between the cells exposed to the 
therapeutic agent and containing the probes compared with 
emissions from a control sample of cells containing the 
probes but which were not exposed to the therapeutic agent 
indicates that the therapeutic agent modulates expression of 
the target polynucleotide in the host. It will be appreciated 
by one of skill in the art that more than one probe specific 
for more than one target polynucleotide can be used to 
establish a profile of gene expression modulation by a 
particular agent or compound for an individual host. Such 
data can provide information to a medical practitioner to 
assist in determining course of treatment and use of specific 
medicines personalized to one individual or host. Typically, 
the agent or compound will be an agent believed to exert a 
therapeutic effect, i.e., treat or alleviate a pathology or 
symptom of a pathology. 
Split Protein Probes 
FIG. 21 shows another exemplary embodiment of the 
disclosure. This embodiment provides activatable hairpin 
probe pairs comprising at least two polynucleotide stem-
loop hairpins wherein each is conjugated with an N-terminal 
or C-terminal fragment of a reporter protein so that when 
both probes hybridize to adjacent regions of the same 
mRNA target, the two protein fragments reconstitute the 
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nucleobase is missing or has a hydroxyl group in place 
thereof). Various salts, mixed salts and free acid forms are 
also included. 
Representative United States patents that teach the prepa-
fluorophore and generate a fluorescent signal upon excita-
tion. Since each individual protein fragment is not fluores-
cent, no background signal is generated even if the hairpin 
probe is degraded by nucleases or opens nonspecifically due 
to nucleic acid binding proteins. 
In one embodiment an exemplary set of dual-hairpin 
probes comprise fragments of yellow fluorescent protein 
variant, Venus. An exemplary molecular probes can contain 
complementary sequence in antisense orientation to the 
GAPDH mRNA: probe #1, 5'-GAGTCCTTCCACGATAC-
CGACTC-3' (SEQ ID NO. 40); probe #2, 5'-CCACAT-
GATGGCATGGACTGTGG-3' (SEQ ID NO. 41). Oligo-
nucleotide-peptide conjugates containing a Cysteine with a 
free N-terminal can be prepared using published procedure 
5 ration of the above phosphorus-containing linkages include, 
but are not limited to, U.S. Pat. Nos. 3,687,808; 4,469,863; 
4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 
5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 
5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 
10 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 
5,571,799; 5,587,361; 5,194,599; 5,565,555; 5,527,899; 
5,721,218; 5,672,697 and 5,625,050. 
of fragment coupling of pre-synthesized short peptides (such 15 
as CysG!yG!y) to the 2'-position of a selected nucleotide 
through a stable amide linkage. Venus can be spliced into 
two halves (amino acids 1-154 and amino acids 155-238) 
that do not self-associate. Each fragment can be fused to an 
11 amino acid TAT-delivery peptide at its C-terminus or at 20 
its N-terminus. The peptide can be linked to a hairpin probe 
through the thiol group. Expressed protein ligation can be 
used for conjugation between the fragments and oligonucle-
otide probes. This procedure has been used in the synthesis 
of a variety of modified proteins including covalent conju- 25 
gates of proteins and polyamide nucleic acids (PNA). In the 
first step, the TAT peptide-linked N-terminal Venus frag-
ment, fused to an intein and a chitin binding domain (CBD), 
is expressed in E. coli. This latter domain allows the affinity 
purification of the intein-fused fragment using a chitin 30 
matrix. Liberation from the colurmi is achieved by mercap-
toethansulfonic acid (MESNA), which produces a C-termi-
nal thioester of the TAT peptide fused N-fragment of Venus. 
The peptide is then conjugated to hairpin probe #1 contain-
ing the N-terminal Cysteine. Hairpin probe #2 is conjugated 35 
with the TAT peptide-fused C-terminal fragment ofVenus in 
a similar fashion. 
It will be appreciated that other fluorescent proteins can 
be used with the disclosed probes. For example, luciferase 
protein fragments can be used to reconstitute the luciferase 40 
when both donor and acceptor probes are hybridized to the 
same target polynucleotide, resulting a bioluminescence 
signal. 
Some oligonucleotide backbones do not include a phos-
phorus atom therein and have backbones that are formed by 
short chain alkyl or cycloalkyl intemucleoside linkages, 
mixed heteroatom and alkyl or cycloalkyl intemucleoside 
linkages, or one or more short chain heteroatomic or het-
erocyclic internucleoside linkages. These include those hav-
ing morpholino linkages (formed in part from the sugar 
portion of a nucleoside); siloxane backbones; sulfide, sul-
foxide and sulfone backbones; formacetyl and thiofor-
macetyl backbones; methylene formacetyl and thiofor-
macetyl backbones; riboacetyl backbones; alkene containing 
backbones; sulfamate backbones; methyleneimino and 
methylenehydrazino backbones; sulfonate and sulfonamide 
backbones; amide backbones; and others having mixed N, 
0, S and CH2 component parts. 
Representative United States patents that teach the prepa-
ration of the above oligonucleosides include, but are not 
limited to, U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 
5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 
5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 
5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 
5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 
5,663,312; 5,633,360; 5,677,437; 5,792,608; 5,646,269 and 
5,677,439. 
In still other embodiments provide probes containing 
oligonucleotide mimetics in which both the sugar and the 
internucleoside linkage, i.e., the backbone, of the nucleotide 
units are replaced with novel groups. The base units are 
maintained for hybridization with an appropriate nucleic 
acid target compound. One such oligomeric compound, an 
oligonucleotide mimetic that has been shown to have excel-
Modified Nucleotide Linkages 
Some embodiments provide probes including a plurality 
of nucleic acids or oligonucleotides containing modified 
backbones or non-natural internucleoside linkages. Exem-
plary modified backbones include those that retain a phos-
phorus atom in the backbone and those that do not have a 
phosphorus atom in the backbone. 
45 lent hybridization properties, is referred to as a peptide 
nucleic acid (PNA). In PNA compounds, the sugar-back-
bone of an oligonucleotide is replaced with an amide con-
taining backbone, in particular an aminoethylglycine back-
bone. The nucleobases are retained and are bound directly or 
Representative modified oligonucleotide backbones 
include, for example, phosphorothioates, chiral phospho-
rothioates, phosphorodithioates, phosphotriesters, ami-
noalkylphosphotriesters, methyl and other alkyl phospho-
nates including 3'-alkylene phosphonates, 5'-alkylene 
phosphonates and chiral phosphonates, phosphinates, phos-
phoramidates including 3'-amino phosphoramidate and ami-
noalkylphosphoramidates, thionophosphoramidates, thion-
50 indirectly to aza nitrogen atoms of the amide portion of the 
backbone. Representative United States patents that teach 
the preparation of PNA compounds include, but are not 
limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719, 
262, each of which is herein incorporated by reference. 
55 Further teaching of PNA compounds can be found in 
Nielsen et al. (1991) Science 254:1497-1500. 
oalkylphosphonates, thionoalkylphosphotriesters, 60 
selenophosphates and boranophosphates having normal 3'-5' 
linkages, 2'-5' linked analogs of these, and those having 
inverted polarity wherein one or more intemucleotide link-
ages is a 3' to 3', 5' to 5' or 2' to 2' linkage. Some 
oligonucleotides having inverted polarity comprise a single 65 
3' to 3' linkage at the 3'-most internucleotide linkage i.e. a 
single inverted nucleoside residue which may be abasic (the 
Some embodiments provide probes having oligonucle-
otides with phosphorothioate backbones and oligonucleo-
sides with heteroatom backbones, and in particular --CH2-
NH--O-CH2-, --CH2-N(CH3)-0--CH2- [known 
as a methylene (methylimino) or MMI backbone], --CH2-
0-N(CH3)--CH2-, --CH2-N(CH3)-N(CH3)--CH2-
and --O-N(CH3)-CH2-CH2- [wherein the native 
phosphodiester backbone is represented as --O-P-O-
CH2-] of the above referenced U.S. Pat. No. 5,489,677, 
and the amide backbones of the above referenced U.S. Pat. 
No. 5,602,240. 
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In other embodiments, the probes may comprise modified 
oligonucleotides containing one or more substituted sugar 
moieties. Other modified oligonucleotides comprise one of 
the following at the 2' position: OH; F; 0-, S-, or N-alkyl; 
0-, S-, or N-alkenyl; 0-, S-, or N-alkynyl; or 0-alkyl- 5 
0-alkyl, wherein the alkyl, alkenyl and alkynyl may be 
substituted or unsubstituted c, to clO alkyl or c2 to clO 
alkenyl and alkynyl. Particularly preferred are O[(CH2)n0lm 
CH3, O(CH2)nOCH3, O(CH2)nNH2, O(CH2)nCH3, O(CH2)n 
ONH2, and O(CH2)nON[(CH2)nCH3b where n and mare 10 
from 1 to about 10. Other oligonucleotides comprise one of 
the following at the 2' position: C1 to C10 lower alkyl, 
substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl, 
0-alkaryl or 0-aralkyl, SH, SCH3, OCN, Cl, Br, CN, CF3, 
OCF3, SOCH3, S02CH3, ON02, N02, N3, NH2, heterocy- 15 
cloalkyl, heterocycloalkaryl, aminoalkylamino, polyalky-
lamino, substituted silyl, an RNA cleaving group, a reporter 
group, an intercalator, a group for improving the pharma-
cokinetic properties of the probe and other substituents 
having similar properties. Another modification includes 20 
2'-methoxyethoxy (2'-0--CH2CH20CH3, also known as 
2'-0-(2-methoxyethyl) or 2'-MOE) (Martin et al. (1995) 
Helv. Chim. Acta, 78, 486-504) i.e., an alkoxyalkoxy group. 
A further preferred modification includes 2'-dimethylami-
nooxyethoxy, i.e., a O(CH2)20N(CH3)2 group, also known 25 
as 2'-DMAOE, and 2'-dimethylaminoethoxyethoxy (also 
known in the art as 2'-0-dimethyl-amino-ethoxy-ethyl or 
2'-DMAEOE), i.e., 2'-0--CH2---0-CH2-N(CH3)2. 
Other modifications include 2'-methoxy (2'-0--CH3), 
2'-aminopropoxy (2'-0CH2CH2CH2NH2), 2'-allyl (2'- 30 
CH2--CH=CH2), 2'-0-allyl (2'-0--CH2--CH=CH2) and 
2'-fluoro (2'-F). The 2'-modification may be in the arabino 
(up) position or ribo (down) position. An exemplary 2'-ara-
bino modification is 2'-F. Similar modifications may also be 
made at other positions on the oligonucleotide, particularly 35 
the 3' position of the sugar on the 3' terminal nucleotide or 
in 2'-5' linked oligonucleotides and the 5' position of 5' 
terminal nucleotide. Oligonucleotides may also have sugar 
mimetics such as cyclobutyl moieties in place of the pento-
furanosyl sugar. Representative United States patents that 40 
teach the preparation of such modified sugar structures 
include, but are not limited to, U.S. Pat. Nos. 4,981,957; 
5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 
5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 
5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 45 
5,646,265; 5,658,873; 5,670,633; 5,792,747; and 5,700,920, 
and each of which is herein incorporated by reference in its 
entirety. 
A further modification includes Locked Nucleic Acids 
(LNAs) in which the 2'-hydroxyl group is linked to the 3' or 50 
4' carbon atom of the sugar ring thereby forming a bicyclic 
sugar moiety. The linkage is preferably a methelyne 
(--CH,-)n group bridging the 2' oxygen atom and the 4' 
carbon atom wherein n is 1 or 2. LNAs and preparation 
thereof are described in U.S. Pat. No. 6,268,490 and WO 55 
99/14226. 
20 
5-halouracil and cytosine, 5-propynyl uracil and cytosine 
and other alkynyl derivatives of pyrimidine bases, 6-azo 
uracil, cytosine and thymine, 5-uracil (pseudouracil), 
4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hy-
droxyl and other 8-substituted adenines and guanines, 5-halo 
particularly 5-bromo, 5-trifluoromethyl and other 5-substi-
tuted uracils and cytosines, 7-methylguanine and 7-methy-
ladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 
8-azaadenine, 7-deazaguanine and 7-deazaadenine and 
3-deazaguanine and 3-deazaadenine. Further modified 
nucleobases include tricyclic pyrimidines such as phenox-
azine cytidine (1H-pyrimido[5,4-b ][1,4]benzoxazin-2 (3H)-
one), phenothiazine cytidine (1H-pyrimido[5,4-b][l,4]ben-
zothiazin-2 (3H)-one ), G-clamps such as a substituted 
phenoxazine cytidine (e.g., 9-(2-aminoethoxy )-H-pyrimido 
[5,4-b][l,4]benzoxazin-2 (3H)-one), carbazole cytidine 
(2H-pyrimido[ 4,5-b ]indol-2-one ), pyridoindole cytidine 
(H-pyrido[3',2':4,5]pyrrolo[2,3-d]pyrimidin-2-one). Modi-
fied nucleobases may also include those in which the purine 
or pyrimidine base is replaced with other heterocycles, for 
example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyri-
dine and 2-pyridone. Further nucleobases include those 
disclosed in U.S. Pat. No. 3,687,808, those disclosed in The 
Concise Encyclopedia of Polymer Science and Engineering, 
pages 858-859, Kroschwitz, J. I., ed. John Wiley & Sons, 
1990, those disclosed by Englisch et al., Angewandte Che-
mie, International Edition, 1991, 30, 613, and those dis-
closed by Sanghvi, Y. S., Chapter 15, Antisense Research 
and Applications, pages 289-302, Crooke, S. T. and Lebleu, 
B., ed., CRC Press, 1993. Certain of these nucleobases may 
be particularly useful for increasing the binding affinity of 
the oligomeric compounds of the disclosure. These include 
5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 
and 0-6 substituted purines, including 2-aminopropylad-
enine, 5-propynyluracil and 5-propynylcytosine. 5-methyl-
cytosine substitutions have been shown to increase nucleic 
acid duplex stability by 0.6-1.2.degree. C. (Sanghvi, Y. S., 
Crooke, S. T. and Lebleu, B., eds., Antisense Research and 
Applications, CRC Press, Boca Raton, 1993. pp 276-278) 
and are presently preferred base substitutions, even more 
particularly when combined with 2'-0-methoxyethyl sugar 
modifications. 
Representative United States patents that teach the prepa-
ration of certain of the above noted modified nucleobases as 
well as other modified nucleobases include, but are not 
limited to, the above noted U.S. Pat. No. 3,687,808, as well 
as U.S. Pat. Nos. 4,845,205; 5,130,302; 5,134,066; 5,175, 
273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484, 
908; 5,502, 177; 5,525, 711; 5,552,540; 5,587,469; 5,594, 
121, 5,596,091; 5,614,617; 5,645,985; 5,830,653; 5,763, 
588; 6,005,096; and 5,681,941, and each of which is herein 
incorporated by reference. 
Fluorescence Energy Transfer 
Some embodiments provide compositions that contain a 
reporter moiety whose reporting ability changes depending 
on whether the probe is bound to its complement or target 
polynucleotide. For example, some probes are designed to 
take advantage of quenching by energy transfer, for example 
Oligonucleotides may also include nucleobase (often 
referred to in the art simply as "base") modifications or 
substitutions. As used herein, "unmodified" or "natural" 
nucleobases include the purine bases adenine (A) and gua-
nine (G), and the pyrimidine bases thymine (T), cytosine (C) 
and uracil (U) Modified nucleobases include other synthetic 
and natural nucleobases such as 5-methylcytosine (5-me-C), 
5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-ami-
noadenine, 6-methyl and other alkyl derivatives of adenine 
and guanine, 2-propyl and other alkyl derivatives of adenine 
and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 
60 fluorescence resonance energy transfer (FRET) or LRET 
(luminescence energy transfer) to detect and report binding 
to target molecules. Other embodiments do not include 
quenchers. In embodiments that do not include quenchers, 
the reporting ability changes depending on whether a donor 
65 probe hybridizes near the acceptor probe on the target 
polynucleotide. FRET is a highly distance-dependent inter-
action between a fluorescent reporter dye and a donor or 
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quencher. Energy is transferred from one molecule (the 
donor) to the other (the reporter or the quencher). Additional 
examples of reporting abilities may also include the use of 
interchelating dyes conjugated to nucleic acid probes, such 
that there is significant increase/decrease in signal upon 5 
binding to target polynucleotide. Further examples may 
include the use of reporters which change the polarization 
state of emission energy upon binding to target polynucle-
otide. 
10 
As noted above, some embodiments of the disclosed 
probes include a pair of labels. Other embodiments provide 
probes that are labeled with a single label, for example a 
quantum dot or a reporter. The single labeled probes are 
designed to work together so that the donor on one probe 15 
transfers energy to the reporter on a second probe. Repre-
sentative pairs of labels include, but are not limited to, at 
least one donor/quencher pair, for example a dye pair, or a 
dye and a non-dye quencher. In some embodiments, the pair 
of labels typically includes a fluorescent donor dye and a 20 
quencher for the donor fluorophore. In one embodiment, the 
labels are linked to a sequence or structure in the probe 
which does not hybridize directly to the target sequence. 
22 
tively quenches fluorescence from an adjacent fluorophore, 
e.g., fluorescein or 5-(2'-aminoethyl) aminonaphthalene 
(ED ANS). 
Any dye pair which produces fluorescence quenching in 
the disclosed probes are suitable for use in the disclosed 
methods, regardless of the mechanism by which quenching 
occurs. Terminal and internal labeling methods are also 
known in the art and may be routinely used to link the donor 
and quencher dyes at their respective sites in the probe. 
Protein Transduction Domains 
As noted above, certain embodiments of the present 
disclosure also include probes operably linked to a protein 
transduction domain. Several small regions (9-16 amino 
acids) of proteins called protein transduction domains 
(PTDs) or cell penetrating peptides (CPPs) that confer the 
ability to traverse biological membranes efficiently. Without 
wishing to be bound by any one theory, it is believed that 
some PTDs are able to cross a cell membrane in a receptor-
independent mechanism (Kabouridis, P. (2003) Trends in 
Biotechnology 21(11):498-503). Although several of PTDs 
have been documented, the two most commonly employed 
PTDs are derived from TAT protein of HIV (Frankel and 
Pabo (1988) Cell 55(6):1189-93) and Antennapedia tran-
The disclosed probes include any nucleic acid sequence or 
structure which can be labeled such that the presence of its 
complement or target polynucleotide indicates the presence 
25 scription factor from Drosophila, whose PTD is known as 
Penetratin (Derossi et al. (1994) J Biol. Chem. 271(30): 
18188-93). 
of the target sequence. In one embodiment, the probe moiety 
is labeled with a donor or a reporter or a donor/quencher dye 
pair such that donor fluorescence is quenched prior to the 30 
sequence specific binding of the probe to the target poly-
nucleotide, and such that quenching of donor fluorescence is 
reduced as an indication of the presence of the target. The 
disclosed probes may have a secondary structure such as a 
stem-loop (or hairpin) as described in U.S. Pat. No. 5,925, 35 
517 or a G-quartet as described in U.S. Pat. No. 5,691,145, 
or a random-coil (stem-less) structure. The secondary struc-
ture is labeled such that the donor and quencher are in close 
proximity when the secondary structure is folded, resulting 
in quenching of donor fluorescence. In the presence of a 40 
target, the secondary structure is unfolded in a target-
dependent reaction so that the distance between the donor 
and quencher is increased. This decreases quenching and 
produces an increase in donor fluorescence which can be 
detected as an indication of the presence of the target 45 
sequence. 
The Antennapedia homeodomain is 68 amino acid resi-
dues long and contains four alpha helices. Penetratin is an 
active domain of this protein which consists of a 16 amino 
acid sequence derived from the third helix of Antennapedia. 
(Fenton et al. (1998) J Immunol Methods 212(1):41-8). TAT 
protein consists of 86 amino acids and is involved in the 
replication of HIV-1. The TAT PTD consists of an 11 amino 
acid sequence domain (residues 47 to 57; YGRKKRRQRRR 
(SEQ ID NO. 38) of the parent protein that appears to be 
critical for uptake (Vives et al. (1997) J Biol. Chem. 272 
(25): 16010-7). Additionally, the basic domain Tat( 49-57) or 
RKKRRQRRR (SEQ ID NO. 39) (Wender et al. (2000) Proc 
Natl Acad Sci USA. 97(24): 13003-8) has been shown to be 
a PTD. In the current literature TAT has been favored for 
fusion to proteins of interest for cellular import. Several 
modifications to TAT, including substitutions of Glutatmine 
to Alanine, i.e., Q to A, have demonstrated an increase in 
cellular uptake anywhere from 90% (Wender et al. (2000) 
Proc Natl Acad Sci USA. 97(24):13003-8) to up to 33 fold 
in marnnialian cells. (Ho et al. (2001) Cancer Res. 61(2): 
4 7 4-7) The most efficient uptake of modified proteins was 
revealed by mutagenesis experiments ofTAT-PTD, showing 
For efficient FRET quenching to take place the fluoro-
phore and quencher molecules are typically less than about 
100 A apart. In some embodiments, the absorption spectrum 
of the quencher overlaps with the emission spectrum of the 
fluorophore. Many donor/quencher dye pairs known in the 
art are useful in some embodiments of the present invention. 
These include, for example, fluorescein isothiocyanate 
(FITC)/tetramethylrhodamine isothiocyanate (TRITC), 
FITC/Texas Red™ (Molecular Probes), FITC/N-hydrox-
ysuccinimidyl 1-pyrenebutyrate (PYB), FITC/eosin isothio-
cyanate (EITC), N-hydroxysuccinimidyl 1-pyrenesulfonate 
(PYS)/FITC, FITC/Rhodamine X, FITC/tetramethyl-
rhodamine (TAMRA), and others. 
50 that an 11 arginine stretch was several orders of magnitude 
more efficient as an intracellular delivery vehicle. Thus, 
some embodiments include PTDs that are cationic or amphi-
pathic. Additionally exemplary PTDs include but are not 
limited to poly-Arg-RRRRRRR (SEQ ID NO. 42); PTD-5-
55 RRQRRTSKLMKR (SEQ ID NO. 43); Transportan 
GWTLNSAGYLLGKINLKALMLAKKIL (SEQ ID NO. 
44); KALA-WEAKLAKALAKALAKHLAKALAKALK-
CEA (SEQ ID NO. 45); DAATATRGRSMSRPTERPRA-
PARSASRPRRPVE (SEQ ID NO. 46), and RQIKIWFQN-
60 RRMKWKK (SEQ ID NO. 47). For energy transfer quenching mechanisms donor/ 
quencher pairs can be selected so that the emission wave-
lengths of the donor fluorophore overlap the excitation 
wavelengths of the quencher or reporter, i.e., there must be 
sufficient spectral overlap between the two dyes to allow 
efficient energy transfer, charge transfer or fluorescence 65 
quenching. P-(dimethyl aminophenylazo) benzoic acid 
(DABCYL) is a non-fluorescent quencher dye which effec-
The disclosed probes can have the protein transduction 
domain linked directly or indirectly to the polynucleotide. 
One embodiment provides a probe having a modified mono-
mer, such as a nucleotide, to facilitate linking chemistries. 
The monomer can be modified with a reactive group such as 
an amine, carbonyl, carboxyl, and thiol or have a biotin 
group attached to the nucleotide. Such modified monomers 
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are known in the art, and are connnercially available and 
include modified nucleotides such as dT (Link Technologies, 
Scotland, UK). The protein transduction domain can be 
directly linked using conventional linking chemistry to the 
modified nucleotide or can be indirectly linked to the amine 
modified nucleotide using a linker or spacer group. The 
linker group can be linked to the modified nucleotide at one 
end, and linked to the PTD on the other end. 
In another embodiment, the protein transduction domain 
is operably linked to the probe using a streptavidin-biotin 10 
linkage. The probe includes a modified monomer, for 
example biotin-dT, in the region of the probe that is not 
complementary to the target polynucleotide, for example to 
the quencher arm of the stem. The linkage can be through a 
carbon linker. Protein transduction domains can be modified 15 
to include a biotin moiety. The modified PTD and the 
modified probe can then be linked through a streptavidin 
molecule. 
24 
of the probe to its target polynucleotide. Typically, the linker 
is modified to link the protein transduction domain or target 
signal via conventional linking chemistry. 
The linkers can be linked with or contain cleavable bonds, 
for example photo cleavable, thermally cleavable, or enzy-
matically cleavable bonds. Such bonds are known in the art. 
Upon entry into the cell, the cleavable bond can be cleaved. 
The cleavage of the bond can result in the separation of the 
PTD or targeting signal or both from the probe. 
Linking Chemistry 
Of the various linking chemistries that can be used to link 
molecules with other molecules or reagents, the most com-
mon are amine, carbonyl, carboxyl, and thiol. It will be 
appreciated by those of skill in the art, that any linking 
chemistry may be utilized. Indirect crosslinking of the 
amines in one molecule to the thiols in a second molecule is 
the predominant method for forming a heteroconjugate. If 
the probe, the linker, or the protein transduction domain does In another embodiment, a thiol-maleimide linkage is used 
to link the PTD to the probe. In one aspect, the non-
complementary region of the probe, for example, the stem 
region, in particular the stem region linked to a quencher, is 
modified by adding a thiol group to a monomer of the probe. 
The thiol group can react with a maleimide group placed at 
the C terminus of the PTD or targeting signal to form a 
linkage, in particular a direct and stable linkage. 
20 not already contain one or more thiol groups, the thiol 
groups can be introduce using a thiolation procedure. 
Thiol groups (also called mercaptans or sulfhydryls) are 
present in cysteine residues of proteins. Thiols can also be 
generated by selectively reducing cystine disulfides with 
25 reagents such as dithiothreitol (DTT) or -mercaptoethanol. 
Removal of DTT or -mercaptoethanol is sometimes accom-
panied by air oxidation of the thiols back to the disulfides. 
Reformation of the disulfide bond can be avoided by using 
the reducing agent tris-(2-carboxyethyl)phosphine (TCEP), 
Another embodiment incorporates a cleavable disulfide 
bridge in which the PTD or targeting signal is modified by 
adding a cysteine residue at the C terminus which forms a 
disulfide bridge with the thiol-modified probe. This disulfide 
bridge design allows the PTD or targeting signal to be 
cleaved from the probe by the reducing environment of the 
cytoplasm. 
Another embodiment allows for combined synthesis of 
the delivery peptide sequence along with the probe, for 
example, in the case of a PNA probe, where both the 
delivery peptide and the nucleic acid probe sequence can be 
generated using a single peptide. Further the linkage 
between the delivery peptide and the nucleic acid probe can 
be tailored to allow for specific cleavage using reducing 
disulfide bridge or using enzymatic cleavage sites in the 
linkage. 
30 which does not contain thiols. TCEP is generally imperme-
able to cell membranes and to the hydrophobic protein core, 
permitting its use for the selective reduction of disulfides 
that have aqueous exposure. The pH-insensitive and less 
polar phosphine derivative tris-(2-cyanoethyl)phosphine 
35 may yield greater reactivity with buried disulfides. 
Several methods are available for introducing thiols into 
molecules, including the reduction of intrinsic disulfides, as 
well as the conversion of amine, aldehyde or carboxylic acid 
groups to thiol groups. Disulfide crosslinks, for example of 
40 cystines in proteins, can be reduced to cysteine residues by 
dithiothreitol, tris-(2-carboxyethyl)phosphine or tris-(2-cya-
noethyl)phosphine. 
Amines can be indirectly thiolated by reaction with suc-
cinimidyl 3-(2-pyridyldithio )propionate, followed by reduc-
45 tion of the 3-(2-pyridyidithio )propionyl conjugate with DTT 
or TCEP. Alternatively, amines can be indirectly thiolated by 
reaction with succinimidyl acetylthioacetate, followed by 
removal of the acetyl group with 50 mM hydroxylamine or 
hydrazine at near-neutral pH. 
Another embodiment allows for indirect linkage of the 
probe with delivery peptide, e.g., the delivery vehicle itself 
may be dendrimer-based or lipid-based such as liposomes/ 
polymeric or any combination of the above, in which nucleic 
acid probes are packaged inside the delivery vehicle, with 
delivery peptides attached to the surface of such construct. 
The attached delivery peptides (single or multiple types) 
may allow efficient delivery of the probes to a specific organ, 50 
tissue, cell type or subcellular compartment. 
Linkers 
Thiols can also be incorporated at carboxylic acid groups 
by an EDAC-mediated reaction with cystamine, followed by 
reduction of the disulfide with DTT or TCEP. Tryptophan 
residues in thiol-free proteins can be oxidized to mercap-
totryptophan residues, which can then be modified by 
55 iodoacetamides or maleimides. 
The disclosed probes can be linked to a protein transduc-
tion domain or targeting signal via a linker or spacer. The 
linker can be one or more monomer units including atoms, 
amino acids, nucleic acids, sugars, or natural or synthetic 
polymer monomers. Generally, the linker is composed of 
monomers that are substantially inert or do not otherwise 
chemically react once coupled to the probe. Representative 
linkers include alkyl linkers of 1 to 12 carbons, typically 
about 6 carbons. The alkyl groups of the linker can be 
substituted, for example with alkyl or aryl groups, hetero-
cycles, halogens, and the like. The number of monomers of 
the linker can vary, however, the linker should have enough 65 
monomers to prevent the protein transduction domain or 
targeting signal from sterically interfering with the binding 
Thiol-reactive functional groups are primarily alkylating 
reagents, including iodoacetamides, maleimides, benzylic 
halides and bromomethylketones. Arylating reagents such as 
NBD halides react with thiols or amines by a similar 
60 substitution of the aromatic halide. Reaction of any of these 
functional groups with thiols usually proceeds rapidly at or 
below room temperature in the physiological pH range (pH 
6.5-8.0) to yield chemically stable thioethers. 
Thiols also react with many of the amine-reactive 
reagents described in including isothiocyanates and succin-
imidyl esters. Although the thiol-isothiocyanate product (a 
dithiocarbamate) can react with an adjacent amine to yield 
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a thiourea, the dithiocarbamate is more likely to react with 
water, consuming the reactive reagent without forming a 
covalent adduct. 
Iodoacetamides readily react with all thiols, including 
those found in peptides, proteins and thiolated polynucle-
otides, to form thioethers. Iodoacetamides can sometimes 
react with methionine residues. They may also react with 
histidine or tyrosine, but generally only if free thiols are 
absent. Although iodoacetamides can react with the free base 
form of amines, most aliphatic amines, except the amino 10 
group at a protein's N-terminus, are protonated and thus 
relatively unreactive below pH 8. In addition, iodoaceta-
mides react with thiolated oligonucleotide primers, as well 
26 
Targeting Signals 
The disclosed probes can also include targeting signals or 
domains that target the probe to a specific cell, tissue or 
organ as well as specific intracellular locations or organelles. 
Such target signals are known in the art. For example, 
nuclear targeting signals can be found in the Nuclear Local-
ization Signal Database at http://cubic.bioc.columbia.edu/ 
db/NLSdb/ which is incorporated by reference herein in its 
entirety. 
Representative nuclear localization signals include, but 
are not limited to, SV 40 T antigen or a fragment thereof, 
such as PKKKRKV (SEQ ID NO. 48). The NLS can be 
simple cationic sequences of about 4 to about 8 amino acids, 
or can be bipartite having two interdependent positively as with thiophosphates and thiouridine residues present in 
certain nucleic acids, but usually not with the common 
nucleotides. 
Iodoacetamides are intrinsically unstable in light, espe-
cially in solution; reactions should therefore be carried out 
under subdued light. Adding cysteine, glutathione or mer-
captosuccinic acid to the reaction mixture will quench the 
reaction of thiol-reactive probes, forming highly water-
soluble adducts that are easily removed by dialysis or gel 
filtration. Although the thioether bond formed when an 
iodoacetamide reacts with a protein thiol is very stable, 
during amino acid hydrolysis the bioconjugate loses its 
fluorophore to yield S-carboxymethylcysteine. 
15 charged clusters separated by a mutation resistant linker 
region of about 10-12 amino acids. Additional representative 
NLS include but are not limited to GKKRSKV (SEQ ID NO. 
49); KSRKRKL (SEQ ID NO. 50); KRPMTKK-
AGQAKKKKLDK (SEQ ID NO. 51); RKKRK-
20 TEEESPLKDKAKKSK (SEQ ID NO. 52); KDCVMNKH-
HRNRCQYCRLQR (SEQ ID NO. 53); PMKRVKLD (SEQ 
ID NO. 54); and KKYENWIKRSPRKRGRPRK (SEQ ID 
NO. 55). 
The targeting signal can also target the probe to the 
25 mitochondria which are also known in the art. Representa-
tive mitochondrial targeting signals include, but are not 
limited to include the mitochondrial localization signal of 
subunit VIII of human cytochrome oxidase, the yeast cyto-Maleimides are excellent reagents for thiol-selective 
modification, quantitation and analysis. The reaction 
involves addition of the thiol across the double bond of the 30 
maleimide to yield a thioether. Maleimides apparently do 
not react with methionine, histidine or tyrosine. Reaction of 
maleimides with amines usually requires a higher pH than 
reaction of maleimides with thiols. Hydrolysis of maleim-
ides to a mixture of isomeric nonreactive maleamic acids 35 
can compete significantly with thiol modification, particu-
larly above pH 8. Furthermore, maleimide adducts can 
hydrolyze or they can ring-open by nucleophilic reaction 
with an adjacent amine to yield crosslinked products. This 
latter reaction can potentially be enhanced by raising the pH 40 
above 9 after conjugation. 
For example, a disulfide-containing linker or spacer, 
including but not limited to an alkyl linker or spacer of about 
1 to about 12 carbon atoms, is photo- or thermally coupled 
chrome c oxidase subunit IV presequence and the amino-
terminal leader peptide of the rat ornithine-transcarbamy-
lase. 
The identification of the specific sequences necessary for 
translocation of a linked probe into a chloroplast or mito-
chondria can be determined using predictive software 
known to those skilled in the art, including the tools located 
at http://www.mips.biochem.mpg.de/cqi-bin/proi/medgen/ 
mitofilter. 
Targeting signals can also include vitamins such as folate 
to target the probes to cells having a high number of folate 
receptors, including but not limited to, cancer cells. Asia-
loglycoprotein receptor ligands can also be linked to the 
disclosed probes to target them to the liver. For example, 
N-acetylgalactosamine containing peptides, asialoorosomu-
coid, and galactoside-containing cluster ligands can be used. 
Targeting sequences can also be synthetic small mol-
ecules/ligands with high affinity for specific compartments 
in addition to specific localizing sequences, e.g. mitochon-
dria can be targeted using amphiphilic synthetic molecules. 
to the target nucleobase or polynucleotide using conven- 45 
tional chemistry, for example azide chemistry. The disulfide 
bond is reduced, yielding a free thiol. A covalent bond is 
formed between the reagent thiol and a thiol-reactive linker, 
hapten, fluorochrome, sugar, affinity ligand, or other mol-
ecule. 50 Dual Labeled Probes 
One embodiment provides a composition for the detection 
of a target polynucleotide comprising, a first nucleic acid 
probe that hybridizes to a first nucleic acid target sequence 
on the target polynucleotide, forms a stem-loop structure 
The linking of two molecules can be achieved using 
heterobifunctional crosslinkers. Representative heterobi-
functional crosslinkers include, but are not limited to, p-ma-
leimidophenyl isocyanate; succinimidyl acetylthioacetate; 
succinimidyl-trans-4(maleimidylmeythyl)-cyclohexane-
lcarboxylate (SMCC); succinimidyl acetylthioacetate 
(SATA); succinimidyl 3-(2-pyridyldithio )propionate 
(SPDP); N-( (2-pyridyldithio )ethyl)-4-azidosalicylamide 
55 when not bound to the first nucleic acid target sequence, and 
incorporates a energy transfer donor moiety. This embodi-
ment of the disclosure further provides a second nucleic acid 
probe that hybridizes to a second nucleic acid target 
(PEAS; AET); 4-azido-2,3,5,6-tetrafluorobenzoic acid, suc-
cinimidyl ester (ATFB, SE); 4-azido-2,3,5,6-tetrafluoroben- 60 
zoic acid, STP ester, sodium salt (ATFB, STP ester); 
4-azido-2,3,5,6-tetrafluorobenzyl amine, hydrochloride; 
benzophenone-4-isothiocyanate; benzophenone-4-maleim-
ide; 4-benzoylbenzoic acid, succinimidyl ester. The hetero-
bifunctional crosslinkers can be photoreactive, amine and/or 65 
thiol reactive, or aldehyde/ketone reactive, or a combination 
thereof. 
sequence on the target polynucleotide, forms a stem-loop 
structure when not bound to the second nucleic acid target 
sequence, and incorporates a energy transfer acceptor moi-
ety. The disclosure provides that the first nucleic acid target 
sequence and the second nucleic acid target sequence are 
separated by a number of nucleotides on the target poly-
nucleotide such that a energy transfer signal from interaction 
between the donor moiety of the first nucleic acid probe and 
the acceptor moiety of the second nucleic acid probe can be 
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detected to determine hybridization of both the first nucleic 
acid probe and the second nucleic acid probe to the target 
polynucleotide. Preferably, the energy transfer signal is a 
florescent or luminescent signal. 
28 
the energy transfer source used, and can be routinely deter-
mined by one of skill in the art in view of the present 
disclosure. 
In one embodiment, the resonance energy signals are due 
to fluorescence resonance energy transfer (FRET) or lumi-
nescence resonance energy transfer (LRET). In embodi-
ments wherein the energy transfer signal is due to fluores-
cence energy transfer, the donor moiety can be for example 
a 6-Fam fluorophore. In embodiments wherein the energy 
transfer signal is due to fluorescence energy transfer, the 
acceptor moieties can be Cy-3, ROX or Texas Red. Addi-
tional examples of FRET donor and acceptor moieties useful 
in the present disclosure are provided below. 
In other embodiments, the energy transfer signal is due to 
luminescence energy transfer (LRET) and the donor moiety 
is a lanthanide chelate. In some one embodiment where the 
resonance energy signal is due to LRET, the donor moiety 
can be Europium or Terbium. Furthermore, in some embodi-
ments where the resonance energy signal is due to LRET, the 
donor moiety can be a lanthanide chelate such as DTPA-
cytosine, DTPA-cs124, BCPDA, BHHCT, Isocyanato-
EDTA, Quantum Dye, or Wl 024 and the acceptor moiety 
can be Cy-3, ROX or Texas Red. In some embodiments, due 
to the range of effective energy transfer of the lanthanide 
chelate, multiple acceptor moieties may be employed. The 
donor moiety can be a lanthanide chelate and the acceptor 
moiety can be a phycobiliprotein. In certain embodiments, 
In an alternative embodiment, the disclosure provides a 
first nucleic acid probe that hybridizes to a first nucleic acid 
target sequence on the target polynucleotide, and incorpo-
rates a luminescence energy transfer lanthanide chelate 
donor moiety; and second nucleic acid probe that hybridizes 10 
to a second nucleic acid target sequence on the target 
polynucleotide, and incorporates an organic energy transfer 
acceptor moiety, wherein the first nucleic acid target 
sequence and the second nucleic acid target sequence are 
separated by a number of nucleotides on the target poly- 15 
nucleotide such that a luminescence energy transfer signal 
from interaction between the lanthanide chelate donor moi-
ety of the first nucleic acid probe and the acceptor moiety of 
the second nucleic acid probe can be detected to determine 
hybridization of both the first nucleic acid probe and the 20 
second nucleic acid probe to the target polynucleotide. In 
certain embodiments of this disclosure, the first nucleic acid 
probe or second nucleic acid probe is linear or randomly 
coiled when not hybridized to the first or second nucleic acid 
target sequences, respectively. In other embodiments of this 25 
disclosure, the first nucleic acid probe or second nucleic acid 
probe forms a stem-loop structure when not hybridized to 
the first or second nucleic acid target sequences, respec-
tively. 
30 the phycobiliprotein is Red Phycoerythrin (RPE), Blue 
Phycoerythrin (BPE), or Allophycocyanin (APC). Addi-
tional examples ofLRET donor and acceptor moieties useful 
in the present disclosure are provided below. 
In certain one embodiment of the disclosure, the first 
nucleic acid probe further incorporates a quencher moiety, 
such that an interaction between the donor moiety of the first 
nucleic acid probe and the quencher moiety can be detected 
to differentiate between the first nucleic acid probe in the 35 
stem-loop (or random-coil) structure and non-stem-loop (or 
non-random-coil) structure. Similarly, in other embodi-
ments, the second nucleic acid probe further incorporates a 
quencher moiety, such that an interaction between the accep-
tor moiety of the second nucleic acid probe and the quencher 40 
moiety can be detected to differentiate between the second 
nucleic acid probe in the stem-loop (or random-coil) struc-
ture and non-stem-loop (or non-random-coil) structure. In 
embodiments utilizing a quencher moiety on a nucleic acid 
probe, the disclosure provides that the quencher moiety can 45 
be selected from, for example, dabcyl quencher, black hole 
quencher or Iowa Black quencher or other moieties well-
known in the art to change the energy transfer wavelength 
emission of an unquenched donor or acceptor moiety. 
In certain other embodiments, the first nucleic acid probe 50 
further incorporates a energy transfer moiety pair, such that 
a energy transfer signal from interaction between the donor 
moiety and the acceptor moiety on the first nucleic acid 
probe can be detected to differentiate between the first 
nucleic acid probe in the stem-loop structure and non-stem- 55 
loop structure. Similarly, other embodiments provide that 
the second nucleic acid probe further incorporates a energy 
transfer moiety pair, such that a energy transfer signal from 
interaction between the donor moiety and the acceptor 
moiety on the second nucleic acid probe can be detected to 60 
differentiate between the second nucleic acid probe in the 
stem-loop structure and non-stem-loop structure. 
In certain embodiments, the disclosure provides that the 
first or second nucleic acid probes each comprise from 5 to 
50 nucleotides, 10 to 40 nucleotides, or 15, 16, 17, 18, 19, 
20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides. In 
other one embodiment, the nucleic acid probes comprise a 
2'-0-methyl nucleotide backbone, among many alternative 
or synthetic nucleotides, described below. The disclosure 
further provides that one end of the first and/or the second 
nucleic acid probes participates in both stem-loop formation 
and hybridization to the target polynucleotide. Such embodi-
ments are referred to herein as a shared-stem molecular 
beacon, or probe, herein, and are described in more detail 
below, particularly in Example 2. 
In additional embodiments, the disclosure provides meth-
ods for detecting a target polynucleotide, comprising com-
bining the composition described herein with a sample 
suspected of containing a target polynucleotide, and detect-
ing hybridization by differential energy transfer signal to 
determine the presence or absence, and/or the expression 
level of the target polynucleotide in the sample in vitro or in 
vivo. In some one embodiment, the methods can be per-
formed in vivo. Therefore, in a preferred embodiment ofthis 
method, the sample contains a living cell. The disclosure 
provides that the methods may be performed with samples 
comprising cell lysates, tissue extracts, living tissues and 
cells that are taken out of the body, or that remain in situ. 
The methods of the present disclosure further include 
detection of changes in the levels of expression of a nucleic 
acid target, or in RNA transcript, such that alterations of 
gene expression can be monitored as a result of the dose-
In various embodiments, the first nucleic acid target and 
the second nucleic acid target are separated by 1 to 20 
nucleotides, or separated by 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 
13, 14, or 15 nucleotides. As discussed below, the preferred 
number of separating nucleotides will vary depending upon 
65 dependent cellular response to external stimuli, such as drug 
molecules, hormones, growth factors, temperature, shear 
flow, or microgravity, for example. The disclosure further 
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provides that the compositions can be used to visualize, i.e., 
through fluorescence or luminescence, the location and 
relative amount of gene expression in tissues and cells. 
In diagnostic or prognostic detection methods the target 
polynucleotide can comprise a genetic point mutation, dele-
tion, or insertion relative to a naturally occurring or control 
nucleic acid. Such screening methods can permit the detec-
tion of the target polynucleotide indicating the presence of 
30 
a genetically associated disease, such as certain cancers, in 
the sample. There are many well-known examples of genetic 
mutations already in the art that are indicative of a disease 
state. The methods include the detection of nucleic acids 
comprising K-ras, survivin, p53, p16, DPC4, or BRCA2. 
Furthermore, the methods can be used to detect the amount 
disclosure can be achieved by employing an oligonucleotide 
probe with a lanthanide chelate as the donor and a molecular 
beacon with a traditional organic fluorophore as the acceptor 
(reporter) moiety. In contrast to organic fluorophores that 
have a fluorescence lifetime of -10 ns, lanthanide chelates 
can have emission lifetimes greater than 1 ms. The mecha-
nism that is responsible for the long lifetime emission of 
lanthanide chelates is complex and involves energy transfer 
from the triplet state of the aromatic ligand. Specifically, 
10 
upon excitation the ligand is excited to its singlet state and 
then undergoes an intersystem transition to its triplet state, 
whereas the energy is either quenched by water molecules or 
transferred to the lanthanide ion. Fluorescence is then emit-
of a target polynucleotide being produced by an organism 15 
for purposes other than diagnosis or prognosis of a disease 
ted from the lanthanide ion as it returns to the ground state 
(Lemmetyinen et al., 2000). Since such fluorescence emis-
sion does not result from a singlet-to-singlet transition, the 
use of lanthanide chelates as a donor results in luminescent 
energy transfer (LRET). Therefore, by using pulse excitation 
or condition. Energy transfer detections of the present dis-
closure can be performed with the assistance of single- or 
multiple-photon microscopy, time-resolved fluorescence 
microscopy or fluorescence endoscopy, as detailed below. 20 and time-gating techniques, it is possible to selectively 
record emission after the background fluorescence from 
organic dyes, scattering, and autofluorescence has decayed. 
The only signals remaining in this long-time domain are the 
emission from the lanthanide chelate and from acceptor 
The disclosure further provides kits for the detection of a 
target polynucleotide comprising the nucleic acid probe 
compositions described herein, necessary reagents and 
instructions for practicing the methods of detection. Such 
alternative compositions, methods and kits therefor are 25 
described in more detail by way of the examples, and still 
others will be apparent to one of skill in the art in view of 
the present disclosure. 
fluorophores that have participated in LRET. In this case the 
narrow emission peaks of a lanthanide chelate render the 
background fluorescence close to zero at certain wave-
lengths, leading to extremely large signal-to-background 
ratio. The donor probe in a LRET pair can be a simple linear 
probe, i.e., neither quencher nor hairpin structure are nec-
essary. 
Furthermore, the disclosure provides a design variant for 
molecular beacons where one arm of the stem participates in 
both hairpin formation and target hybridization, referred to 
herein as "shared-stem" molecular beacons. In contrast, 
conventional molecular beacons are designed such that the 
loop sequence is complementary to the target while the stem 
sequences are self-complementary but unrelated to the target 
sequence. This new design offers certain advantages over 
conventional molecular beacon design, especially in two-
probe fluorescence energy transfer, for example fluorescence 
resonance energy transfer (FRET) assays. The disclosure 
provides the thermodynamic and kinetic properties of both 
shared-stem and conventional molecular beacons and makes 
One embodiment of the present disclosure provides com-
positions and methods that measure a energy transfer, for 30 
example, a fluorescent signal due to FRET or LRET as a 
result of direct interaction between two molecular beacons 
when hybridized to the same target polynucleotide of inter-
est. This method can dramatically reduce false-positive 
signals in gene detection and quantification in living cells. 35 
As shown in FIG. 1 and alternatively in FIG. 11, this 
approach utilizes a pair of molecular beacons, one with a 
donor fluorophore and a second with an acceptor fluoro-
phore. Probe sequences are chosen such that the molecular 
beacons hybridize adjacent to each other on a single nucleic 40 
acid target in a way that positions their respective fluoro-
phores in optimal configuration for FRET (Mergny et al., 
1994; Sixou et al. 1994). Emission from the acceptor fluo-
rophore serves as a positive signal in the FRET based 
detection assay. 
If acceptor and donor fluorophores are well matched, 
excitation of the donor can be achieved at a wavelength that 
has little or no capacity to excite the acceptor; excitation of 
the acceptor will therefore only occur if both molecular 
beacons are hybridized to the same target polynucleotide 50 
and FRET occurs. Molecular beacons that are degraded or 
open due to protein interactions will result in the presence of 
unquenched fluorophore, however, fluorescence emitted 
from these species is different in character from the signal 
obtained from donor/acceptor FRET pair, making back- 55 
ground and true positive signal more readily differentiated. 
Thus, by detecting FRET instead of direct single-molecule 
fluorescence, nucleic acid probe/target binding events can be 
distinguished from false-positives. 
45 a systematic comparison between them. In particular, the 
present description quantifies the changes in enthalpy and 
entropy upon the formation of probe/target duplexes as 
determined by the probe and stem lengths. Further provided 
herein is a study of the melting behavior, specificity, and 
hybridization on-rate depend on the stem length of molecu-
lar beacons, such that one of skill in the art may make and 
use a variety of embodiments to suit the specific purposes of 
each situation. 
The nucleic acid probes of the disclosure utilize the 
principle of energy transfer between a donor moiety and an 
acceptor moiety. In a preferred embodiment, the energy 
transfer is fluorescence energy transfer, for example fluo-
rescence resonance energy transfer (FRET), in which the 
first and second probes are labeled with donor and acceptor 
moieties, respectively, wherein the donor moiety is a fluo-
rophore and the acceptor moiety may be a fluorophore, such 
that fluorescent energy emitted by the donor moiety is 
absorbed by the acceptor moiety when both probes are 
hybridized to the first and second target sequences respec-
In contrast to prior labeling of two linear oligonucleotide 60 
probes with donor and acceptor fluorophores, the stem-loop 
hairpin structure of molecular beacons offers further reduc-
tion in background fluorescence as well as enhanced speci-
ficity, which is helpful particularly when detection of allelic 
variants or point mutations is desired. 65 tively on the same nucleic acid subject. In one embodiment 
of the present disclosure, the acceptor moiety is a fluoro-
phore that releases the energy absorbed from the donor at a 
Further benefit from another embodiment of the dual 
energy transfer molecular beacons and method of the present 
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different wavelength; the emissions of the acceptor may then 
be measured to assess the progress of the hybridization 
reaction. 
32 
target polynucleotide can be a sense strand of one of the 
target polynucleotide sequences, an anti-sense sequence, or 
naturally occurring mutants thereof. Preferably, the nucleic 
acid target is an mRNA. 
Probes based on the nucleotide sequences can be used to 
detect or amplify transcripts or genomic sequences encoding 
the same or homologous proteins. In other embodiments, the 
probe further comprises a label group attached thereto, e.g., 
the label group can be a radioisotope, an enzyme, or an 
In a preferred embodiment, the probe is a hairpin stem-
loop structure (often referred to in the art as a molecular 
beacon) that contains either a donor or acceptor moiety and 
optionally a quencher moiety, such that the quencher moiety 
reduces the fluorescence of the donor or acceptor when the 
probe is in the stem-loop structure (i.e., not hybridized). 
When the probe is hybridized to the target polynucleotide in 
this embodiment, its conformation changes, eliminating the 
quenching effect, and the resulting fluorescence of the donor 
or acceptor moiety may be detected. In certain cases, the 
probe has a random-coil (stem-les) structure. 
10 enzyme co-factor. Such probes can be used as a part of a 
genomic marker test kit for identifying cells which express 
a particular protein, such as by measuring a level of the 
protein-encoding nucleic acid in a sample of cells, e.g., 
detecting the target polynucleotide mRNA levels or deter-
In an alternative embodiment, the present disclosure pro-
vides a nucleic acid probe that forms a hairpin stem-loop (or 
15 mining whether the gene encoding the mRNA has been 
mutated or deleted. 
a random-coil) structure in which energy transfer will 
decrease when the probe is hybridized with the target 
polynucleotide. In such an embodiment, the quencher moi-
ety on the first probe is replaced with a reciprocating moiety 20 
to form a energy transfer moiety pair, and the differential in 
energy transfer is detectable between the hairpin stem-loop 
structure and a non-stem-loop structure. Alternatively, the 
quencher moiety on the second probe is replaced with a 
reciprocating moiety to form a energy transfer moiety pair, 25 
and the differential in energy transfer is detectable between 
the hairpin stem-loop structure and a non-stem-loop struc-
ture. In such embodiments of the present disclosure, a third 
energy transfer moiety pair forms by the dual probes, a 
donor moiety on the first probe, and an acceptor moiety on 30 
the second probe, such that the energy transfer signal due to 
the interaction of donor and acceptor may be measured to 
assess the progress of the hybridization reaction of both 
probes on the target polynucleotide. 
In an additional preferred embodiment, an isolated 
nucleic acid molecule of the disclosure comprises a nucleic 
acid probe sequence that hybridizes, e.g., hybridizes under 
stringent conditions, to a target nucleotide sequence of 
interest. These hybridization conditions include washing 
with a solution having a salt concentration of about 0.02 
molar at pH 7 at about 60° C. As used herein, the term 
"hybridizes under stringent conditions" is intended to 
describe conditions for hybridization and washing under 
which nucleotide sequences at least 60% homologous to 
each other typically remain hybridized to each other. Pref-
erably, the conditions are such that sequences at least about 
65%, more preferably at least about 70%, and even more 
preferably at least about 75% or more homologous to each 
other typically remain hybridized to each other. Such strin-
gent conditions are known to those skilled in the art and can 
be found in Current Protocols in Molecular Biology, John 
Wiley & Sons, N.Y. (1989) 6.3.1-6.3.6. A preferred, non-
limiting example of stringent hybridization conditions are 
hybridization in 6x sodium chloride/sodium citrate (SSC) at 
about 45° C., followed by one or more washes in 0.2xSSC, 
0.1 % SDS at 50-65° C. As used herein, a "naturally-
occurring" nucleic acid molecule refers to an RNA or DNA 
molecule having a nucleotide sequence that occurs in nature 
(e.g., encodes a natural protein). 
Nucleic acid probes of the disclosure may be synthesized 
by standard methods known in the art, e.g. by use of an 
automated DNA synthesizer (such as are commercially 
One aspect of the disclosure pertains to nucleic acids 35 
sufficient for use as hybridization probes for the identifica-
tion of a target polynucleotide (e.g., DNA or mRNA). As 
used herein, the term "nucleic acid" is intended to include 
DNA molecules (e.g., cDNA or genomic DNA) and RNA 
molecules (e.g., mRNA) and analogs of the DNA or RNA 40 
generated using nucleotide analogs. As referred to herein, 
nucleic acids that are "complementary" can be perfectly or 
imperfectly complementary, as long as the desired property 
resulting from the complementarity is not lost, e.g., ability to 
hybridize. 45 available from Biosearch, Applied Biosystems, etc.). As 
examples, phosphorothioate oligonucleotides may be syn-
thesized by the method of Stein et al. (1988, Nucl. Acids 
Res. 16:3209), methylphosphonate oligonucleotides can be 
The nucleic acids of the present disclosure may be sub-
stantially isolated or alternatively unpurified. An "isolated" 
or "purified" nucleic acid is one that is substantially sepa-
rated from other nucleic acid molecules that are present in 
the natural source of the nucleic acid. Preferably, an "iso- 50 
lated" nucleic acid is substantially free of sequences that 
naturally flank the nucleic acid (i.e., sequences located at the 
5' and 3' ends of the nucleic acid) in the genomic DNA of the 
organism from which the nucleic acid is derived. Moreover, 
an "isolated" nucleic acid molecule can be substantially free 55 
of other cellular material, or culture medium when produced 
by recombinant techniques, or chemical precursors or other 
chemicals when chemically synthesized. (see, Sambrook et 
al. 2001, Molecular Cloning: A Laboratory Manual. 3rd, 
ed., Cold Spring Harbor Laboratory, Cold Spring Harbor 60 
Laboratory Press, Cold Spring Harbor, N.Y.). 
The probe typically comprises substantially purified 
nucleic acid. The nucleic acid probe typically comprises a 
region of nucleotide sequence that hybridizes to at least 
about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 65 
21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45 or 50 
consecutive nucleotides of a target polynucleotide. The 
prepared by use of controlled pore glass polymer supports 
(Sarin et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7448-
7451), etc. 
Once the desired oligonucleotide is synthesized, it is 
cleaved from the solid support on which it was synthesized 
and treated, by methods known in the art, to remove any 
protecting groups present. The oligonucleotide may then be 
purified by any method known in the art, including extrac-
tion and gel purification. The concentration and purity of the 
oligonucleotide may be determined by examining oligo-
nucleotide that has been separated on an acrylamide gel, or 
by measuring the optical density at 260 nm in a spectro-
photometer. 
Nucleic acid probes of the disclosure may be labeled with 
donor and acceptor moieties during chemical synthesis or 
the label may be attached after synthesis by methods known 
in the art. In a specific embodiment, the following donor and 
acceptor pairs are used: a luminescent lanthanide chelate, 
e.g., terbium chelate or lanthanide chelate, is used as the 
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donor, and an organic dye such as fluorescein, rhodamine or 
CY-5, is used as the acceptor. Preferably, terbium is used as 
34 
a donor and fluorescein or rhodamine as an acceptor, or 
europium is used as a donor and CY-5 as an acceptor. In 
another specific embodiment, the donor is fluorescent, e.g. 5 
fluorescein, rhodamine or CY-5, and the acceptor is lumi-
nescent, e.g. a lanthanide chelate. In yet another embodi-
ment, the energy donor is luminescent, e.g., a lanthanide 
chelate, and the energy acceptor may be non-fluorescent. 
Phenol Red 
B-phycoerythrin 
o-phthaldialdehyde 
Pyrene and Derivatives: 
pyrene 
pyrene butyrate 
succinimidy 1 1-pyrene butyrate 
Reactive Red 4 (Cibacron® Brilliant Red 3B-A) 
In another specific embodiment, the donor moiety is a 10 
fluorophore. In another specific embodiment, both donor and 
acceptor moieties are fluorophores. Suitable moieties that 
can be selected as donor or acceptors in FRET pairs are set 
below: 
Rhodamine and Derivatives: 
6-carboxy-X-rhodamine (ROX) 
6-carboxyrhodamine (R6G) 
lissamine rhodamine B sulfonyl chloride 
rhodamine (Rhod) 
4-acetamido-4'-isothiocyanatostilbene-2,2'disulfonic 
Acridine and Derivatives: 
Acid 15 rhodamine B 
rhodamine 123 
acridine 
acridine isothiocyanate 
5-(2'-aminoethyl)aminonaphthalene-l-sulfonic acid 
(ED ANS) 
4-amino-N-[3-vinylsulfonyl)phenyl]naphthalimide-3,5dis-
ulfonate(LuciferYellow VS) 
N-( 4-anilino-1-naphthyl)maleimide 
Anthranilamide 
Brilliant Yellow 
Coumarin and Derivatives: 
coumann 
7-amino-4-methylcoumarin (AMC, Coumarin 120) 
7-amino-4-trifluoromethylcoumarin (Coumarin 151) 
cyanosine 
4'-6-diaminidino-2-phenylindole (DAPI) 
5',5"-dibromopyrogallol-sulfonephthalein (Bromopyro-
gallol Red) 
7 -diethy lamino-3-( 4 '-isothiocyanatophenyl )-4-methylcou-
marin diethylenetriamine pentaacetate 
4-( 4'-diisothiocyanatodihydro-stilbene-2,2'-disulfonic acid 
4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid 
5-[ dimethylamino ]naphthalene-1-sulfonyl chloride (DNS, 
dansyl chloride) 
4-( 4'-dimethylaminophenylazo )benzoic acid (DABCYL) 
4-dimethy laminophenylazopheny 1-4 '-isothiocyanate 
(DAB ITC) 
Eosin and Derivatives: 
eosm 
eosin isothiocyanate 
Erythrosin and Derivatives: 
erythrosin B 
erythrosin isothiocyanate 
ethidium 
Fluorescein and Derivatives: 
5-carboxyfluorescein (FAM) 
5-( 4,6-dichlorotriazin-2-yl)aminofluorescein (DTAF) 
2'7'-dimethoxy-4'5'-dichloro-6-carboxyfluorescein (JOE) 
fluorescein 
fluorescein isothiocyanate 
QFITC (XRITC) 
fluorescamine 
IR144 
IR1446 
Malachite Green isothiocyanate 
4-methylumbelliferone 
ortho cresolphthalein 
nitrotyrosine 
pararosaniline 
rhodamine X isothiocyanate 
sulforhodamine B 
sulforhodamine 101 
20 sulfonyl chloride derivative of sulforhodamine 101 (Texas 
Red) 
N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA) 
tetramethyl rhodamine 
tetramethyl rhodamine isothiocyanate (TRITC) 
25 riboflavin 
rosolic acid 
terbium chelate derivatives 
One of ordinary skill in the art can easily determine, using 
art-known techniques of spectrophotometry, which fluoro-
30 phores will make suitable donor-acceptor FRET pairs. For 
example, FAM (which has an emission maximum of 525 
nm) is a suitable donor for TAMRA, ROX, and R6G (all of 
which have an excitation maximum of 514 nm) in a FRET 
pair. Probes are preferably modified during synthesis, such 
35 that a modified T-base is introduced into a designated 
position by the use of Amino-Modifier C6 dT (Glen 
Research), and a primary amino group is incorporated on the 
modified T-base, as described by Ju et al. (1995, Proc. Natl. 
Acad. Sci. USA 92:4347-4351 ). These modifications may be 
40 used for subsequent incorporation of fluorescent dyes into 
designated positions of the nucleic acid probes of the present 
disclosure. 
The optimal distance between the donor and acceptor 
moieties will be that distance wherein the emissions of the 
45 donor moiety are maximally absorbed by the acceptor 
moiety. This optimal distance varies with the specific moi-
eties used, and may be easily determined by one of ordinary 
skill in the art using well-known techniques. For energy 
transfer in which it is desired that the acceptor moiety be a 
50 fluorophore that emits energy to be detected, the donor and 
acceptor fluorophores are preferably separated when hybrid-
ized to target polynucleotide by a distance of up to 30 
nucleotides, more preferably from 1-20 nucleotides, and still 
more preferably from 2 to 10 nucleotides and more prefer-
55 ably separated by 3, 4, 5, 6, 7, 8 and 9 nucleotides. For 
energy transfer wherein it is desired that the acceptor moiety 
quench the emissions of the donor, the donor and acceptor 
moieties are preferably separated by a distance of less than 
10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 nucleotide (e.g., on the opposite 
60 strand, complementary nucleotides of a duplex structure), 
although a 5 nucleotide distance (one helical tum) is also 
advantageous for use. 
In yet another embodiment, the nucleic acid probes of the 
disclosure may be further labeled with any other art-known 
65 detectable marker, including radioactive labels such as 32P, 
35 S, 3H, and the like, or with enzymatic markers that 
produce detectable signals when a particular chemical reac-
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tion is conducted, such as alkaline phosphatase or horserad-
ish peroxidase. Such enzymatic markers are preferably heat 
stable, so as to survive the denaturing steps of the amplifi-
cation process. Nucleic acid probes may also be indirectly 
labeled by incorporating a nucleotide linked covalently to a 
hapten or to a molecule such as biotin, to which a labeled 
avidin molecule may be bound, or digoxygenin, to which a 
labeled anti-digoxygenin antibody may be bound. Nucleic 
acid probes may be supplementally labeled during chemical 
synthesis or the supplemental label may be attached after 
synthesis by methods known in the art. 
The nucleic acid probes of the disclosure have use in 
nucleic acid detection, or amplification reactions as primers, 
or in the case oftriamplification, blocking oligonucleotides, 
to detect or measure a nucleic acid product of the amplifi-
cation, thereby detecting or measuring a target polynucle-
otide in a sample that is complementary to a 3' primer 
sequence. Accordingly, the nucleic acid probes of the dis-
closure can be used in methods of diagnosis, wherein a 
sequence is complementary to a sequence (e.g., genomic) of 
an infectious disease agent, e.g. of human disease including 
but not limited to viruses, bacteria, parasites, and fungi, 
thereby diagnosing the presence of the infectious agent in a 
sample of nucleic acid from a patient. The target polynucle-
otide can be genomic or cDNA or mRNA or synthetic, 
human or animal, or of a microorganism, etc. 
In one embodiment the disclosure provides a useful 
screening tool for drug discovery where a rapid specific and 
sensitive assay can detect in vivo changes in the expression, 
suppression, mutation, or interaction of polynucleotides of 
interest, either at a steady state or in response to the 
administration of drug candidates. In another embodiment 
that can be used in the diagnosis or prognosis of a pathology, 
syndrome, disease or disorder. The target polynucleotide can 
be a naturally occurring, wild type, or genomic DNA, RNA 
or cDNA sequence, the mutation or alteration of which can 
indicate the presence or predisposition of a pathology, 
disease or disorder. Generally, a healthy organism expresses 
a target polynucleotide having a first sequence. An organism 
having a pathology or predisposition of a pathology typi-
cally expresses a variation of the target polynucleotide. The 
variation of the target polynucleotide includes deletions, 
mutations, substitutions, transpositions, insertions, inver-
sions, single-nucleotide polymorphisms, and combinations 
thereof. In some instances, an organism having a pathology 
or predisposition of a pathology may not express a target 
polynucleotide, express reduced levels of the target poly-
nucleotide, or express excessive levels of the target poly-
nucleotide compared to levels of the target polynucleotide 
expressed by a healthy organism. Alternatively, the target 
polynucleotide can be a mutated or altered sequence. In one 
embodiment, an amplification reaction can be repeated for a 
same sample with different sets of probes that amplify, 
respectively, the naturally occurring sequence or the mutated 
version. By way of example, the mutation can be an inser-
tion, substitution, and/or deletion of one or more nucle-
otides, or a translocation. 
Pharmaceutical Compositions 
Pharmaceutical compositions and dosage forms of the 
disclosure comprise a pharmaceutically acceptable salt of 
disclosed or a pharmaceutically acceptable polymorph, sol-
vate, hydrate, dehydrate, co-crystal, anhydrous, or amor-
phous form thereof. Specific salts of disclosed compounds 
include, but are not limited to, sodium, lithium, potassium 
salts, and hydrates thereof. 
36 
Pharmaceutical compositions and unit dosage forms of 
the disclosure typically also comprise one or more pharma-
ceutically acceptable excipients or diluents. Advantages 
provided by specific compounds of the disclosure, such as, 
but not limited to, increased solubility and/or enhanced flow, 
purity, or stability (e.g., hygroscopicity) characteristics can 
make them better suited for pharmaceutical formulation 
and/or administration to patients than the prior art. 
Pharmaceutical unit dosage forms of the compounds of 
10 this disclosure are suitable for oral, mucosa! (e.g., nasal, 
sub lingual, vaginal, buccal, or rectal), parenteral (e.g., intra-
muscular, subcutaneous, intravenous, intraarterial, or bolus 
injection), topical, or transdermal administration to a patient. 
Examples of dosage forms include, but are not limited to: 
15 tablets; caplets; capsules, such as hard gelatin capsules and 
soft elastic gelatin capsules; cachets; troches; lozenges; 
dispersions; suppositories; ointments; cataplasms (poul-
tices); pastes; powders; dressings; creams; plasters; solu-
tions; patches; aerosols (e.g., nasal sprays or inhalers); gels; 
20 liquid dosage forms suitable for oral or mucosa! adminis-
tration to a patient, including suspensions (e.g., aqueous or 
non-aqueous liquid suspensions, oil-in-water emulsions or 
water-in-oil liquid emulsions), solutions, and elixirs; liquid 
dosage forms suitable for parenteral administration to a 
25 patient; and sterile solids (e.g., crystalline or amorphous 
solids) that can be reconstituted to provide liquid dosage 
forms suitable for parenteral administration to a patient. 
The composition, shape, and type of dosage forms of the 
compositions of the disclosure will typically vary depending 
30 on their use. For example, a dosage form used in the 
detection of nucleic acids involved in a disease or disorder 
but expressed at a low level may contain larger amounts of 
the probe, for example the disclosed compounds or combi-
nations thereof, than a dosage form used to detect nucleic 
35 acids that are overexpressed in a disease or disorder. Simi-
larly, a parenteral dosage form may contain smaller amounts 
of the probe than an oral dosage form used to detect the same 
disease or disorder. These and other ways in which specific 
dosage forms encompassed by this disclosure will vary from 
40 one another will be readily apparent to those skilled in the 
art. See, e.g., Remington's Pharmaceutical Sciences, 18th 
ed., Mack Publishing, Easton, Pa. (1990). 
Typical pharmaceutical compositions and dosage forms 
comprise one or more excipients. Suitable excipients are 
45 well known to those skilled in the art of pharmacy or 
pharmaceutics, and non-limiting examples of suitable 
excipients are provided herein. Whether a particular excipi-
ent is suitable for incorporation into a pharmaceutical com-
position or dosage form depends on a variety of factors well 
50 known in the art including, but not limited to, the way in 
which the dosage form will be administered to a patient. For 
example, oral dosage forms such as tablets or capsules may 
contain excipients not suited for use in parenteral dosage 
forms. The suitability of a particular excipient may also 
55 depend on the specific active ingredients in the dosage form. 
For example, the decomposition of some active ingredients 
can be accelerated by some excipients such as lactose, or 
when exposed to water. Active ingredients that comprise 
primary or secondary amines are particularly susceptible to 
60 such accelerated decomposition. 
The disclosure further encompasses pharmaceutical com-
positions and dosage forms that comprise one or more 
compounds that reduce the rate by which an active ingre-
dient will decompose. Such compounds, which are referred 
65 to herein as "stabilizers," include, but are not limited to, 
antioxidants such as ascorbic acid, pH buffers, or salt 
buffers. In addition, pharmaceutical compositions or dosage 
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forms of the disclosure may contain one or more solubility 
modulators, such as sodium chloride, sodium sulfate, 
sodium or potassium phosphate or organic acids. A specific 
solubility modulator is tartaric acid. 
Like the amounts and types of excipients, the amounts and 
specific type of active ingredient in a dosage form may differ 
depending on factors such as, but not limited to, the route by 
which it is to be administered to patients. However, typical 
dosage forms of the compounds of the disclosure comprise 
a pharmaceutically acceptable salt, or a pharmaceutically 10 
acceptable polymorph, solvate, hydrate, dehydrate, co-crys-
tal, anhydrous, or amorphous form thereof, in an amount 
sufficient to detect the target polynucleotide and include a 
range of from about 10 mg to about 1000 mg, preferably in 
an amount of from about 25 mg to about 750 mg, and more 15 
preferably in an amount of from 50 mg to 500 mg. 
Additionally, the compounds and/or compositions can be 
delivered using lipid- or polymer-based nanoparticles. For 
example, the nanoparticles can be designed to improve the 
pharmacological and therapeutic properties of drugs admin- 20 
istered parenterally (Allen, T. M., Cullis, P. R. Drug delivery 
systems: entering the mainstream. Science. 303(5665): 1818-
22 (2004)). 
38 
solid forms comprising a carrier or one or more excipients 
compatible with topical application and having a dynamic 
viscosity preferably greater than water are typically 
employed. Suitable formulations include, without limitation, 
solutions, suspensions, emulsions, creams, ointments, pow-
ders, liniments, salves, and the like, which are, if desired, 
sterilized or mixed with auxiliary agents (e.g., preservatives, 
stabilizers, wetting agents, buffers, or salts) for influencing 
various properties, such as, for example, osmotic pressure. 
Other suitable topical dosage forms include sprayable aero-
sol preparations wherein the active ingredient, preferably in 
combination with a solid or liquid inert carrier, is packaged 
in a mixture with a pressurized volatile (e.g., a gaseous 
propellant, such as freon), or in a squeeze bottle. Moistur-
izers or humectants can also be added to pharmaceutical 
compositions and dosage forms if desired. Examples of such 
additional ingredients are well known in the art. See, e.g., 
Remington's Pharmaceutical Sciences, 18th Ed., Mack Pub-
lishing, Easton, Pa. (1990). 
Transdermal and mucosa! dosage forms of the composi-
tions of the disclosure include, but are not limited to, 
ophthalmic solutions, patches, sprays, aerosols, creams, 
lotions, suppositories, ointments, gels, solutions, emulsions, Parenteral Dosage Forms 
Parenteral dosage forms can be administered to patients 25 suspensions, or other forms known to one of skill in the art. 
See, e.g., Remington's Pharmaceutical Sciences, 18th Ed., 
Mack Publishing, Easton, Pa. (1990); and Introduction to 
Pharmaceutical Dosage Forms, 4th Ed., Lea & Febiger, 
30 Philadelphia, Pa. (1985). Dosage forms suitable for treating 
mucosa! tissues within the oral cavity can be formulated as 
mouthwashes, as oral gels, or as buccal patches. Additional 
transdermal dosage forms include "reservoir type" or 
"matrix type" patches, which can be applied to the skin and 
by various routes, including, but not limited to, subcutane-
ous, intravenous (including bolus injection), intramuscular, 
and intraarterial. Since administration of parenteral dosage 
forms typically bypasses the patient's natural defenses 
against contaminants, parenteral dosage forms are prefer-
ably sterile or capable of being sterilized prior to adminis-
tration to a patient. Examples of parenteral dosage forms 
include, but are not limited to, solutions ready for injection, 
dry products ready to be dissolved or suspended in a 
pharmaceutically acceptable vehicle for injection, suspen-
sions ready for injection, and emulsions. In addition, con-
trolled-release parenteral dosage forms can be prepared for 
administration of a patient, including, but not limited to, 
administration DUROS®-type dosage forms, and dose-
40 dumping. 
35 worn for a specific period of time to permit the penetration 
of a desired amount of active ingredient. 
Suitable vehicles that can be used to provide parenteral 
dosage forms of the disclosure are well known to those 
skilled in the art. Examples include, without limitation: 
sterile water; Water for Injection USP; saline solution; 
45 glucose solution; aqueous vehicles such as but not limited to, 
Sodium Chloride Injection, Ringer's Injection, Dextrose 
Injection, Dextrose and Sodium Chloride Injection, and 
Lactated Ringer's Injection; water-miscible vehicles such 
as, but not limited to, ethyl alcohol, polyethylene glycol, and 
50 propylene glycol; and non-aqueous vehicles such as, but not 
limited to, corn oil, cottonseed oil, peanut oil, sesame oil, 
ethyl oleate, isopropyl myristate, and benzyl benzoate. 
Compounds that alter or modify the solubility of a phar-
maceutically acceptable salt of a disclosed composition 
55 herein can also be incorporated into the parenteral dosage 
forms of the disclosure, including conventional and con-
trolled-release parenteral dosage forms. 
Examples of transdermal dosage forms and methods of 
administration that can be used to administer the active 
ingredient(s) of the disclosure include, but are not limited to, 
those disclosed in U.S. Pat. Nos. 4,624,665; 4,655,767; 
4,687,481; 4,797,284; 4,810,499; 4,834,978; 4,877,618; 
4,880,633; 4,917,895; 4,927,687; 4,956,171; 5,035,894; 
5,091,186; 5,163,899; 5,232,702; 5,234,690; 5,273,755; 
5,273,756; 5,308,625; 5,356,632; 5,358,715; 5,372,579; 
5,421,816; 5,466;465; 5,494,680; 5,505,958; 5,554,381; 
5,560,922; 5,585,111; 5,656,285; 5,667,798; 5,698,217; 
5,741,511; 5,747,783; 5,770,219; 5,814,599; 5,817,332; 
5,833,647; 5,879,322; and 5,906,830, each of which are 
incorporated herein by reference in their entirety. 
Suitable excipients (e.g., carriers and diluents) and other 
materials that can be used to provide transdermal and 
mucosa! dosage forms encompassed by this disclosure are 
well known to those skilled in the pharmaceutical arts, and 
depend on the particular tissue or organ to which a given 
pharmaceutical composition or dosage form will be applied. 
With that fact in mind, typical excipients include, but are not 
limited to water, acetone, ethanol, ethylene glycol, propy-
lene glycol, butane-1,3-diol, isopropyl myristate, isopropyl Topical, Transdermal and Mucosa! Dosage Forms 
Topical dosage forms of the disclosure include, but are not 
limited to, creams, lotions, ointments, gels, shampoos, 
sprays, aerosols, solutions, emulsions, and other forms know 
60 palmitate, mineral oil, and mixtures thereof, to form dosage 
forms that are non-toxic and pharmaceutically acceptable. 
to one of skill in the art. See, e.g., Remington's Pharma-
ceutical Sciences, 18th ed., Mack Publishing, Easton, Pa. 
(1990); and Introduction to Pharmaceutical Dosage Forms, 65 
4th ed., Lea & Febiger, Philadelphia, Pa. (1985). For non-
sprayable topical dosage forms, viscous to semi-solid or 
Depending on the specific tissue to be treated, additional 
components may be used prior to, in conjunction with, or 
subsequent to treatment with pharmaceutically acceptable 
salts of the disclosed compositions. For example, penetra-
tion enhancers can be used to assist in delivering the active 
ingredients to or across the tissue. Suitable penetration 
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enhancers include, but are not limited to: acetone; various 
alcohols such as ethanol, oleyl, an tetrahydrofuryl; alkyl 
sulfoxides such as dimethyl sulfoxide; dimethyl acetamide; 
dimethyl formamide; polyethylene glycol; pyrrolidones 
such as polyvinylpyrrolidone; Kollidon grades (Povidone, 
Polyvidone ); urea; and various water-soluble or insoluble 
sugar esters such as TWEEN 80 (polysorbate 80) and SPAN 
60 (sorbitan monostearate). 
The pH of a pharmaceutical composition or dosage form, 
or of the tissue to which the pharmaceutical composition or 10 
dosage form is applied, may also be adjusted to improve 
delivery of the active ingredient(s). Similarly, the polarity of 
40 
utes. The oligonucleotides were additionally purified by 
IE-HPLC using a Source™ column (Amersham Pharmacia 
Biotech, Piscataway, N.J.) and eluted with a linear 0% to 
50% 1 M LiCl gradient in 0.1 M Tris pH 8.0 over 40 
minutes. Unmodified (target) oligonucleotides were purified 
using polyacrylamide gel electrophoresis. All oligonucle-
otides were synthesized at Integrated DNA Technologies, 
Inc. (Coralville, Iowa). 
Probe and Target Design. All oligonucleotide probes were 
designed to be complementary in antisense orientation to the 
human GAPDH gene, as illustrated in FIG. 2. Specifically, 
a dabcyl quencher was attached to the 5'-end and a 6-Fam 
fluorophore was attached to the 3'-end of donor molecular 
beacons; a dabcyl quencher was attached to the 3'-end and 
either a Cyanine 3 (Cy3), 6-carboxyrhodamine (ROX), or 
Texas Red fluorophore was attached to the 5'-end of acceptor 
molecular beacons. The stem sequence was designed to 
participate in both hairpin formation and target hybridization 
(Tsourkas et al., 2002b). This beacon design was chosen to 
help fix the relative distance between the donor and acceptor 
fluorophores and improve energy transfer efficiency. Both 
the donor and acceptor beacons were designed with a probe 
a solvent carrier, its ionic strength, or tonicity can be 
adjusted to improve delivery. Compounds such as stearates 
can also be added to pharmaceutical compositions or dosage 15 
forms to advantageously alter the hydrophilicity or lipophi-
licity of the active ingredient(s) so as to improve delivery. In 
this regard, stearates can serve as a lipid vehicle for the 
formulation, as an emulsifying agent or surfactant, and as a 
delivery-enhancing or penetration-enhancing agent. Differ- 20 
ent hydrates, dehydrates, co-crystals, solvates, polymorphs, 
anhydrous, or amorphous forms of the pharmaceutically 
acceptable salt of a disclosed composition can be used to 
further adjust the properties of the resulting composition. 
25 length of 18 bases and a stem length of 5 bases. The probe 
length is defined as the portion of the molecular beacon that 
is complementary to the target. The synthetic wild-type 
GAPDH target has 4-base gap between the donor dye and 
the acceptor dye. Gap spacing was adjusted to 3, 5, and 6 
bases by either removing a guanine residue or adding 1 or 2 
thymine residues, as shown in Table 1. 
EXAMPLES 
Example 1 
Dual Nucleic Acid Probes 
Oligonucleotide Synthesis. Oligonucleotide probes and 
targets were synthesized using standard phosphoramidite 
TABLE 1 
Design of Probes and Target Oligonucleotides 
Name Sequence (5'-3') Note 
Fam donor-MB ( 1 l Dabcyl-ccacaTGATGGCATGGACTGTGG-Fam SEQ ID NO:l Probe 18/Stem 5 
Tb donor probe TGATGGCATGGACTGTGG-DTPA-cs124-(Tb) SEQ ID N0:2 Probe 18/Stem 0 
Cy3 acceptor-MB Cy3-GAGTCCTTCCACGATACCgactc-Dabcyl SEQ ID N0:3 Probe 18/Stem 5 
ROX acceptor-MB ROX-GAGTCCTTCCACGATACCgactc-Dabcyl SEQ ID N0:4 Probe 18/Stem 5 
Texas Red Texas Red-GAGTCCTTCCACGATACCgactc-Dabcyl SEQ ID NO:S Probe 18/Stem 5 
acceptor-MB 
Target( 2 l n - 1 ACTTTGGTATCGTGGAAGGACTCATACCACAGTCCATGCCATCA CTGCC SEQ ID N0:6 3 base gap 
Target n (WT) ACTTTGGTATCGTGGAAGGACTCATGACCACAGTCCATGCCATCA CTGCC SEQ ID N0:7 4 base gap 
Target n + 1 ACTTTGGTATCGTGGAAGGACTCATTGACCACAGTCCATGCCATCA CTGCC SEQ ID N0:8 5 base gap 
Target n + 2 ACTTTGGTATCGTGGAAGGACTCATTTGACCACAGTCCATGCCATCA CTGCC SEQ ID N0:9 6 base gap 
(llMB =Molecular Beacon. Lower case =bases added to create stem domains. Upper case =probe-target 
hlbridizing domains. Upper case bold ~ bases participating in both stem formation and target binding 
( lunderscore = 18 base sequence complementary to MB target binding domains. n = 4 bases the wild-type 
gap size 
chemistry on an Applied Biosystems model 394 automated 
DNA synthesizer (Foster City, Calif.). Molecular beacons 
were purified using dual reverse phase (RP) plus ion-
exchange (IE) high performance liquid chromatography 
(HPLC) on a Waters Model 600E HPLC system (Millipore 
Corp., Milford, Mass.). For RP-HPLC purification, oligo-
nucleotides were loaded on a Hamilton PRP-1 column and 
eluted with a linear 5% to 50% acetonitrile gradient in 0.1 
M triethyl-ammonium acetate (TEM) pH 7.2 over 40 min-
Lanthanide Chelate Synthesis. A linear oligonucleotide 
with a probe length of 18 bases was labeled at its 3'-end with 
60 a diethylenetriaminepentaacetic acid (DTPA) chelate 
covalently joined to a sensitizer, cs124 (Cooper and 
Sanimes, 2000). As demonstrated in Table 1, the sequence of 
this linear probe was identical to the probe domain of the 
donor molecular beacons specific for exon 7 of the human 
65 GAPDH gene. 
The lanthanide chelate was prepared by first dissolving 
DTPA (500 mg, 1.4 µmole) in 30 mL ofDMF and 1 mL of 
US 7,297,494 B2 
41 
triethylamine. Cs124 (240 mg, 1.4 µmole), dissolved in 4 
mL of DMF, was then added dropwise and mixed for 30 
minutes. To this mixture, 5 mL (75 µmole) of ethylenedi-
amine (EDA) was added and stirred at room temperature for 
two hours. The mixture was then stored in the refrigerator 
overnight. A slightly off-white precipitate had formed and 
was centrifuged down further. The DMF supernatant was 
removed and the pellet was washed with isopropanol several 
times and then with ether resulting in a fine white powder, 
which was dried under a vacuum for 2 hours. The powder 
was resuspended in water and RP-HPLC purified using a 
Hamilton PRP-1 colunm. The sample was eluted with a 
linear 0% to 30% acetonitrile gradient in 0.1 M TEAA pH 
7 .2 over 20 minutes at a flow rate of 10 mL/min. The first 
peak was collected, and the DTPA-cs124 product was dried 
and reconstituted to a concentration of 15 mM in 0.1 M 
Borate Buffer, pH 8.5. 
Disuccinimidyl suberate (1.84 mg, 5 µmoles; Pierce 
Chemical) was dissolved in 100 µL ofDMSO and added to 
10 
15 
0.1 µmoles of oligonucleotides with a 3'-amine, dissolved in 
100 uL ofDMSO. The mixture was incubated at 40° C. for 20 
2 hours. The oligonucleotides were then acetone precipitated 
and reconstituted in 100 µI of0.1 M sodium borate pH 8.5. 
42 
TABLE 2 
Maximal Excitation and Emission Wavelengths of Organic and 
Lanthanide Dyes 
Dye Excitation Emission Extinction Coefficient 
Molecule (nm) (nm) (M- 1 · cm- 1) Note 
6-Fam 494 518 83,000 Donor 
Terbium 300-340 546 10,000-35 ,000 Donor 
Chelate 
Europium 300-340 620 10,000-35 ,000 Donor 
Chelate 
Cy3 552 570 150,000 Acceptor 
Rox 585 605 82,000 Acceptor 
Taxes Red 583 603 116,000 Acceptor 
FRET of Organic Dye Pairs. A series of solution-phase 
assays were conducted to determine whether the signal 
generated by a pair of molecular beacons hybridized to the 
same target oligonucleotide can be differentiated from the 
signal due to false-positive events. For organic dye pairs, the 
same donor beacon (i.e., a molecular beacon with a fluo-
rescent donor dye) was tested with three acceptor (reporter) 
beacons for the magnitudes of background signal and posi-
25 tive (FRET) signal. Here, "background" is defined as fluo-
rescence detected from one or both beacons in the absence 
of target or from either beacon alone in the presence of 
target. Thus background represents any fluorescence emis-
50 uL of 1.5 mM DTPA-cs124-EDA product in borate buffer 
was added to the oligonucleotide solution and mixed over-
night. Oligonucleotide-DTPA-cs124-EDA conjugates were 
purified using reversed-phase (RP)HPLC. The oligonucle-
otides were loaded on a PRP-1 colunm and eluted with a 
linear 5% to 50% acetonitrile gradient in 0.1 M TEM pH 7.2 
over 40 minutes. The collected peak was lyophilized and 
reconstituted in dH20 at 5 µM. TbCl3 (Terbium) dissolved in 30 
PBS was then added to the sample at a 10: 1 molar ratio and 
incubated at room temperature for 30 minutes. The 
Europium chelates were synthesized following the same 
protocol. 
sion detected in the absence of a FRET event due to the 
simultaneous hybridization of the donor and acceptor bea-
cons to the same target. If fluorescence excitation is limited 
to wavelengths Ae optimal for the donor fluorophore and 
signal detection is limited to wavelengths Ad optimal for the 
acceptor (reporter) fluorophore, fluorescent signal should be 
35 low unless both beacons hybridize to the same target and 
FRET occurs. However, since fluorescence from organic 
fluorophores occurs over a broad range of wavelengths, it is 
possible for fluorescence emission from the donor at Ad and 
from the acceptor due to direct excitation at Ae to contribute 
Hybridization and Detection Assays. Hybridization 
experiments were conducted with 50 pmoles of donor bea-
con, 50 pmoles of acceptor beacon and 50 pmoles of 
complementary target in a total volume of 100 µL (0.5 µM). 
All experiments were conducted at 37° C. in HB buffer 
containing 10 mM KC!, 5 mM MgCl2 , and 10 mM Tris-HCI, 
pH 7.5, which was supplemented with 1% Bovine Albumin 
Serum to block non-specific interactions with the micro-
plate. The samples were mixed and allowed to equilibrate at 
37° C. for 20 minutes before performing fluorometry. A 
Satire microplate fluorometer (Tecan, Zurich, Switzerland) 45 
was used to excite the donor beacons and detect resulting 
emission (500 nm to 650 nm) in FRET measurements. The 
excitation wavelength was varied from 395 nm to 495 nm to 
determine the wavelength that resulted in the maximal 
FRET between the donor and acceptor molecules. In a 50 
two-photon experimental set-up, the excitation spectra of 
Fam- and Cy3-labeled linear oligonucleotides were 
obtained. A tunable laser was adjusted to excite the samples 
40 to background. "Positive signal" is defined as FRET-induced 
fluorescence detected when both beacons are bound to the 
same target, again restricting excitation to wavelengths Ae 
and limiting detection to wavelengths Ad. 
As illustrated in Table 1, the donor molecular beacon was 
labeled with 6-Fam on the 3'-end, and the acceptor molecu-
lar beacons were labeled with Cy3, ROX, or Texas Red on 
the 5'-end. Sequences of donor and acceptor molecular 
beacons were chosen to be complementary to adjacent sites 
within exon 6 and exon 7 of the human GAPDH gene and 
were positioned with a four base separation between donor 
and acceptor fluorophores when wild-type target was used. 
at wavelengths ranging from 700 nm to 875 nm. The 
fluorescence emission between 505 nm and 555 nm was 55 
Four types of assays were performed with each donor/ 
acceptor beacon pair: (1) both donor and acceptor beacons 
in the absence of target, with a typical emission spectrum 
(i.e., fluorescence intensity as a function of wavelength) 
shown as curve a in FIG. 3 (spectrum a); (2) donor beacon detected from the Fam sample and the emission between 590 
and 650 nm was detected from the Cy3 sample using 
ultra-sensitive, low noise avalanche photodiodes. 
For LRET measurements, the Terbium and Europium 
donor probes were excited at a wavelength of 325 nm, and 
the emission was recorded from 500 nm to 650 nm for 
assays with Terbium donors, and from 550 nm to 750 nm for 
assays involving Europium donors. The emission detection 
had a lag time of 50 µs with an integration time of 1 ms. The 
maximal excitation and emission wavelengths of the organic 
and lanthanide dyes used in this study are summarized in 
Table 2. 
only in the presence of target, with a typical emission 
spectrum shown as curve b in FIG. 3 (spectrum b ); (3) 
acceptor beacon only in the presence of target, with a typical 
60 emission spectrum shown as curve c in FIG. 3 (spectrum c); 
and (4) both donor and acceptor beacons in the presence of 
target, with a typical emission spectrum shown as curve d in 
FIG. 3 (spectrum d). Assays (2) and (3) simulate the limiting 
false positive scenario where most of the molecular beacons 
65 open as a result of nuclease degradation, denaturation, or 
non-specific protein interactions (which hereafter will col-
lectively be referred to as 'degraded' beacons). 
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To illustrate the advantages of using duel FRET molecular 
beacons and to compare the performance of different accep-
tor molecular beacons, several signal-to-background ratios 
were calculated. As illustrated in FIG. 3, the first is S:BdMB' 
the ratio of the peak fluorescence intensity of emission 
spectrum b defined above for donor molecular beacons 
44 
Moreover, as A was increased from 455 nm to 475 nm the 
value of S:Bdeg increased from -2 to over 10 and remained 
around 10 for A>475 nm, as demonstrated in FIG. 4c. 
Therefore, the signal generated by binding of both donor and 
acceptor beacons to a target could be 10 times brighter than 
false-positive signals. An example of the spectra generated 
using the Fam-Texas Red FRET pair is given in FIG. 5. ( dMB) to that of emission spectrum a at the same wave-
length. Although spectrum a was generated with both the 
donor and acceptor beacons in solution, the fluorescence 
signal is largely due to the donor beacons, for the emission 
Although the performance of dual FRET molecular bea-
10 cons is better than non-FRET molecular beacons due to 
of the acceptor beacons at the corresponding wavelength is 
almost zero, as can be seen from curve c in FIG. 3. Thus, 
S:BdMB represents the signal-to-background ratio of the con-
ventional single molecular beacon assay. The second is 
S:BaMB' the ratio of the peak fluorescence intensity of 15 
emission spectrum d of the acceptor molecular beacon 
(aMB) due to FRET to that of emission spectrum a at the 
same wavelength. Clearly, S:BaMB represents the signal-to-
background ratio of the dual FRET molecular beacons assay 
without degraded beacons. The third one, S:Bdeg' is defined 20 
as the ratio of the peak fluorescence intensity of emission 
spectrum d due to FRET to that of emission spectrum b or 
c at the same wavelength, whichever is higher. S:Bdeg 
represents the signal-to-background ratio of the dual FRET 
molecular beacons assay for the limiting case that most of 25 
the donor and acceptor beacons are being degraded. Here, 
with up to lxl05 molecular beacons per cell, the probability 
of having both degraded donor and acceptor beacons at the 
same spatial location (i.e., within a cylinder of 0.2 µm in 
diameter and 1 µm in thickness) in a fluorescence imaging 30 
assay is small. This is especially true considering that, with 
chemical modifications of the beacon backbone, only a 
small fraction ( <50%) of the molecular beacons would be 
degraded in an intracellular environment. It is worth men-
tioning that all the signal-to-background ratios discussed 35 
above change with the donor excitation wavelength. As 
shown in FIG. 4a, S:BaMB of the FRET assay with Cy3-
labeled acceptor beacons was almost identical to S:BdMB of 
the donor beacon alone over the entire range of excitation 
wavelengths tested. Neither parameter varied significantly, 40 
ranging between 20 and 25, as the excitation wavelength A 
was increased. The dual FRET molecular beacons, however, 
did generate a signal 2 to 3 times stronger compared with 
that of degraded beacons, i.e., S:Bdeg has a value of 2-3, 
while conventional molecular beacons cannot differentiate 45 
between signals due to degraded and hybridized probes. 
Signal enhancement upon molecular beacon/target binding 
is strongly affected by cation concentration and temperature. 
In this case, the S:Bdeg was relatively low since the assay 
temperature of 37° C. was near the stem melting tempera- 50 
ture. 
increased signal-to-background ratio and the ability to dif-
ferentiate between bound and degraded molecular beacons, 
the peak fluorescence intensity of the acceptor beacons was 
typically lower than that of the Fam-labeled donor beacons, 
as shown in FIG. 6. Specifically, at wavelengths where 
optimal FRET signal-to-background ratios were obtained, 
for Fam-Texas Red FRET pair the peak signal intensity of 
the acceptor was only about 40% of that emitted by the 
Fam-donor alone, and only about 25% for the Fam-ROX 
FRET pair, which may limit ultimate sensitivity. 
The efficiency E of fluorescence energy transfer between 
the donor and acceptor fluorophores varies according to 
(1) 
where R is the distance between donor and acceptor dyes, 
and R0 is the Forster energy transfer distance or the distance 
at which E=0.5. For typical fluorophores R0 =1-5 nm. Equa-
tion (1) implies that the gap (i.e., the number of bases) 
between the donor and acceptor beacons should be kept 
small. However, too small a gap size may result in steric 
interference between fluorophores or might lead to other 
interaction between donor and acceptor (such as ground 
state quenching), which is unfavorable. The gap size can 
influence the relative orientation of the fluorophores, also 
affecting energy transfer efficiency. A gap size of 8 bases was 
found to be optimal for energy transfer in the single-stranded 
random-coil conformation (Ju et al., 1995; Hung et al., 
1997). Further, base composition can influence fluorescence 
efficiency. The combination of a fluorescein dye attached to 
a guanine base can decrease peak fluorescence intensity by 
as much as 30% (M. Behike, unpublished observation). To 
optimize design parameters, hybridization experiments were 
conducted using targets that separate the donor and acceptor 
beacons by 3, 4, 5, and 6 bases. The nucleotides closest to 
the probe-binding region were identical for each target 
sequences. When the distance between the donor and accep-
tor beacons was increased from 3 to 6 bases, there was a 
slight increase in the FRET signal intensity, as demonstrated 
by the curves displayed in FIG. 7. This trend was found to 
be the same for all the acceptor fluorophores studied. 
LRET of Lanthanide Dyes. Conventional organic dyes 
used for FRET assays are limited by problems associated 
with the overlapping of donor/acceptor excitation and emis-
When a ROX fluorophore was used as the acceptor dye, 
S:BaMB was found to be -10, about half of S:BdMB' at low 
excitation wavelengths A (e.g., 395 nm to 425 nm), as shown 
in FIG. 4b. However, when A was increased, S:BaMB also 
increased. In fact, when A became larger than 460 nm, 
S:BaMB was higher than S:BdMB' reaching values above 30. 
This indicates that the dual FRET molecular beacons with a 
Fam-ROX FRET pair can perform better than the conven-
tional molecular beacons even in the absence of beacon 
degradation issues. The value of S:Bdeg also increased with 
increasing A, reaching values close to 5 at A.=455 nm, 
remaining between 4 and 5 for wavelengths ranging from 
455 nm to 495 nm. Acceptor beacons labeled with Texas Red 
were found to perform the best among the three acceptor 
dyes considered. Value of S:BaMB increased from 10 to 
nearly 50 as A was increased from 395 nm to 495 nm. 
55 sion spectra. To dramatically improve the signal-to-back-
ground ratio, the inventor takes advantage of the sharp 
emission peaks and the long lifetime of a lanthanide chelate 
(Li and Selvin, 1997; Cooper and Sammes, 2000). Specifi-
cally, a lanthanide donor is substituted for the Fam donor 
60 and modified the detection system to employ time-resolved 
spectroscopy. The lanthanide donor was a linear oligonucle-
otide probe labeled at its 3'-end with the Terbium chelate 
DTPA-cs124 (Table 1 ). The same series of acceptor molecu-
lar beacons were tested as before, including beacons with 
65 Cy3, ROX, or Texas Red fluorophores. Note that the use of 
lanthanide donor allows for shorter wavelength excitation, 
as demonstrated in Table 2. 
US 7,297,494 B2 
45 
The results ofLRET experiments with a lanthanide donor 
are shown in FIGS. Sa, b. As shown by curve (1) in FIG. Sa, 
46 
at 325 nm excitation, when the Terbium-chelate labeled 
donor probes bound to Cy3 labeled acceptor beacons, they 
exhibited several sharp emission peaks separated by valleys 
with fluorescence intensity close to zero; while the fluores-
cence emission from acceptor molecular beacons alone 
hybridized to targets was extremely low, as shown by curve 
(2). With binding of both donor probes with Terbium-chelate 
and acceptor molecular beacons to target, a sensitized emis- 10 
sion of the acceptor due to LRET was observed, shown as 
curve (3). As clearly demonstrated by the insert in FIG. Sa, 
target, there was a sensitized emission of the acceptor due to 
LRET, as shown by curve (3). Evidently, at certain wave-
lengths (such as 670 nm), the background signal due to 
degraded donor and acceptor probes becomes very low, 
leading to a high signal-to-background ratio. It was found 
that with the DTPA-cs124 chelate used in this study, the 
LRET probe pairs with a Terbium donor performs better 
than the LRET probe pair with a Europium donor and a Cy5 
acceptor. 
Although conventional molecular beacons can in theory 
detect mRNA transcripts in living cells, conditions within 
the intracellular environment can limit their utility in cellular 
imaging of gene expression. Specifically, molecular beacons 
bound to target mRNAs cannot be distinguished from those 
at emission wavelengths where background from the lan-
thanide donor was near zero, extremely high signal-to-
background ratios were observed. For Cy3-labeled acceptor 
beacon, the optimal detection wavelength is around 573 nm. 
Similar features were exhibited in FIG. Sb in which the time 
resolved emission spectra obtained with 325 nm excitation 
in a dual LRET probe assay using Terbium chelate as a 
donor and ROX as an acceptor were displayed. It is again 
very clear that at certain emission wavelengths the signal-
to-background ratio approaches infinity. As seen from the 
insert of FIG. Sb, for ROX-labeled acceptor beacon, the 
optimal detection wavelength is around 614 nm. Although 
the fluorescence emission due to energy transfer was very 
low, these results nevertheless suggest that there is a sig-
nificant potential for use of lanthanide donors with dual 
energy transfer molecular beacons. 
To determine the possible detrimental effect of small gap 
size between donor and acceptor probes on LRET, the 
spacing between the Terbium-labeled donor probe and the 
Cy3 or ROX-labeled acceptor beacon was varied from 3 to 
9 bases. It was found that the detected fluorescence intensity 
is not sensitive to the gap spacings tested, i.e., with a spacing 
of3, 4, 5, 6 and 9 bases, the signal levels were similar (data 
not shown), suggesting that the possible detrimental effect 
was negligible when both probes hybridized to the target 
with a relatively small gap spacing. Using Equation (1), it is 
readily shown that, with the gap spacing varying from 3 to 
9 bases, the energy transfer efficiency does not change much, 
since the Forster distance R0 for the Terbium/Cy3 LRET pair 
is large 6 (0.12 nm) (Selvin, 2002). For example, when R in 
Equation (1) increases from 1 nm (-3 bases) to 2 nm (-6 
bases) and to 3 nm (-9 bases), the energy transfer efficiency 
E only decreases by 0.12% and 1.37%, respectively. 
Due to the narrow emission peaks exhibited by lanthanide 
dyes, and the use of time-resolved fluorescence detection, it 
15 degraded by nucleases, or destabilized due to interactions 
with proteins. The disclosure provides a dual molecular 
beacon method that combines the advantages of molecular 
beacons with two-probe energy transfer methods. Conven-
tional and time-resolved fluorescence spectroscopy studies 
20 indicate that dual FRET molecular beacon pairs are capable 
of distinguishing between bound and degraded beacons with 
improved signal to background than previous methods. 
Moreover, with a lanthanide chelate as the donor dye, the 
signal-to-background ratio can be extremely high at certain 
25 wavelengths. 
These features are especially important in the detection 
and quantification of gene expression in living cells where 
false-positive signals due to probe degradation and interac-
tion with DNA binding proteins must be distinguished from 
30 the 'true' signal that results from probe/target binding. 
Widespread applications of the dual energy transfer molecu-
lar beacon methods will become common in laboratory and 
clinical studies of gene expression in cell lysates, tissue 
extracts, living cells, tissues and even animals using single-
35 or multi-photon microscopy, time-resolved fluorescence 
microscopy, and fluorescence endoscopy. For example, it is 
plausible to use this methodology for the specific and 
sensitive detection of the expression of oncogenes and 
tumor-suppresser genes in living cells, potentially making it 
40 a very simple and effective clinical tool for the early 
detection and diagnosis of malignancy. 
When using the dual LRET molecular beacons for gene 
detection and quantification examples of chelates that can be 
employed include DTPA-cs124, BCPDA (4, 7-bis( chlorosul-
45 fophenyl)-1,1 O-phenanthroline-2,9-dicarboxylic acid) and 
BHHCT ( 4,4-bis(l, 1, 1,2,2,3,3-heptafluoro-4,6-hexanedion-
6-yl)-chlorosulfo-o-terphenyl (Evangelista et al., 1988; 
Lopez et al., 1993; Yuan et al., 1998; Sueda et al., 2000; is not necessary to include a quencher molecule in the 
acceptor molecular beacons, although the stem-loop hairpin 
structure of the beacon may still be beneficial. However, 50 
when the detection of point mutations is not involved, the 
use of linear LRET pairs of oligonucleotide probes is 
attractive owing to its potential in reducing cost while 
having comparable performance. To demonstrate the con-
cept, donor oligonucleotide probes labeled with a Europium 
chelate at its 3'-end, and acceptor oligonucleotide probes 
labeled at its 5'-end with a Cy5 fluorophore were synthe-
sized, and in-solution hybridization and time-resolved emis-
sion detection assays were performed. The resulting emis-
sion spectra are displayed in FIG. 9. Similar to the results 
obtained using Terbium-chelate donors, at 325 nm excita-
tion, the emission spectrum of Europium donor bound to 
target showed several peaks within the range of 550 nm to 
750 nm, as demonstrated by curve (1). The fluorescence 
emission of the Cy5-labled acceptor probe due to probe/ 
target hybridization is again almost zero (curve (2)). When 
both donor and acceptor probes hybridized to the same 
Cooper and Sammes, 2000). 
Another improvement is to use two photon excitation 
instead of one-photon excitation. So far, all the dual FRET 
beacon/target hybridization assays performed were based on 
a one-photon excitation source (Xenon flash lamp). How-
ever, because of the overlapping excitation-emission spec-
55 trums of the organic donor and acceptor molecules for 
FRET, it is often difficult to excite the donor without also 
directly exciting the acceptor For example, as demonstrated 
in FIG. lOa, the maximum excitation of a donor Fam 
molecule occurs at -500 nm, but at the same wavelength an 
60 acceptor Cy3 molecule is also excited to 25% of its maxi-
mum. Therefore, if an acceptor beacon is degraded by 
nucleases and the fluorophore is separated from the dabcyl 
quencher it will be excited, giving a false-positive signal. 
Ideally, free acceptor fluorophores should be minimally 
65 excited by the excitation source and the only ones that are 
excited would be those due to FRET when both the donor 
and acceptor beacon are bound to the same target. 
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One strategy to minimize the direct excitation of the 
acceptor fluorophore is to use a two-photon excitation 
source. Two-photon excitation cross-sections of fluoro-
phores do not necessarily follow the same trends as one-
photon excitation spectrums. For example, as shown in FIG. 
lOb, although the maximum excitation of Cy3 occurs at 
higher wavelengths than Fam when one-photon excitation is 
used, with two-photon excitation the Cy3 fluorophore is 
actually excited at lower wavelengths. Further, when a donor 
Fam molecule is maximally excited at - 790 nm, the Cy3 10 
acceptor is only excited about 4% of its maximum. This 
alone is more than a 6-fold reduction in the direct excitation 
using polyacrylamide gel electrophoresis. All oligonucle-
otides were synthesized at Integrated DNA Technologies, 
Inc. (Coralville, Iowa). 
Molecular Beacon Design. Two types of molecular bea-
cons were designed and synthesized; both contain target-
specific probe sequence complementary in antisense orien-
tation to exon 6 of the human GAPDH gene, a Cy3 
fluorophore at the 5'-end, and a dabcyl quencher at the 
3'-end. As illustrated in FIG. lla, one type follows the 
conventional design of molecular beacons in that the target-
specific probe domain was centrally positioned between two 
complementary arms that form the stem; the sequence of 
these arms were independent of the target sequence. Shared-
of the Cy3 acceptor compared with one-photon excitation. 
Two-photon excitation also has the advantage of reduced 
photo-bleaching, reduced background fluorescence from 
scattering, and the ability to penetrate deeper into biological 
tissue than one-photon excitation. Therefore, two-photon 
excitation is potentially a powerful approach in dual FRET 
molecular beacon studies. 
Example 2 
Shared Stem Nucleic Acid Probes 
Oligonucleotide Synthesis. Oligonucleotide probes and 
targets were synthesized using standard phosphoramidite 
chemistry on an Applied Biosystems model 394 automated 
DNA synthesizer (Foster City, Calif.). Molecular beacons 
were purified using a 2-step reverse phase (RP) plus ion-
exchange (IE) high performance liquid chromatography 
(HPLC) on a Waters Model 600E HPLC system (Millipore 
Corp., Milford, Mass.). For RP-HPLC purification, oligo-
nucleotides were loaded on a Hamilton PRP-1 column and 
eluted with a linear 5% to 50% acetonitrile gradient in 0.1 
M triethyl-ammonium acetate (TEM) pH 7.2 over 40 min-
utes. The oligonucleotides were additionally purified by 
IE-HPLC using a Source™ colunm (Amersham Pharmacia 
Biotech, Piscataway, N.J.) and eluted with a linear 0% to 
50% 1 M LiCl gradient in 0.1 M Tris pH 8.0 over 40 
minutes. Unmodified (target) oligonucleotides were purified 
15 stem molecular beacons, on the other hand, were designed to 
have one arm of the stem complementary to the target 
sequence, as shown schematically in FIG. llb. In both cases, 
the probe length LP is defined as the portion of the molecular 
beacon that is complementary to the target, and the stem 
20 length Ls is the number of bases of each complementary arm. 
All the molecular beacons had LP=19 bases (see Table 3). 
Conventional molecular beacons were synthesized with 
Ls=4, 5 and 6 bases. The shared-stem molecular beacons 
were synthesized with Ls =4, 5 and 7 bases. As illustrated by 
25 FIG. 12a, a 6-base stem may not be synthesized because the 
shared-stem molecular beacon sequence is constrained, i.e., 
part of the arm sequence that makes up the 6-base stem is 
predetermined since the 5'-end of the shared-stem molecular 
beacon must complement the target sequence and the 
30 3'-stem is created solely to complement the 5'-stem 
sequence. This inadvertently forces an additional base pair-
ing in the stem. It should be noted that the stem sequence of 
a shared-stem molecular beacon is not adjustable since one 
arm of the stem is designed to complement the target. This 
35 limitation often precludes the design of certain stem/probe 
length combinations, as demonstrated in FIG. 12b for a 
molecular beacon with a probe length of 18 bases and a stem 
length of 4 bases Five target oligonucleotides were also 
synthesized, one wild-type and four with mismatches at 
assorted locations, as shown in Table 3. 
TABLE 3 
The Design of Probes and Target Oligonucleotides 
Name Sequence (5'-3') 
Shared-stem Cy3-GAGTCCTTCCACGATACCActc-Dabcyl 
19/4 
Shared-stem Cy3-GAGTCCTTCCACGATACCAgactc-Dabcyl 
19/5 
Shared-stem Cy3-GAGTCCTTCCACGATACCAggactc-Dabcyl 
19/7 
Notes 
SEQ ID N0:13 Probe 19/Stem 4 
SEQ ID N0:14 Probe 19/Stem 5 
SEQ ID N0:15 Probe 19/Stem 7 
Conventional Cy3-cctcGAGTCCTTCCACGATACCAgagg-Dabcyl SEQ ID N0:16 Probe 19/Stem 4 
19/4 
Conventional Cy3-ctgacGAGTCCTTCCACGATACCAgtcag-Dabcyl SEQ ID N0:17 Probe 19/Stem 5 
19/5 
Conventional Cy3-ctgagcGAGTCCTTCCACGATACCAgctca-Dabcyl SEQ ID NO:lS Probe 19/Stem 6 
19/6 
Target WT ACTTTGGTATCGTGGAAGGACTCATGA SEQ ID N0:19 Perfect match 
Target A ACTTTGGTATCGTGGAAGGAaTCATGA SEQ ID N0:20 Single mismatch 
Target B ACTTTGGTATCGTaGAAGGACTCATGA SEQ ID N0:21 Single mismatch 
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TABLE 3-continued 
The Design of Probes and Target Oliqonucleotides 
Name Sequence (5'-3') Notes 
Target C ACTTTGGTATCGTaGAAGGAaTCATGA SEQ ID N0:22 Double mismatch 
Target D ACTTTGGTATCGTaaAAGGACTCATGA SEQ ID N0:23 Double mismatch 
(llMolecular Beacons: Lower case = bases added to create stem domains. Upper case 
= probe-target hybridizing domains. Upper case bold = bases participating in both 
stem hairpin and target binding 
( 2 lTargets: Underscore= 19 base sequence complementary to beacons. Lower case bold 
mismatch bases in targets 
Equilibrium Analysis. Molecular beacons in the presence 15 
of target were assumed to exist in three phases: 1) as duplex 
with target, 2) as stem-loop hairpin, and 3) in random coil 
conformation. Dissociation constants describing the transi-
tion between these phases were determined by analyzing the 
20 
thermal denaturation profile of molecular beacons in the 
presence and absence of target (Bonnet et al., 1999). Dena-
turation profiles were obtained by recording the fluorescence 
intensity of a 50 µL solution containing 200 nM of molecular 
beacon in the presence of 0 to 20 µM of target at tempera-
25 tures ranging from 5° C. to 95° C. Specifically, the tem-
perature of the hybridization solution was brought to 95° C. 
and reduced by 1 ° C. increments to 5° C. The temperature 
was then raised with 1 ° C. increments back to 95° C. to 
ensure that the solution reached equilibrium and no hyster-
30 
esis had occurred. The temperature was held at each tem-
perature increment for ten minutes and fluorescence was 
measured for the final 30 seconds. The fluorescence intensity 
of each test solution was adjusted to correct for the intrinsic 
variance of fluorescence over temperature. Each thermal 
35 denaturation assay was performed in hybridization buffer 
containing 10 mM Tris, 50 mM KC!, and 5 mM MgCl2 . 
tion of temperature for samples containing B0 =200 nM of 
molecular beacon and T 0=400 nM of target. The melting 
temperature em is defined as the temperature at which half of 
the molecular beacons are bound to target, i.e., a=0.5. 
Kinetic Analysis. A SPEX fluorolog-2 spectrofluorometer 
with an SFA-20 rapid kinetics stopped-flow accessory and a 
temperature/trigger module (SFA-12) was used to measure 
molecular beacon-target binding kinetics. Specifically, the 
fluorescence intensity emitted from a rapidly mixed solution 
containing 250 nM molecular beacons and 2.5 µM targets 
was recorded over time for each molecular beacon-target 
pair. The hybridization reaction was assumed to obey the 
second order reaction kinetics 
B+T D, 
<----
k2 
d[D] 
- = ki[B][T] -k2[D] 
dt 
(3) 
where [BJ, [T] and [DJ are the concentrations of unbound 
molecular beacon, unbound target, and molecular beacon-
target duplex, respectively; k 1 is the on-rate and k2 the 
off-rate of molecular beacon-target hybridization. The exact 
40 solution of Equation 3 gives 
The fluorescence intensity data describing the thermal 
denaturation profile of each molecular beacon and molecular 
beacon-target duplex was used to determine the respective 
dissociation constant as described in Bonnet et al. 1999. 
Specifically, dissociation constants K12 characterizing the 
transition between phase 1 (bound to target) and phase 2 
(closed beacon) of molecular beacons were obtained for all 
beacon-target pairs and for all molecular beacons in the 45 
absence of target. Further, the dissociation constants K12 
were used to determine the changes in enthalpy (li.H12) and 
entropy (li.S12) associated with each beacon-target duplex. 
The errors calculated for the thermodynamic parameters 
signify a 95% confidence interval. Molecular Beacon Speci- 50 
ficity. The fraction of molecular beacons bound to target, a, 
was calculated for each molecular beacon-target pair as a 
function of temperature. All calculations utilized the ther-
modynamic parameters, enthalpy change li.H12 and entropy 
change li.Sw obtained from the thermal denaturation pro- 55 
files for each beacon-target duplex 
___ a: ___ = e(-t:.H)2/R(!)+(!:.S12/R) (2) 
(1 - a:J('I - a:JBo 60 
where 8 is the temperature in Kelvin, R is the gas constant, 
ri=T0/B0 , B0 =B0 /c0 , T0 and B0 are respectively initial con-
centration of target and beacons, and c0 is the unit concen- 65 
tration IM (Ratilainen et al., 1998). The value of a was 
calculated for each molecular beacon-target pair as a func-
(4) 
where li.=VB0 +T0 +K12) 2 -4B0T0 , [Deq]=(B0 +T0 +K12-li.)/2, 
A.=[Deq] 2 /B0/T0 , and K12=k/k1 is the dissociation constant 
discussed above. Since the concentration of molecular bea-
con-target duplex is unknown at any given time, it was 
assumed that (F(t)-F 0 )/(F eq-F 0 )=[D(t)]/[Deql where F(t) is 
the fluorescence intensity at time t, F 0 is the initial fluores-
cence intensity, and Feq is the fluorescence intensity as t---;.oo. 
In order to obtain the on-rate k 1 based on the fluorescence 
measurement, two different curve-fitting schemes were 
used. The first utilized a least-square method by fitting a 
straight line to a logarithmic form of Equation 4, 
(5) 
with a slope equal to k 1 . Alternatively, a non-linear least-
square method was used to determine the value of k 1 from 
Equation 4 directly. The results obtained using these two 
approaches were compared. 
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conventional molecular beacon do not bind to the target and 
are thus more likely to interact with each other as driven by 
thermal energy, increasing the tendency of forming a closed 
molecular beacon by dissociating from the target. Not sur-
prisingly, the stem length of a molecular beacon influenced 
the equilibrium state of both the shared-stem and conven-
tional beacons in the presence of target. As shown in FIG. 
14, as the stem length was increased from 4 to 6 bases, 
conventional molecular beacons were found to dissociate 
Thermal Analysis. To better understand how the perfor-
mance of shared-stem molecular beacons differ from that of 
the conventional molecular beacons, thermodynamic param-
eters of these two types of molecular beacon were obtained 
and compared. In particular, the enthalpy and entropy 
changes li.H12 and li.S 12 describing the phase transition 
between bound-to-target and stem-loop conformations were 
determined for conventional and shared-stem molecular 
beacons using van't Hoff plots. As demonstrated in FIG. 13, 
these plots display the inverse of melting temperature 1/8m 
as determined by R·In(T0 -0.5B0 ) shown as the ordinate. 
Since at melting temperature, 
10 from target molecules more readily. A very similar trend was 
true for shared-stem molecular beacons (data not shown). 
This indicates that hybridization is less favorable for 
molecular beacons with longer stems. 
1 
R ln(To - O.SBo) = -llH12 - + llS12 
em 
(6) 15 
The changes in enthalpy and entropy that control the 
dissociation of conventional and shared-stem molecular 
beacons from targets with mismatches were also determined 
(see Table 4). It was found that shared-stem molecular 
beacons formed more stable duplexes with each of the target 
molecules tested. However, as displayed in FIG. 15, when the slope of the fitted straight line of each curve in FIG. 13 
represents the enthalpy change -li.H12 and the y-intercept 
represents the entropy change li.S 12 . It was found that in 
general, the shared-stem molecular beacons have a higher 
melting temperature, i.e., they form more stable probe/target 
duplexes than conventional molecular beacons. The changes 
of enthalpy and entropy for all the molecular beacon-target 
combinations tested are summarized in Table 4. 
20 point mutations were present in the target oligonucleotide, 
both types of molecular beacons dissociated from their 
targets more readily. The magnitude of change depended on 
both the number of mismatches and their location. Com-
pared with the wild-type target, a point mutation near the 
center of the probe-binding domain (Target B) was found to 
have a larger effect on molecular beacon dissociation than a 
TABLE 4 
Changes in Enthalpy and Entropy of Conventional and Shared-stem 
Molecular Beacons in the Presence of Target 
Conventional Molecular Beacons Shared-stem Molecular Beacons 
Probe Stem -/lH 
Target Length Length (kJ/mol) 
WT 19 4 823 ± 168 
A 19 4 577 ± 62 
B 19 4 527 ± 27 
c 19 4 472 ± 23 
D 19 4 480 ± 38 
WT 19 649 ± 28 
A 19 418 ± 23 
B 19 385 ± 24 
c 19 324 ± 17 
D 19 291 ± 25 
WT 19 467 ± 16 
A 19 404 ± 25 
B 19 380 ± 26 
c 19 367 ± 19 
D 19 373 ± 29 
/lS 
(kJ/mol · K) 
2281 ± 489 
1595 ± 184 
1471 ± 79 
1336 ± 70 
1352 ± 115 
1784 ± 83 
1133 ± 70 
1055 ± 73 
901 ± 54 
790 ± 76 
Stem 
Length 
4 
4 
4 
4 
4 
1265 ± 48 7 
1105 ± 76 7 
1055 ± 79 7 
1058 ± 61 7 
1065 ± 91 7 
-/lH 
(kJ/mol) 
862 ± 116 
708 ± 36 
586 ± 54 
478 ± 49 
521 ± 87 
690 ± 16 
446 ± 20 
391 ± 24 
369 ± 57 
319 ± 28 
413 ± 10 
370 ± 13 
351 ± 39 
260 ± 30 
245 ± 25 
50 
/lS 
(kJ/mol · K) 
2383 ± 336 
1967 ± 106 
1628 ± 161 
1340 ± 148 
1461 ± 262 
1887 ± 46 
1205 ± 59 
1057 ± 72 
1025 ± 175 
861 ± 85 
1096 ± 28 
998 ± 38 
956 ± 117 
707 ± 93 
653 ± 79 
mutation near the end of the probe-binding domain (Target 
A). As expected, two point mutations (Targets C and D) on 
a target had a more profound effect on the dissociation of 
molecular beacons from targets than that with one point 
mutation. 
Melting Temperature. To further elucidate the effect of 
molecular beacon structure on the stability of the probe-
target duplex, the melting temperatures em for conventional 
and shared-stem molecular beacons with a probe length of 
To m1mm1ze the number of independent variables 
involved in controlling probe/target hybridization, all the 
molecular beacons were designed to have identical probe 
sequences. Further, for molecular beacons with a stem 
length of 5 bases and a probe length of 19 bases, the stem 55 
sequence of the conventional molecular beacons was chosen 
such that energetically the stem was similar to that of the 
shared-stem molecular beacons. The free energy changes 
were calculated using nearest neighbor approximations 
(Zucker 2000). 
The difference in thermodynamic behavior between con-
ventional and shared-stem molecular beacons can be under-
stood in terms of the ability of the flanking arms to interact 
with each other. With shared-stem molecular beacons, once 
part of the stem (one arm) is bound to the target, it is less 65 
likely to interact with its complementary arm, resulting in a 
more stable probe/target duplex. In contrast, the arms of a 
60 19 bases and stem lengths ranging from 4 to 7 bases were 
compared, as shown in FIG. 6. It was found that conven-
tional molecular beacons had lower melting temperatures 
than shared-stem molecular beacons for each of the stem 
lengths considered; however, both types of molecular bea-
cons exhibited similar trends. Specifically, the melting tem-
perature progressively decreased as the stem length 
increased. In fact, it appears that the melting temperature 
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would be quite low for conventional molecular beacons with 
a probe length of 19 bases and a stem length of 7 bases or 
greater. This is because that with long free arms of the stem 
a bound molecular beacon is very easy to dissociate from the 
target and form a stable hairpin structure even at low 
temperatures. 
54 
probes. However, to optimize the performance of molecular 
beacons for different applications, it is necessary to under-
stand their structure-function relationships. Here is 
described a new design of molecular beacons, i.e., the 
shared-stem molecular beacons, of which the stem-arm 
nearest the reporter dye participates in both hairpin forma-
tion and target hybridization. In contrast to conventional 
molecular beacons whose stems are independent of the 
target sequence and thus can freely rotate around the probe-
Molecular Beacon Specificity. Melting curves that display 
the fraction of molecular beacons in duplex form, a, as a 
function of temperature were obtained for each molecular 
beacon and probe-target pair. As demonstrated in FIG. l 7a, 
the difference in melting temperature em (i.e., temperature at 
a=0.5) between beacon/wild-type-target and beacon/mu-
tant-target duplexes was found to be slightly larger for 
conventional molecular beacons compared with correspond-
ing shared-stem molecular beacons. Further, the difference 
in the fraction of molecular beacons bound to wild-type 
target and mutant target, awrararget B' as a function of 
temperature was found to be similar for conventional and 
shared-stem molecular beacons, although the maximum 
value of awrararget B is slightly higher for the former, as 
shown in FIG. 15b. The conventional molecular beacons 
was also found to maintain a value of awrararget B>O over 
10 target duplex, this new design helps immobilize the fluoro-
phores of molecular beacons when they hybridize to the 
target, which is desirable when two molecular beacons are 
used in a fluorescence energy transfer, for example a fluo-
rescence resonance energy transfer (FRET) assay (Tsourkas 
15 and Bao 2001). Specifically, with shared-stem molecular 
beacons, there is a better control of the distance between the 
donor dye on one beacon and the acceptor dye on the other 
beacon, since the rotational motion of the fluorophore-
attached stem-arm is constrained, as illustrated in FIG. llb. 
a slightly broader range of temperatures than shared-stem 
molecular beacons, but again the different is very small. This 
implies that the conventional molecular beacons may exhibit 
only a slightly higher specificity than shared-stem molecular 
beacons. 
20 To facilitate the design and application of, and to reveal the 
differences between, shared-stem and conventional molecu-
lar beacons, a systematic study of the thermodynamic and 
kinetic parameters that control the hybridization of these 
molecular beacons with complementary and mismatched 
25 targets was performed. 
In general, it was found that compared with shared-stem 
molecular beacons, conventional molecular beacons form 
less stable duplexes with single-stranded nucleic acid targets 
but have a slightly improved ability to discriminate between 
The effect of stem length on molecular beacon specificity 
was also found to be similar for conventional and shared-
stem molecular beacons. Specifically, the curves in FIG. 18 
demonstrate that, as the stem length is increased the height-
ened competition between a unimolecular reaction and 
bimolecular hybridization broadens the transition between 
bound and unbound states. This results in an improved 
ability to discriminate between targets over a widei range of 
temperature but lowers the maximum difference in the 
fraction of beacons bound to wild-type and mutant targets. 
30 wild-type and mutant targets. The difference in the duplex 
stability can be explained by the thermal-driven interactions 
between the two stem-forming arms after the molecular 
beacon hybridized to a target molecule. Unlike linear oli-
gonucleotide probes, a molecular beacon can have two 
35 stable conformations: bound to target, and as a stem-loop 
hairpin. These two stable states compete with each other, 
giving rise to an improved specificity. The additional free-
dom inherent in both arms of conventional molecular beacon Kinetic Analysis. The on-rate of shared-stem and conven-
tional molecular beacons hybridized to wild-type target as a 
function of stem length is displayed in FIG. l9a. It is seen 40 
that for shared-stem molecular beacons, an increase in stem 
length from 4 to 5 bases induced a 5-fold reduction in its 
on-rate, which was further reduced by 3-fold when the stem 
length was increased from 5 to 7 bases. In contrast, the 
on-rate of conventional molecular beacons only decreased 45 
slightly when the stem length was increased from 4 to 6 
bases. It is interesting to note that, with stem lengths of 5 
bases or larger, the shared-stem and conventional molecular 
beacons have on-rates differing only by less than a factor of 
2. However, the shared-stem molecular beacons with a 50 
4-base stem hybridized to wild-type targets four times faster 
than the corresponding conventional molecular beacons. 
This large difference in the rate of hybridization most likely 
resulted from the variations in the stability of the hairpin 
structure. To further illustrate, the dissociation constants K23 55 
of the conventional and shared-stem molecular beacons in 
the absence of target are shown in FIG. l9b. Interestingly, 
there seems to be a clear correlation between the on-rate of 
beacon hybridization and the stability of the stem-loop 
structure. This is understandable since K23 represents the 60 
transition from hairpin (phase 2) to random coiled (phase 3) 
conformations of molecular beacons, and a higher K23 
implies that the molecular beacons are easier to open. 
Molecular beacons have become a very useful tool for 
many homogeneous single-stranded nucleic acid detection 65 
assays due to their ability to differentiate between bound and 
unbound states and their improved specificity over linear 
increases the likelihood that, driven by thermal fluctuations, 
these arms will encounter with each other, allowing the 
molecular beacon to dissociate from the target with a higher 
probability. This reduced stability also corresponds to a 
smaller value in the free energy difference between bound 
and unbound states of the probe-target duplex. The change 
in free energy due to any mismatch between the probe and 
target, therefore, will have a more profound effect on the 
preference of the stem-loop hairpin conformation of the 
conventional molecular beacons, leading to an improved 
ability to differentiate between wild-type and mutated tar-
gets. However, this improvement was found to be marginal. 
With any given probe length and sequence, the hybrid-
ization kinetics of molecular beacons appears to be primarily 
dependent on the length and sequence of the stem, regardless 
of whether they are designed in the conventional or shared-
stem configuration. Both types of molecular beacons exhib-
ited comparable hybridization rates when the dissociation 
constants describing the thermal fluctuation induced open-
ing of the stem-loop structure, K23 , were similar. When the 
difference in K23 for the shared-stem and conventional 
molecular beacons was increased, so was the difference in 
the hybridization on-rate. 
In addition to the above-mentioned differences in the 
behavior of shared-stem and conventional molecular bea-
cons, the choice of the stem length is independent of the 
probe length for conventional molecular beacons, whereas 
there are certain constraints on the stem-length and probe-
length combinations in designing the share-stem molecular 
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beacons. This, together with the dependence of the thermo-
dynamic and kinetic properties on the probe and stem 
lengths demonstrated in this study, should be considered in 
the design of molecular beacons for specific applications. 
Example 3 
K-ras and Survivin Detection 
It is well established that cancer cells develop due to 10 
genetic alterations in oncogenes and tumor suppressor genes 
and abnormalities in gene expression that provide growth 
advantage and metastatic potential to the cells. A critical step 
in diagnosing and treating cancer in its early stages is to 
detect cancer cells based on the genetic alterations. An 15 
important example is pancreatic cancer, the fifth most fatal 
cancer in the US. Only 12% of patients diagnosed with 
pancreatic cancer can survive for one year; the 5-year overall 
survival rate is approximately 3-5%. The main reason for the 
poor prognosis of pancreatic cancer is that very few of these 20 
cancers can be found early. Current clinical diagnostic 
procedures such as CT-scan and endoscopic retrograde cho-
langiopancreatography (ERCP) have a low sensitivity in 
detecting pancreatic tumors less than 2 cm in size. In spite 
of the extensive biomedical research efforts during the last 25 
few decades, over 90% of the patients with pancreatic cancer 
have already undergone local and/or distant metastases by 
the time of diagnosis, often making it too late to cure. 
Therefore, it is extremely important to detect pancreatic 
cancer in its early stages based on molecular markers rather 30 
than the size of the tumor. 
56 
found in inflammatory cells around tumor cells. The absence 
of survivin expression in normal pancreas, pancreatic tissue 
of chronic pancreatitis patients and other normal tissues 
makes it an ideal molecular marker for the detection of 
pancreatic cancer cells. Although molecular beacons can be 
designed to target alterations of many oncogenes and tumor-
suppressor genes, the detection of K-ras mutations and the 
expression of survivin in pancreatic cells were investigated. 
It has been shown that K-ras mutations can be detected in 
blood, pancreatic juice and pancreatic tissue samples of 
pancreatic cancer patients using DNA purification and 
mutant-enriched PCR followed by single strand conforma-
tion polymorphism (SSCP), restriction fragment-length 
polymorphisms (RELP), or allele-specific oligodeoxynucle-
otide hybridization (ASOH). Although identification of 
K-ras mutations by PCR is a fairly sensitive molecular 
approach, the procedures for PCR and subsequent assays are 
very time-consuming, making them difficult to become 
clinical procedures. Furthermore, detection of K-ras muta-
tions in DNA from peripheral blood or pancreatic juice alone 
is not sufficient for diagnosis of pancreatic cancer since it 
lacks the specificity for the determination of the cellular 
origin of the K-ras mutation. A better way to detect pancre-
atic cancer is to use nucleic acid probes of the present 
disclosure to detect K-ras mutations in cancer cells directly. 
Utilization of prior nucleic acid probes to detect K-ras 
mutations in PCR products of DNA samples isolated from 
lung cancers has been reported and the specificity has been 
established. However, to date the use of nucleic acid probes 
forthe detection of mutant K-ras mRNAin intact tumor cells 
has not been reported. One advantage of using the molecular 
beacons approach is that a cocktail of multiple such probes 
can be delivered into cells for different molecular markers of 
A novel way of achieving early detection of cancer is to 
identify cancer cells through detection of mRNA transcripts 
that exist in cancer cells but not in normal cells. Here is 
demonstrated the dual-FRET molecular beacons of the 
present disclosure for the early detection of cancer cells. 
35 cancer. 
K-ras is one of the most frequently mutated genes in 
human cancers. A member of the G-protein family, K-ras is 
involved in transducing growth-promoting signals from the 
cell surface. Point mutations ofK-ras are found in 80-100% 
of pancreatic, 40-60% of colon, and 25-50% of lung adeno-
carcinomas, suggesting that mutant K-ras is a sensitive 
marker for pancreatic cancer detection. Further, K-ras muta-
tions occur almost exclusively in three hot spots (codons 12, 
13 and 61). Most of them are concentrated at codon 12, 
which facilitates the design of molecular beacons. Since 
K-ras mutations occur very early in the development of 
pancreatic cancer, assays targeting K-ras mutations can lead 
An important issue in detecting K-ras mutations in cells is 
that as a signaling protein the expression level of K-ras 
mRNA may not be very high ( <1,000 copies per cell), even 
in cancer cells. Further, the secondary structures of K-ras 
40 and survivin mRNAs may influence the binding between 
nucleic acid probes of the present disclosure and the targets. 
Thus, it is preferred to optimize the design of molecular 
beacons and the beacon delivery conditions so that high 
detection specificity and sensitivity can be achieved. By 
45 routinely combining the nucleic acid probes of the present 
disclosure approach with high-sensitivity fluorescence 
microscopy, it will likely be possible to detect as few as 10 
copies of mRNA per cell. 
to early detection of pancreatic carcinomas. Other onco-
genes and tumor-suppressor genes involved in pancreatic 50 
cancer include p53, p16, MADH4, DPC4, BRCA2, MKK4, 
STKll, TGFBRl and TGFBR2. 
To further examine probe-target hybridization and energy 
transfer between nucleic acid probes of the present disclo-
sure, dual-FRET molecular beacons were designed and 
synthesized. Specifically, the molecular beacons were 
designed to target human GAPDH mRNA. The donor proes 
were synthesized with a 6-FAM donor fluorophore (D) at the 
There is increasing evidence recently suggesting that 
survivin, one of the inhibitor of apoptosis proteins (IAPs ), is 
a good tumor marker for several types of cancers. Survivin 
is normally expressed during fetal development but not in 
most normal adult tissues. However, high levels of survivin 
are detected in many human cancer types and transformed 
human cells. In particular, a recent study has demonstrated 
the presence of survivin in 77% (20 out of 26 cases) of 
pancreatic duct cell adenocarcinomas by immunohistochem-
istry, immunoblotting and RT-PCR assays. The results from 
this study also suggested that the expression of survivin is 
present in early stages of neoplastic transition in pancreatic 
cancer cells. However, expression of survivin was not 
detected in pancreatic tissues obtained from 5 normal per-
sons and 12 patients with chronic pancreatitis, nor was it 
55 3' end and a Dabcyl quencher (0) at the 5' end. Similarly, 
acceptor probes were synthesized with a Cy3 acceptor 
fluorophore (A) at the 5' end and a Dabcyl quencher (0) at 
the 3' end (see Table 5 below). The donor and acceptor 
beacons are chosen such that they are complementary to part 
60 of the target sequence. The loop portion, therefore, is 13 
bases in length. The synthetic targets mimicking the 
GAPDH IVT RNA exon 6/exon 7 junction are designed so 
that the gap between the two beacons hybridizing on the 
same target is respectively 3, 4, 5 or 6 bases, with 4-base gap 
65 being that of the wild-type. All the nucleic acid probes of the 
present disclosure were synthesized at Integrated DNA 
Technologies (IDT, Inc). 
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As illustrated above, thermodynamics and binding kinet-
ics of molecular interactions underlies the design of the 
nucleic acid probes of the present disclosure. The free 
energy difference between keeping the stem-loop structure 
and forming the probe-target duplex is the main driving 
force for hybridization. The nucleic acid probes of the 
present disclosure can have three different phases in solu-
tion: hairpin, random coil, and probe-target duplex. The 
relative portions of these phases depend on the structure of 
the probe, probe and target concentrations, solution chem-
istry, sequences of the pro be and target, and temperature. For 
example, if the stem length is too large, it will be difficult for 
the stem-loop probe to open upon hybridization. On the 
other hand, if the stem length is too small, a large fraction 
of probes may open due to Brownian forces. Similarly, 
relative to the stem length, a longer probe may lead to a 
lower dissociation constant, however, it may also reduce the 
specificity, since the relative free energy change due to 
one-base mismatch would be smaller. To further establish 
the structure-function relationships of probes, one can for 
example routinely design and synthesize a series of dual-
FRET probes for targeting different K-ras codon 12 muta-
tions, such as shown in Table 5. For each pair of donor and 
acceptor beacons, the donor beacon will contain one of the 
most common K-ras point mutations in pancreatic cancer 
such as GGT-GAT transitions (Gly to Asp) or GGT-GTT 
(Gly to Val), GGT-CGT (Gly to Arg), GGT-TGT (Gly to 
Cys) transversions. The same acceptor beacon can used with 
58 
ization studies are carried out by mixing the donor nucleic 
acid probes of the present disclosure with respectively 
wild-type K-ras mRNA targets, the corresponding mutated 
K-ras mRNA targets and survivin targets at different probe/ 
target concentrations. Thermal denaturation profiles are gen-
erated and the corresponding transition temperatures 
obtained. Since the detection specificity depends on the 
initial concentrations of probes and targets, the results ofthis 
study not only demonstrate the detection specificity but also 
10 provide guidelines for optimizing beacon delivery condi-
tions. Furthermore, stopped-flow studies of the hybridiza-
tion kinetic rates are performed with each nucleic acid probe 
of the present disclosure design and each target type. This 
15 helps select the optimal structure of the nucleic acid probes 
of the present disclosure with the best possible combination 
of specificity and rate of hybridization. 
To address potential issues with secondary structures of 
the mRNAs, synthetic targets with lengths three to four 
20 times the probe length are used in in-solution studies. To 
further utilize the nucleic acid probes of the present disclo-
sure, total mRNAs of survivin and the mutant K-ras are 
isolated from pancreatic cancer cells known to carry them, 
amplified, and in-solution hybridization assays are per-
25 formed to determine the extent of binding between the 
nucleic acid probes of the present disclosure and these 
mRNAs. 
all donor beacons having different mutated sequences. As an 
example, a specific beacon design for nucleic acid probes of 30 
the present disclosure has a probe length of 21 nucleotides, 
As mentioned earlier, in a cellular environment, nucleic 
acid probes can be degraded by cytoplasmic nucleases. To 
address this issue, the present disclosure provides probes 
synthesized with structural modifications such as 2'-0-me-
thyl ODNs. Methylated-probe/target duplexes are more 
stable than DNA-probe/target duplexes, and methylated 
nucleic acid probes of the present disclosure hybridize to 
RNA targets faster than DNA probes. After delivery into 
primary human dermal fibroblast (HDF) cells, the fluores-
cence signal of unmodified molecular beacons with a ran-
dom DNA sequence and methylated nucleic acid probes of 
the present disclosure with the same sequence are monitored 
over time to determine how long these probes can survive in 
a cellular environment. 
a stem length of 4 nucleotides, and a gap size of 4 nucle-
otides between the donor and acceptor beacons bound on the 
same target. One can routinely examine the effect of beacon 
structure on hybridization rate and specificity by varying: 1) 35 
probe length of 17, 19 and 21 bases; 2) stem length of 4 and 
5 bases; 3) gap sizes of 4 and 5 bases between donor and 
acceptor beacons along the target mRNA. For different 
parameter combinations, kinetic and thermodynamic mod-
eling described above will be performed to build the analysis 40 
of the experimental data. 
TABLE 5 
Design of Molecular Beacons for K-ras Codon 12 Mutation 
Wild-type K-ras (Bases 1-78) 
1 ATGACTGAAT ATAAACTTGT GGTAGTTGGA GCTGGTGGCG 
41 TAGGcaagAG TGCCTTGACG ATACAGCTAA TTCAGAAT 
Dual-FRET Molecular Beacons 
Donor Beacon: 5'-Dabcyl-AGTGCGCTGTATCGTCAAGGCACT-6-Fam-3' 
Acceptor Beacon: 5'-Cy3-CCTACGCCATCAGCTCCGTAGG-Dabcyl-3' Mut: GGT-GAT 
Acceptor Beacon: 5'-Cy3-CCTACGCCAACAGCTCCGTAGG-Dabcyl-3' Mut: GGT-GTT 
Acceptor Beacon: 5'-Cy3-CCTACGCCACGAGCTCCGTAGG-Dabcyl-3' Mut: GGT-CGT 
Acceptor Beacon: 5'-Cy3-CCTACGCCACAAGCTCCGTAGG-Dabcyl-3' Mut: GGT-TGT 
60 
SEQ ID N0:27 
SEQ ID N0:28 
SEQ ID N0:29 
SEQ ID N0:30 
SEQ ID N0:31 
SEQ ID N0:32 
To further increase the detection sensitivity, for example, 
one can synthesize nucleic acid probes of the present dis-
closure to target a second cancer marker, such as survivin, 
which is expressed in pancreatic carcinomas but not in 
normal tissues. To demonstrate the specificity of molecular 
beacons targeting K-ras point mutations, in-solution hybrid-
To determine the specificity of the molecular beacons 
approach for detecting K-ras mutations in pancreatic cancer 
cells, nucleic acid probes of the present disclosure are 
65 synthesized to target four different K-ras codon 12 mutations 
(GGT-GAT, GGT-GTT, GGT-CGT and GGT-TGT). Deliv-
ery, hybridization and imaging assays are carried out using 
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pancreatic cancer cell lines such as Pane-I (GGT to GAT), 
Capan-I (GGT to GTT), PSN-1 (GGT to CGT), and Mia-
paca-2 (GGT to TGT) with the corresponding mutant K-ras 
mRNAs. Also used is the pancreatic cell line BXPC-3 as a 
control which has the 'wild-type' K-ras mRNA. 
Preliminary studies have shown that the K-ras codon 12 
mutation GGT-GAT in Pane- I cell lines has been confirmed. 
Further confirmation of the other three mutations (GGT-
GTT, GGT-CGT and GGT-TGT) in the corresponding pan-
creatic cancer cell lines using PCR amplification of K-ras 
exon I sequence followed by DNA sequencing is routinely 
performed. The K-ras mRNA concentration in each cell line 
60 
A critical issue concerning the specificity of detecting 
pancreatic cancer cells is that both K-ras codon 12 mutations 
and survivin are being expressed in colorectal and lung 
cancers as well. To assure high specificity for detecting 
cancer cells originated from the pancreatic ducts, in addition 
to using nucleic acid probes of the present disclosure tar-
geting survivin and K-ras mutations, a third probe pair for 
the chymotrypsinogen gene can be synthesized, which is 
pancreas-specific. An example of the design of donor and 
10 
acceptor probes are respectively: donor probe: 5'-AMCA-
ACCTGGATGTTGTCCTCGTCAGGT-dabcyl-3' SEQ ID 
N0:36 and acceptor probe: 5'-dabcyl-
AAGATTGAAGACCTTGGCGATCTT-Diakylamino cou-is also be quantified using real time RT-PCR. During a pilot 
study, the delivery, hybridization, and buffer conditions for 
the nucleic acid probes of the present disclosure have been 
optimized to target mutant K-ras mRNA in Pane-I cells 
(with GGT to GAT mutation). As mentioned earlier, the 
disclosure provides a preferred condition for this type of 
probe of 150 nM of the probes in Opti-MEM I medium 
(GIBCO) and incubated at 37° C. for 30 to 60 minutes. It is 20 
anticipated that the optimal delivery and hybridization con-
ditions for nucleic acid probes of the present disclosure 
targeting different mutant K-ras mRNAs may vary from 
those identified. Nucleic acid probes of the present disclo-
sure designed for each specific K-ras mutation are incubated 25 
with at least four cell lines with the optimal delivery 
condition; these cell lines include the cell line containing the 
specific K-ras mutation, the 'wild-type' K-ras cell line 
BXPC-3, and two other cell lines with different K-ras 
mutations. The FRET-induced fluorescence signal in cells 30 
can be imaged using a confocal microscope. The specificity 
15 marin-3' (underlined bases are complementary bases to form 
a stem) SEQ ID N0:37. This nucleic acid probe pair of the 
present disclosure will be delivered into pancreatic, lung and 
colon cancer cell lines as well as the normal human fibro-
blast cell line HDF and the resulting fluorescence images 
recorded. This will assure that only cells originated from 
pancreatic duct are detected. All the detection assays with 
cells are performed at 37° C. The assays determining detec-
tion specificity with lanthanide-dye based nucleic acid 
probes of the present disclosure are carried out using a Satire 
monochromator reader (Tecan). 
To determine the sensitivity of the probe-based method-
ology in detecting pancreatic cancer cells, pancreatic cancer 
and normal cells are mixed with I: 1,000 (i.e., one cancer cell 
in 1,000 normal cells), 1:10,000, 1:100,000 and 1:1,000,000 
ratios and incubate the mixture with the dual-FRET molecu-
lar beacons designed for the specific cancer cell line under 
of the present probe detection methodology is confirmed 
when strong fluorescence signal are observed only in the cell 
line expressing the corresponding K-ras mutation but not in 
BXPC-3 nor other cell lines. 
Similar assays are routinely performed to examine the 
specificity of survivin-targeting nucleic acid probes of the 
present disclosure using pancreatic cancer cell lines express-
ing different levels of survivin gene as well as the normal 
human fibroblast cells as a control. For example, using 
RT-PCR and Northern blotting, the level of survivin expres-
sion in pancreatic cell line Miapaca-2 has been found to be 
high, in BXPC-3 it is much lower, while in HDF the 
expression level is almost zero. The probe sequence of the 
survivin probes is shown in Table 6 and the steps of the assay 
are similar to that described above. The tumor cell lines 
expressing different levels of survivin mRNA and the nor-
mal cell line HDF are incubated with the survivin nucleic 
acid probes of the present disclosure, and the resulting 
fluorescence are imaged using a confocal microscope. 
TABLE 6 
optimized conditions (probe concentration and duration). 
After placing cells on glass coverslips, FRET-induced fluo-
rescence images of the hybridized nucleic acid probes of the 
35 present disclosure in cancer cells are obtained using a 
confocal microscope. Further, a FACS Vantage SE cell 
sorter (Becton-Dickinson) is used to sort out the cancer cells 
in the mixture in suspension. The cell sorter, which has a 
sorting sensitivity of 1: I 00,000, has three excitation wave-
40 lengths: 488 nm, 547 nm, and UV. The fluorescence emis-
sion due to dual-FRET probes in cells can be detected by 
using the proper filter. The dual-FRET probe pairs for 
detecting survivin, K-ras mutations and chymotrypsinogen 
are so designed such that the donor dye molecules are 
45 respectively excited with laser at 353 nm, 488 nm and 547 
nm. A fluorescence intensity threshold in the detection is 
chosen such that the effect of background due to auto-
fluorescence of cells and digested nucleic acid probes of the 
present disclosure is minimized. In this study, the pancreatic 
cell lines Pane-I, Capan-I, PSN-1 and Miapaca-2 are used 
Design of Molecular Beacons for Survivin mRNA 
Survivin (Bases 1-121) 
1 A TGGGTGCCCC GACGTTGCCC CCTGCCTGGC AGCCCTTTCT SEQ ID N0:33 
42 CAAGGaccak CGCATCTCTA CATTCAAGAA CTGGCCCTTC 
82 TTGGAGGGCT GCGCCTGCAC CCCGGAGCGG ATGGCCGAGG 
Dual-FRET Molecular Beacons 
Donor Beacon: 5'-Alexa546-CCTTGAGAAAGGGCTGCCCAAGG-Dabcyl-3' SEQ ID N0:34 
Acceptor Beacon: 5'-Dabcyl-CCGCATTGAATGTAGAGATGCGG-Texas Red-3' SEQ ID N0:35 
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as cancer cells, and a human dermal fibroblast cell line 
(HDF) serves as normal cells. 
62 
TABLE 7 
Target sequences and 
the design of molecular beacons 
Wild-type K-ras target (Bases 1-78) 
5'-ATGACTGAATATAAACTTGTGGTAGTT 
GGAGCTGGTGGCGTAGGcaag 
SEQ ID N0:56 
In obtaining images of hybridized molecular beacons in 
cancer cells, having ultra-sensitive fluorescence measure-
ments is important, since typically only a very small number 
of cancer cells are present in a sample. The FACS Vantage 
Flow Cytometer (cell sorter) will be used due to its very high 
detection sensitivity, capability of 5 color analysis and 
sorting, wide flexibility of excitation wavelengths, and cross 
beam laser compensation for separation of overlapping 
excitation. An imaging analysis will also be carried out to 
enhance the results of FRET fluorescence measurements. In 
this example, in carrying out imaging assays of detection 
sensitivity, only nucleic acid probes of the present disclosure 
with organic dye pairs for FRET will be used, since currently 
the Zeiss confocal microscope and the FACS cell sorter do 
not have an imaging capability with time resolved FRET. 
10 AGTGCCTTGACGATACAGC TAATTCAGAAT-3' 
K-ras dual FRET molecular beacons 
Donor MB: 
5'-/Cy3/CCTACGCCACCAGCTCCGTAGG/ SEQ ID N0:57 
15 BHQ-2/-3' 
Acceptor MB: 
5'-/BHQ-3/AGTGCGCTGTATCGTCAAGGCACT/ 
Cy5/-3' 
SEQ ID N0:58 
This example is based on the rational that detection of 
tumor markers including survivin and mutant K-ras mRNAs 
in pancreatic duct cells using dual-FRET nucleic acid probes 
20 Survivin target (Bases 1-78) 
5'-ATGGGTGCCCCGACGTTGCCCCCTGCC SEQ ID N0:59 
of the present disclosure can lead to early diagnosis of 
pancreatic cancer especially in high-risk patients. It demon-
25 
strates that the novel dual-FRET molecular beacons meth-
odology of the present disclosure has the potential to 
become a simple clinical procedure for early detection of 
pancreatic cancer with high sensitivity, specificity, signal-
to-noise ratio, and efficiency. This is further demonstrated 30 
with subsequent translational research using clinical 
samples. The same methodology can be routinely extended 
TGGCAGCCCTTTCTCaagg 
ACCACCGCATCTCTAC ATTCAAGAACTGGCCC-3' 
Survivin dual FRET molecular beacons 
Donor MB: 
5'-/Cy3/GAGAAAGGGCTGCCATTCTC/ 
BHQ-2/-3' 
Acceptor MB: 
5'-/BHQ-3/ACCACGTAGAGATGCGGTGGT/ 
Cy5/-3' 
SEQ ID N0:60 
SEQ ID N0:61 
to the early detection and diagnosis of other cancers, and the 
study of gene expression in live cells relevant to solving 
other biomedical problems. 35 'Random' sequence target 5'-ATCGGTGCGCTTGTCG-3' 
Example 4 'Random' sequence molecular beacon 
Donor MB: 
5'-/Cy3/CACGTCGACAAGCGCACCGATACGTG/ SEQ ID N0:62 
mRNA Detection in Living Cells 
40 BHQ-2/-3' 
To facilitate subsequent studies of early cancer detection, 
the K-ras-targeting molecular beacons were designed such 
that the donor beacon is complementary to a region of the 
K-ras gene containing codon 12 whose mutations are 45 
involved in many cancers. The survivin-targeting molecular 
beacons were designed such that the target sequence is 
unique, having no overlap with other genes in the IAP 
family. As shown in Table 7, a BHQ-2 quencher was 
attached to the 3'-end and a Cyanine 3 (Cy3) fluorophore 50 
was attached to the 5'-end of the random beacon and donor 
molecular beacons; a BHQ-3 quencher was attached to the 
5'-end and a Cyanine 5 (Cy5) fluorophore was attached to 
the 3'-end of the acceptor molecular beacons. The probe 
lengths of K-ras-targeting donor and acceptor molecular 55 
beacons are respectively 17 and 19 bases; the probe lengths 
of survivin-targeting donor and acceptor molecular beacons 
are 15 and 16 bases, respectively. The random beacons have 
a probe length of 16 bases. All molecular beacons are with 60 
the shared-stem design, with a stem length of 5 bases; they 
have urnnodified oligonucleotide backbone. The K-ras and 
survivin molecular beacons and Cy5 random beacon were 
synthesized by Biosource International (Camarillo, Calif.) 
and MWG Biotech (High Point, N.C.). The Cy3 random 65 
beacon and all of the synthetic targets were synthesized by 
Integrated DNA Technologies, Inc. (Coralville, Iowa). 
Acceptor MB: 
5'-/BHQ-3/ACGTGCGACAAGCGCACCGATCACGT/ SEQ ID N0:63 
Cy5/-3' 
Solution Assays of Probe-target Hybridization. 
All solution studies of probe-target hybridization were 
carried out in a 1 xPBS buffer without calcium and magne-
sium using a Satire fluorescent microplate fluorometer 
(Tecan, Zurich, Switzerland), with 545 nm Cy3 (donor) 
excitation and 560 nm to 680 nm emission detection. Con-
centrations of 200 nM donor, 200 nM acceptor molecular 
beacons and 200 nM target were used in a total volume of 
50 µL. 
Cell Culture and Stimulation 
Normal human dermal fibroblasts (Cambrex, N.J.) were 
grown in Clonetics fibroblast growth medium supplemented 
with 2% fetal bovine serum (Cambrex, N.J.), insulin, fibro-
blast growth factor, Gentamicin Sulfate and Amphotericin-
B. HDF cells used for stimulation studies were allowed to 
grow for 24 h before starved with Clonetics fibroblast 
growth medium supplemented with 0.1 % fetal bovine serum 
and no other supplements for 24 h. They were then stimu-
lated with typical growth medium containing 20% fetal 
bovine serum. MIAPaCa-2 (ATCC, VA) pancreatic carci-
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noma cells were grown in DMEM supplemented with 10% 
FBS, 2.5% horse serum and 50 U/ml of penicillin and 50 
µg/ml of streptomycin. 
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probe pair consisted of two molecular beacons, one labeled 
with a donor fluorophore (donor beacon) and a second 
labeled with an acceptor fluorophore (acceptor beacon). 
Molecular beacon delivery using reversible permeabliza-
tion. Molecular beacons were delivered into living cells 5 
using a reversible permeabilization method with streptolysin 
These molecular beacons were designed to hybridize to 
adjacent regions on an mRNA target so that the two fluo-
rophores will lie within the FRET range (-6 nm) when 
0 (SLO), which was shown to be rapid, efficient, less 
damaging, and more versatile (in terms of cell type) com-
pared with conventional transfection methods. Specifically, 
SLO was activated first by adding 5 mM ofTCEP to 2U/ml 10 
of SLO for 30 min at 37° C. Cells grown in 24-well plates 
were incubated for 10 min in 200 µL of serum free medium 
containing 0.2 U/ml of activated SLO (0.5 U SLO per 106 
cells) and 5 µL of each molecular beacon type for cell 
permeabilization and beacon delivery. Cells were then 15 
resealed by adding 0.5 ml of the typical growth medium and 
incubated for 1 hr at 37° C. before performing fluorescence 
microscopy imaging. 
probe/target binding occurs for both beacons. Excitation of 
the donor fluorophore then results in fluorescence emission 
at a wavelength characteristic of the acceptor fluorophore, 
which serves as a positive FRET signal readily differentiable 
from non-FRET false-positive signals due to probe degra-
dation and non-specific probe opening. As shown in Table 7, 
dual FRET molecular beacon pairs were designed in a 
shared-stem fashion, i.e., the sequence of the fluorophore-
attached arm of the stem (FIG. 1) is complementary to the 
target so that it participates in both stem formation and target 
hybridization. This design was chosen to help fix the relative 
distance between the donor and acceptor fluorophores and 
improve energy transfer efficiency. For all FRET molecular Fluorescence microscopy imaging. Fluorescence imaging 
of live cells was performed using a Zeiss Axiovert 100 TV 
epifluorescence microscope coupled to a Cooke Sensicam 
SVGA cooled CCD camera. For assays using dual FRET 
molecular beacons, excitation and emission detection were 
performed using 545 nm and 665 nm filters, respectively. 
For single beacon assays using either donor beacon alone, or 
the random beacons, a filter of 570 nm was used for 
fluorescence detection. Exposure time of 2 s was used for all 
imaging assays. Maximum signal to background ratios were 
calculated based on the maximum signal intensity in cells 
within the field of view divided by the average background 
pixel value from a portion of the field of view not containing 
any cell. 
RT-PCR Assay. Total RNA was isolated from HDF cells 
using a Qiagen RN easy Mini Kit. The yield was 15 sg/ml for 
stimulated HDFs and 37 sg/ml for non-stimulated HDFs. 
The cDNA synthesis was performed using Invitrogen's 
Thermoscript RT-PCR kit with 150 ng of RNA and priming 
with random hexamers. The forward primier used for K-ras 
was GATTCCTACAGGAAGCMGT (SEQ ID NO: 64), and 
reverse primer was TMTGGTGMTATCTTC (SEQ ID NO: 
65). For GAPDH, the forward primer used was CCAC-
CCATGGCAAATTCCATGGCA (SEQ ID NO: 66) and the 
reverse primer was TCTAGACGGCAGGTCAGGTC-
CACC (SEQ ID NO: 67). PCR conditions were as follows: 
95° C. for 5 mins, followed by 95° C. for 30 sec, 52° C. for 
30s, and 720 for 1 min (repeated for each cycle) with tubes 
removed after 15, 20, 25, 30, 35, and 40 cycles. Samples 
were run through on a 1 % agarose gel and stained with EtBr. 
Fluorescence in-situ hybridization. Normal human dermal 
fibroblast cells were cultured in 8-well chambered cover-
slides for 24 hours in normal growth medium (FGM-2 
Cambrex Co.) and then washed with lxPBS (without Ca or 
Mg). The slide was fixed in 100% methanol at -20° C. for 
10 minutes. After removing the methanol, the slides were 
allowed to air dry and stored overnight at -80° C. In-situ 
hybridization assays were then performed by first washing 
the slides for 5 minutes in 1 xPBS and hybridizing them 
overnight at 37° C. in lxPBS (no Ca or Mg) containing 400 
nM of fluorescently labeled linear probes targeting wild-type 
K-ras (5'-Cy5-CCTACGCCACCAGCTCC-3') (SEQ ID 
NO: 68) or as a control (5'-Cy5-
AAAAAAAAAAAAAAA-3') (SEQ ID NO: 69). After 
removing the hybridization solution with washing and add-
ing 1 xPBS, the cells were imaged using an Axiovert 100 
epi-fluorescent microscope 
In this Example, three molecular beacon FRET pairs were 
designed, synthesized and tested in solution. Each FRET 
20 beacons pairs, Cy3 (peak excitation at 545 nm) and Cy5 
(peak emission at 665 nm) were used as the donor and 
acceptor fluorophores, respectively, and BHQ-2 and BHQ-3 
were used as quenchers for the donor and acceptor molecu-
lar beacons, respectively One pair of molecular beacons 
25 targets a segment of the wild-type K-ras gene (Table 7) 
whose codon 12 mutations are involved in the pathogenesis 
of many cancers. A member of the GTPases family, K-ras is 
involved in regulating cell growth, proliferation and differ-
entiation. As shown in Table 7, the target sequence for 
30 K-ras-targeting donor beacon has 17 bases (red), and that for 
the acceptor beacon has 19 bases (blue). The other pair of 
molecular beacons targets the survivin gene, which is a 
member in the inhibitor of apoptosis protein (IAP) family. 
The target sequences for survivin-targeting donor and accep-
35 tor molecular beacons are respectively 15 bases (red) and 16 
bases (blue) long. For both K-ras- and survivin-targeting 
molecular beacon pairs, the stem size is 5 bases, and the gap 
size between the donor and acceptor beacons on a target is 
4 bases. For use in negative controls, Cy3- and Cy5-labeled 
40 'random' -sequence molecular beacons ('random beacon') 
whose specific 16-base target sequence does not match with 
any manmialian gene were designed. Note that both the 
donor (Cy3-labeled) and acceptor (Cy5-labeled) random 
beacons have an identical sequence, and the 'random 
45 sequence' target is for a signal beacon only (Table 7). 
Solution studies of FRET signal and specificity. In-solu-
tion probe-target hybridization studies were carried out to 
determine the extent of energy transfer between, and signal-
to-background ratio of, dual FRET molecular beacons, as 
50 well as the specificity of the random beacon. Shown in FIG. 
22A are five fluorescence emission spectra of molecular 
beacons targeting wild-type K-ras under Cy3 excitation (545 
nm); they were generated by having: (1) donor beacons only 
in the presence of target (blue curve), representing the signal 
55 of a single beacon assay; (2) both donor and acceptor 
beacons in solution with target (green curve), representing 
the FRET signal; (3) donor beacons only without target (red 
curve), representing the background of a single-beacon 
assay; ( 4) donor and acceptor beacons in solution without 
60 target (light blue curve), representing the background of a 
FRET assay and (5) acceptor beacons with target (black 
curve). These results implies that, even when a large amount 
of single (donor or acceptor) molecular beacons are 
degraded by nucleases or open due to non-specific interac-
65 tions, the resulting fluorescence signal at the FRET detection 
wavelength of 665 nm (dark blue curve) is still much lower 
than the FRET signal (green curve). The FRET signal-to-
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background ratio (green curve vs. light blue curve at 665 
run) is approximately 9.0. The survivin-targeting molecular 
beacons under Cy3 excitation (545 run) exhibited essentially 
the same spectroscopic features, as shown by the five curves 
in FIG. 22B. When the random beacons were mixed respec-
tively with the complementary random-sequence target, or 
the wild-type K-ras target, or the survivin target, only targets 
complementary to the probe sequence of random beacons 
gave strong fluorescence signal, other targets gave very low 
background (FIG. 22C), confirming the high specificity of 10 
random-sequence molecular beacons. 
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detection sens1tJv1ty and allows for a more quantitative 
measurement of relative changes in mRNA level in living 
cells upon stimulation. This capability is important for both 
basic biological studies and drug discovery research in 
which it is critical to quantify changes of gene expression in 
living cells in response to stimuli including hormones, 
growth factors, candidate drug molecules and other chemi-
cal/mechanical insults. 
In comparing the ratios of K-ras mRNA expression in 
stimulated and unstimulated HDF cells, it was assumed that 
the K-ras expression level in different cells imaged simul-
taneously is roughly the same, which is supported by FIGS. 
23B, 23D, 23F and 23H. Consequently, although the quan-
titative analysis of fluorescence intensity was performed 
based on, and averaged over, only a few cells, the results 
should remain valid when a large number of cells are 
examined. Therefore, the ratios of 1.2 (single-beacon) and 
2.25 (dual-beacon) given in FIG. 23I represent fairly accu-
rately the difference in K-ras mRNA detection using single 
and dual molecular beacon approaches. Further, the result of 
dual-beacon FRET detection is more accurate than that of 
the single-beacon approach, since it yielded a much lower 
background signal as demonstrated by FIGS. 23A, 23C, 23E 
and 23G. However, when specific mRNA expression has 
large variations from cell to cell, analyses of fluorescence 
intensity of only a few cells may not be statistically signifi-
cant and the results may not be reproducible. In this case the 
fluorescence intensity of a large number of cells (say, at least 
a few hundred cells) must be analyzed in order to obtain 
accurate quantification of mRNA expression. 
Survivin mRNA expression in normal and cancerous 
cells. To detect survivin mRNA expression in HDF and 
MIAPaCa-2 cells, survivin-targeting donor beacon alone, 
survivin-targeting dual FRET molecular beacons, and the 
random beacons (Table 7) were delivered respectively into 
these cells using SLO. The resulting fluorescence signal was 
K-ras mRNA detection in normally-growing and stimu-
lated HDF cells. In order to demonstrate the advantages of 
the dual FRET molecular beacons approach, living cell 
assays were performed with both normally-growing and 15 
stimulated HDF cells. To increase the K-ras mRNA expres-
sion level, HDF cells were first starved for 24 h and then 
stimulated with serum for 8 h before molecular beacon 
delivery. Cells were permeabilized using streptolysin 0 
(SLO) and were exposed to either Cy3-labeled random- 20 
sequence or K-ras-targeting single molecular beacons, or 
Cy3- and Cy5-labeled random-sequence or K-ras-targeting 
donor and acceptor molecular beacon pairs. The resulting 
fluorescence signal was observed under Cy3 excitation (545 
run) 1 h after beacon delivery with the Cy3 emission channel 25 
(570 run) for single beacon assays and Cy5 emission channel 
(665 run) for dual beacon assays (FIGS. 23A-H). Signals 
from the single random beacon negative controls (FIGS. 
23A and 23C) should be due entirely to beacon degradation, 
non-specific interactions and possibly other backgrounds 30 
such as autofluorescence of the cell. Signals from single 
Cy3-labeled (i.e., unpaired donor) K-ras-targeting molecular 
beacons (FIG. 23B) were not appreciably greater than those 
found with random beacons (FIG. 23A), clearly demonstrat-
ing the limitation of using single molecular beacons in RNA 35 
detection in living cells, especially when the expression 
level is relatively low. With stimulated HDF cells, the 
fluorescence signal level in single beacon K-ras detection 
increased (FIG. 23D), but it was still not much higher then 
the corresponding background signal (FIG. 23C). 40 visualized 1 h after delivery. FIGS. 24A and 24C display the fluorescence signal of random beacons in HDF and MIA-
PaCa-2 cells, respectively, representing the background sig-
nal level in each cell type with single beacon detection. 
When the fluorescence of single (unpaired) survivin-target-
When random beacon FRET pairs were delivered into 
either normally-growing or stimulated HDF cells, the result-
ing FRET signals detected in the Cy5 channel were very low 
(FIGS. 23E and 23G). The expression levels ofK-ras mRNA 
in normally-growing and stimulated HDF cells were 45 
detected using the dual FRET molecular beacons, and the 
resulting fluorescence signals are shown respectively in 
FIGS. 23F and 23H, respectively. Even with unstimulated 
HDF cells, the fluorescence signal as a result of K-ras 
mRNA detection (FIG. 23F) was much higher than the 50 
background (FIG. 23E), indicating that dual FRET molecu-
lar beacons are capable of distinguishing true and false-
positive signals, which is in sharp contrast with the results 
of single beacon detection shown in FIGS. 23A and 23B. 
With stimulated HDF cells, the fluorescence signal level as 55 
a result of the dual FRET molecular beacon detection of 
K-ras mRNA had a significant increase, as shown in FIG. 
23H. 
ing donor beacons were imaged under Cy3 excitation (545 
run) and Cy3 emission detection (570 run), the signal level 
in MIAPaCa-2 cells (FIG. 24B) was similar to that of 
random beacon (FIG. 24A), indicating that the signal was 
mainly due to false-positive events. The fluorescence signal 
of single survivin-targeting molecular beacons in HDF cells 
was essentially the same as that of the random beacon. 
Therefore, using single beacons, the true signal of survivin 
mRNA detection cannot be distinguished from false-positive 
signals. 
Using FRET detection, i.e., with Cy3 excitation and Cy5 
emission detection, the signal generated by random-beacons 
was very low in both HDF and MIAPaCa-2 cells, as can be 
seen from FIGS. 24E and 24G. This implies that the false-Quantitative analysis of the average signal intensities of 
the images in FIGS. 23F and 23H gave a factor of 2.25 
increase in K-ras expression in stimulated HDF comparing 
with that in normally-growing cells, consistent with the 
result of the RT-PCR assay, which indicated a factor of 1.95 
increase in K-ras expression after stimulation. In contrast, 
single-beacon detection assays yielded an increase of only a 
factor of 1.2 (FIG. 23I). This clearly demonstrates that the 
dual-FRET molecular beacons approach has much better 
60 positive signals due to beacon degradation and non-specific 
opening can be dramatically reduced using FRET optics. 
Using dual FRET molecular beacons targeting survivin 
(Table 7), and with the FRET optics (i.e., 545 run excitation 
and 570 run emission detection), the fluorescence signal 
65 level in MIAPaCa-2 cells (FIG. 4f) was much higher than 
that in HDF cells (FIG. 4h ), with a 250% increase in average 
signal intensity. This demonstrates that dual FRET molecu-
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lar beacons have the ability to quantify specific mRNA 
expression in different cell populations. 
Localization ofK-ras and survivin mRNA in living cells. 
The dual FRET molecular beacons approach can give a clear 
and detailed picture of mRNA localization in living cells 
which may reveal important information on mRNA process-
ing, transport, and protein production. To demonstrate, in 
FIGS. 25Aand 25B, fluorescence images ofK-ras mRNAin 
stimulated HDF cells are shown, indicating an intriguing 
localization pattern. Evidently, the K-ras mRNA molecules 
were not randomly distributed but rather well organized and 
localized in the cytoplasm. It is clear from the fluorescence 
images that the K-ras mRNA molecules were well distrib-
uted in the cytoplasm and followed the cell morphology as 
indicated by the cable-like portion of an elongated cell in 
FIG. 25B. When the fluorescence image of a small periph-
eral region of a cell is expanded, the K-ras mRNAs seem to 
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observed in the cytoplasm than nucleus. It is also possible 
that the intracellular distribution of signal is related to the 
specific delivery method used. For example, when delivered 
via the endocytic pathway (e.g., liposome-based transfec-
tion), antisense oligonucleotide probes tend to be trapped 
inside endocytic vesicles and degraded in the endosomes 
and lysosomes. In this Example a toxin-based delivery 
method was used so that the probes do not go through 
endosomes or lysosomes after entering cells through mem-
10 brane permeabilization. After internalization the probes bind 
to their mRNA targets in the cytoplasm before reaching the 
nucleus. The probe concentrations used are significantly 
lower (at least a factor of 10 lower) than in most of the 
antisense work; therefore the probability of driving the 
15 probes into the nucleus by a high concentration gradient is 
much smaller. As a control fluorescently labeled linear 
oligonucleotides were delivered using SLO and most of the 
signal observed was in the cytoplasm as well (data not be localized along a cytoskeletal filament system, possibly 
the microtubule system. Indeed the co-localization of 
mRNA with cytoskeletal filaments has been suggested. A 20 
similar feature is shown in FIG. 25B in which the image of 
shown). 
It has been revealed over the last few years that RNA 
molecules have a much wider range of functions, from 
physically conveying and interpreting the genetic informa-
tion of living cells, to essential catalytic roles, to providing 
structural support for molecular machines, to gene silencing. 
a small region of a different HDF cell is expanded. This is 
believed to be the first direct visualization of K-ras mRNA 
localization in living cells. Surprisingly, survivin mRNA 
localized in MIAPaCa-2 cell very differently. As shown in 
FIG. 25C in which the fluorescence image was superim-
posed with a white-light image of the cells, survivin mRNAs 
seemed to localize in a non-symmetrical pattern within 
MIAPaCa-2 cells, often to one side of the nucleus of the cell. 
The intriguing differences in mRNA localization is likely a 
consequence of the association of mRNA with the cell 
cytoskeleton or mitochondria. 
Control study using in situ hybridization. As a control, a 
fluorescence in situ hybridization (FISH) assay detecting 
K-ras mRNA in fixed HDF cells was performed. A fluores-
cently labeled linear probe (5'-Cy5-CCTACGCCAC-
CAGCTCC-3') (SEQ ID NO: 68) that has the same probe 
sequence as the K-ras-targeting donor molecular beacon 
(Table 7) was used. As demonstrated in FIG. 26a, the 
fluorescence image obtained in the FISH assay of K-ras 
mRNA detection in HDF cells gave a filamentous localiza-
tion pattern as well, especially in the cell peripheral region, 
similar to that shown in FIGS. 25A and 25B, confirming that 
the mRNA localization revealed in this study is true. How-
ever, in the region near cell nucleus, the fluorescence image 
as a result of FISH has a high background compared with 
that of living cell assays using dual FRET molecular bea-
cons. Since the probes entered both the cell cytoplasm and 
nucleus during FISH, a strong and diffused fluorescence 
signal appeared in the fixed HDF cell nuclei (FIG. 26A). As 
a negative control, a FISH assay with fluorescently labeled 
linear Poly-A probes (5'-Cy5-
AAAAAAAAAAAAAAA-3') (SEQ ID NO: 69) was 
performed and the resulting background signal was very 
low, as can be seen from FIG. 26B. This further confirmed 
that the fluorescence signal observed in the live cell and 
fixed cell studies of specific mRNA detection was truly due 
to probe/target hybridization. 
25 These activities are controlled by the dynamics of both the 
expression levels of specific RNAs and their spatial distri-
butions. Although in vitro assays such as DNA microarrays 
and Northern blotting can reflect the relative changes in 
RNA expression level of a cell population, imaging of 
30 specific RNA (including mRNA and microRNA) in living 
cells in real-time can provide essential information on how 
external stimuli alter the gene expression level in cells, what 
are the processes of RNA localization, transport, and inter-
ference, and how RNAs interact with proteins or protein 
35 complexes. As demonstrated here, the dual FRET molecular 
beacons technique can detect endogenous mRNA in living 
cells rapidly with high specificity, sensitivity, and signal-to-
background ratio, thus providing a powerful tool to address 
all these issues. For example, in drug discovery, this method 
40 can be used in high-throughput assays to quantify and 
monitor the dose-dependent changes of specific mRNA 
expression in response to different candidate drug mol-
ecules. In basic biological studies, this method will allow 
researchers to visualize the dynamics and localization of 
45 specific RNAs. 
A very intriguing observation in this study is the local-
ization of mRNAin living cells. As demonstrated in FIG. 25, 
K-ras mRNAs displayed an interesting filament-like local-
ization pattern in HDF cells, with a clear indication of 
50 spreading out in the cytoplasm and following the cell 
morphology. On the other hand, survivin mRNA was local-
ized on one side of the cell nucleus. But why are K-ras and 
survivin mRNAs localized in such a peculiar way? What are 
the biological implications of such localization? RNA local-
55 ization is an evolutionarily conserved phenomenon and may 
be the first step in targeting proteins to specific locations to 
facilitate protein-protein interactions. For example, mRNA 
localization and translation has been found in dendrites and 
axons in neural cells. It has been indicated that intracellular Intracellular distribution of probe/target binding sites. It 
should be noted that in all of the images shown in FIGS. 23, 60 
24 and 25, very little mRNA expression was detected in the 
cell nucleus. Although the results seemingly contradict the 
observation that antisense oligonucleotide probes rapidly 
accumulate in the nucleus, it remains to be seen if such 
nuclear localization is due to any fundamental biological 65 
reason. In fact, when molecular beacons were microinjected 
into cells, considerably more fluorescence signal was 
mRNA localization may involve interactions between tar-
geting signals within the RNA, motor molecules, and the 
cytoskeleton. Although the association of mRNA with 
microtubules has been suggested based on the results of 
biochemical assays, there is still a lack of direct confirmation 
of mRNA localization to cytoskeletal filaments. One diffi-
culty is that the cytoskeleton is a dynamic network and the 
mechanism of transport for mRNA is largely unknown. 
US 7,297,494 B2 
69 
Studies have been performed using either GFP fusion pro-
teins that bind to RNA or by injecting fluorescently labeled 
mRNAs into cells and tracking them. However, by imaging 
endogenous mRNAs directly insights into the rates of RNA 
synthesis and processing, the dynamics of RNA transport 
and localization, and RNA-protein interactions were gained. 
70 
As demonstrated in this study, the dual FRET molecular 
beacons approach has the advantage that false-positive sig-
nals in living cell gene detection due to nucleases and 
nucleic-acid binding proteins can be significantly reduced or 
even eliminated, leading to high detection sensitivity. This 
approach is based on simultaneous hybridization of two 
probes to the same mRNA target so that a FRET signal can 
be emitted upon proper excitation. Although dual FRET 
linear probes have been used for living cell mRNA detec-
tion, they typically provide a higher background signal than 
molecular beacons as a result of the fluorescence emission of 
unbound probes, including donor emission at the detection 
wavelength and direct acceptor excitation. Further, hairpin 
probes can provide better specificity. While the use of dual 20 
FRET probes may further increase detection specificity, 
compared with single molecular beacon assays, the dual-
probe approach does require twice as many probes to be 
delivered into cells and a longer time for probe targeting and 
hybridization. Therefore, for specific applications where fast 25 
detection (-30 min) is crucial, single molecular beacon 
assays such as that based on peptide-linked molecular bea-
cons may be more suitable. 
Another important issue in living cell gene detection is the 
quantification of mRNA expression in single cells There are 
many challenges in obtaining an accurate measure of the 
number of mRNA molecules per cell using molecular bea-
cons (or any imaging method). For example, it is necessary 
to distinguish true and background signals, determine the 
fraction of mRNA molecules hybridized with probes, and 
quantify the possible self-quenching effect of the reporter, 
especially when mRNA is highly localized. Since the fluo-
lO rescence intensity of the reporter may be altered by the 
intracellular environment, it is also necessary to create an 
internal control by, for example, injecting fluorescently 
labeled oligonucleotides with known quantity into the same 
15 cells and obtaining the corresponding fluorescence intensity. 
As demonstrated in previous studies, the use of 2'-0-
methyl modified molecular beacons has certain potential 30 
advantages including improved intracellular stability and 
faster probe/target hybridization kinetics. However, there 
are issues and potential drawbacks as well. One issue is that 
the 2'-0-methyl modified molecular beacons may be more 
prone to open in living cells due to nucleic acid binding 35 
proteins, therefore generating a higher background. Further, 
2'-0-methyl modified beacons are RNA-like, and therefore 
may form double-stranded RNA upon probe-target binding 
and trigger unwanted RNAi in living cells. A major advan-
tage of using 2'-0-methyl molecular beacons is their 40 
enhanced nuclease resistance. However, most of the 
nucleases are in the endosomes, lysosomes and nucleus. If 
the probes are delivered directly into the cytoplasm and the 
endocytic pathway can be avoided, nuclease resistance may 
not be an essential issue. It is important to compare the 45 
performance of molecular beacons with different backbone 
modifications in living cell gene detection (Santangelo and 
Bao, unpublished work). 
A critical issue in living cell mRNA detection is target 
accessibility, which is largely controlled by mRNA second- 50 
ary and tertiary structures and RNA-binding proteins. Spe-
cifically, mRNA in a cell almost always has proteins bound 
to it, which may alter mRNA structure and prevent probe 
hybridization. Therefore, in selecting the probe sequences of 
the dual FRET molecular beacons, it is important to avoid 55 
targeting sequences that are 'buried' inside the tertiary 
structure or where double stranded RNA is formed. 
Although predictions of mRNA secondary structure can be 
made using existing software (e.g., mfold), they may not be 
accurate due to limitations of the biophysical models used. 60 
Further, there is only very limited knowledge of the 
sequences occupied dynamically by RNA-binding proteins. 
Therefore, for each gene to target, it is often necessary to 
select multiple unique sequences along the target RNA, and 
have corresponding molecular beacons designed, synthe- 65 
sized and tested in cells to achieve high signal-to-back-
ground ratio. 
A related issue in molecular beacon based gene quantifi-
cation in living cells is the detection sensitivity, which is 
dictated not only by probe/target hybridization but also by 
the properties of fluorophore, fluorescence detection 
method, optical imaging instrumentation (microscope and 
camera) and background signal. Due to the low background 
in the dual FRET molecular beacons approach, improved 
detection sensitivity can be achieved compared with fluo-
rescence in situ hybridization (FISH), as demonstrated by 
FIGS. 24 and 26. Using microinjection of probe/target 
duplexes, Sokol et al. found that the molecular beacon based 
approach could detect 10 mRNA molecules per cell when 
they are concentrated at the same spot. It is estimated that the 
current approach can reliably detect a few hundred copies of 
endogenous mRNA per cell in single cell gene detection. 
With the use of advanced fluorophores such as quantum dots 
or lanthanide chelates, fluorescence detection methods such 
as time-resolved FRET, and more sensitive optical imaging 
instruments such as that with photon counting, it is possible 
to detect as low as 1-5 copies of mRNAmolecules in a single 
cell. An alternative approach is to obtain the average mRNA 
expression over a large number of cells (say one million), 
similar to that in RT-PCR studies. In this case a FRET-based 
flow cytometry assay using F ACS (Fluorescence Activated 
Cell Sorter) could be performed to detect the fluorescence 
signal level in living cells. While single cell mRNA detec-
tion can be used to study more accurately the variation of 
gene expression in a cell population with different stages in 
the cell cycle or different disease states, the determination of 
the average mRNA expression level over a large number of 
cells may be advantageous in that, when the cell-cell varia-
tion of mRNA expression is large, it is statistically more 
significant and thus more reproducible compared with the 
mRNA level detected using a relatively small number of 
cells. 
Throughout this application, various references are cited. 
The disclosures of all of these references and those refer-
ences cited within those references in their entireties are 
hereby incorporated by reference into this application. It will 
be apparent to those skilled in the art that various modifi-
cations and variations can be made in the present disclosure 
without departing from the scope or spirit of the disclosure. 
Other embodiments of the disclosure will be apparent to 
those skilled in the art from consideration of the specifica-
tion and practice of the disclosure disclosed herein. It is 
intended that the specification and Examples be considered 
as exemplary only. Those skilled in the art will recognize, or 
will be able to ascertain using no more than routine experi-
mentation, many equivalents to the specific embodiments of 
the disclosure described herein. Such equivalents are 
intended to be encompassed by the following claims. 
US 7,297,494 B2 
71 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS: 69 
<210> SEQ ID NO 
<211> LENGTH: 11 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Protein Transduction Domain 
<400> SEQUENCE: 
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg 
1 5 10 
<210> SEQ ID NO 2 
<211> LENGTH: 9 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Protein Transduction 
<400> SEQUENCE: 2 
Arg Lys Lys Arg Arg Gln Arg Arg Arg 
1 5 
<210> SEQ ID NO 3 
<211> LENGTH: 23 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: molecular probe 
<400> SEQUENCE: 3 
gagtccttcc acgataccga etc 
<210> SEQ ID NO 4 
<211> LENGTH: 23 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Molecular probe 
<400> SEQUENCE: 4 
ccacatgatg gcatggactg tgg 
<210> SEQ ID NO 5 
<211> LENGTH: 7 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Protein Transduction 
<400> SEQUENCE: 5 
Arg Arg Arg Arg Arg Arg Arg 
1 5 
<210> SEQ ID NO 6 
<211> LENGTH: 12 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
Domain 
Domain 
<223> OTHER INFORMATION: Protein Transduction Domain 
<400> SEQUENCE: 
Arg Arg Gln Arg Arg Thr Ser Lys Leu Met Lys Arg 
1 5 10 
72 
23 
23 
<210> SEQ ID NO 7 
<211> LENGTH: 27 
<212> TYPE: PRT 
73 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
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<223> OTHER INFORMATION: Protein Transduction Domain 
<400> SEQUENCE: 
Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Lys Ile Asn Leu 
1 5 10 15 
Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu 
20 25 
<210> SEQ ID NO 8 
<211> LENGTH: 29 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Protein Transduction Domain 
<400> SEQUENCE: 
Trp Glu Ala Lys Leu Ala Lys Ala Leu Ala Lys Ala Leu Ala Lys His 
1 5 10 15 
Leu Ala Lys Ala Leu Ala Lys Ala Leu Lys Cys Glu Ala 
20 25 
<210> SEQ ID NO 9 
<211> LENGTH: 34 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Protein Transduction Domain 
<400> SEQUENCE: 
Asp Ala Ala Thr Ala Thr Arg Gly Arg Ser Ala Ala Ser Arg Pro Thr 
1 5 10 15 
Glu Arg Pro Arg Ala Pro Ala Arg Ser Ala Ser Arg Pro Arg Arg Pro 
20 25 30 
Val Glu 
<210> SEQ ID NO 10 
<211> LENGTH: 60 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Target sequence 
<400> SEQUENCE: 10 
tgacaacttt ggtatcgtgg aaggactcat gaccacagtc catgccatca ctgccaccca 60 
<210> SEQ ID NO 11 
<211> LENGTH: 24 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Acceptor Beacon 
<400> SEQUENCE: 11 
ctcagaccat agcaccttcc tgag 
<210> SEQ ID NO 12 
<211> LENGTH: 23 
<212> TYPE: DNA 
24 
74 
75 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Donor Beacon 
<400> SEQUENCE: 12 
ggtgtcaggt acggtagtac ace 
<210> SEQ ID NO 13 
<211> LENGTH: 16 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
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<223> OTHER INFORMATION: Protein Transduction Domain 
<400> SEQUENCE: 13 
Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys 
1 5 10 15 
<210> SEQ ID NO 14 
<2 11 > LENGTH : 7 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Nuclear localization signal 
<400> SEQUENCE: 14 
Pro Lys Lys Lys Arg Lys Val 
5 
<210> SEQ ID NO 15 
<2 11 > LENGTH : 7 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Nuclear localization signal 
<400> SEQUENCE: 15 
Gly Lys Lys Arg Ser Lys Val 
1 5 
<210> SEQ ID NO 16 
<211> LENGTH: 7 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Nuclear localization 
<400> SEQUENCE: 16 
Lys Ser Arg Lys Arg Lys Leu 
1 5 
<210> SEQ ID NO 17 
<211> LENGTH: 19 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
signal 
<223> OTHER INFORMATION: Nuclear localization signal 
<400> SEQUENCE: 17 
Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys Lys 
1 5 10 15 
Leu Asp Lys 
<210> SEQ ID NO 18 
<211> LENGTH: 20 
<212> TYPE: PRT 
76 
23 
77 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
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<223> OTHER INFORMATION: Nuclear localization signal 
<400> SEQUENCE: 18 
Arg Lys Lys Arg Lys Thr Glu Glu Glu Ser Pro Leu Lys Asp Lys Ala 
1 5 10 15 
Lys Lys Ser Lys 
20 
<210> SEQ ID NO 19 
<211> LENGTH: 20 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Nuclear localization signal 
<400> SEQUENCE: 19 
Lys Asp Cys Val Met Asn Lys His His Arg Asn Arg Cys Gln Tyr Cys 
1 5 10 15 
Arg Leu Gln Arg 
20 
<210> SEQ ID NO 
<211> LENGTH: 9 
<212> TYPE: PRT 
20 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Nuclear localization 
<400> SEQUENCE: 20 
Pro Ala Ala Lys Arg Val Lys Leu Asp 
5 
<210> SEQ ID NO 21 
<211> LENGTH: 20 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
signal 
<223> OTHER INFORMATION: nuclear localization signal 
<400> SEQUENCE: 21 
Lys Lys Tyr Glu Asn Val Val Ile Lys Arg Ser Pro Arg Lys Arg Gly 
1 5 10 15 
Arg Pro Arg Lys 
20 
<210> SEQ ID NO 22 
<211> LENGTH: 23 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Donor probe 
<400> SEQUENCE: 22 
ccacatgatg gcatggactg tgg 
<210> SEQ ID NO 23 
<211> LENGTH: 18 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Donor probe 
<400> SEQUENCE: 23 
78 
23 
tgatggcatg gactgtgg 
<210> SEQ ID NO 24 
<211> LENGTH: 25 
<212> TYPE: DNA 
79 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Stem-loop probe 
<400> SEQUENCE: 24 
gagtccttcc acgtaaccag gactc 
<210> SEQ ID NO 25 
<211> LENGTH: 27 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Target sequence 
<400> SEQUENCE: 25 
actttggtat cgtggaagga ctcatga 
<210> SEQ ID NO 26 
<211> LENGTH: 22 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Stem-loop probe 
<400> SEQUENCE: 26 
gagtccttcc acgataccac tc 
<210> SEQ ID NO 27 
<211> LENGTH: 23 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Acceptor probe 
<400> SEQUENCE: 27 
gagtccttcc acgataccga etc 
<210> SEQ ID NO 28 
<211> LENGTH: 23 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Acceptor probe 
<400> SEQUENCE: 28 
gagtccttcc acgataccga etc 
<210> SEQ ID NO 29 
<211> LENGTH: 23 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Acceptor probe 
<400> SEQUENCE: 29 
gagtccttcc acgataccga etc 
<210> SEQ ID NO 30 
<211> LENGTH: 49 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
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23 
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<220> FEATURE: 
<223> OTHER INFORMATION: Target sequence 
<400> SEQUENCE: 30 
actttggtat cgtggaagga ctcataccac agtccatgcc atcactgcc 
<210> SEQ ID NO 31 
<211> LENGTH: 50 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Target sequence 
<400> SEQUENCE: 31 
actttggtat cgtggaagga ctcatgacca cagtccatgc catcactgcc 
<210> SEQ ID NO 32 
<211> LENGTH: 51 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Target sequence 
<400> SEQUENCE: 32 
actttggtat cgtggaagga ctcattgacc acagtccatg ccatcactgc c 
<210> SEQ ID NO 33 
<211> LENGTH: 52 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Target sequence 
<400> SEQUENCE: 33 
actttggtat cgtggaagga ctcatttgac cacagtccat gccatcactg cc 
<210> SEQ ID NO 34 
<211> LENGTH: 22 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Shared-stem probe 
<400> SEQUENCE: 34 
gagtccttcc acgataccac tc 
<210> SEQ ID NO 35 
<211> LENGTH: 24 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Shared-stem probe 
<400> SEQUENCE: 35 
gagtccttcc acgataccag actc 
<210> SEQ ID NO 36 
<211> LENGTH: 25 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Shared-stem probe 
<400> SEQUENCE: 36 
gagtccttcc acgataccag gactc 
82 
49 
50 
51 
52 
22 
24 
25 
<210> SEQ ID NO 37 
<211> LENGTH: 27 
<212> TYPE: DNA 
83 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Conventional probe 
<400> SEQUENCE: 37 
cctcgagtcc ttccacgata ccagagg 
<210> SEQ ID NO 38 
<211> LENGTH: 29 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Conventional probe 
<400> SEQUENCE: 38 
ctgacgagtc cttccacgat accagtcag 
<210> SEQ ID NO 39 
<211> LENGTH: 30 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Conventional probe 
<400> SEQUENCE: 39 
ctgagcgagt ccttccacga taccagctca 
<210> SEQ ID NO 40 
<211> LENGTH: 27 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Target sequence 
<400> SEQUENCE: 40 
actttggtat cgtggaagga ctcatga 
<210> SEQ ID NO 41 
<211> LENGTH: 27 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Target sequence 
<400> SEQUENCE: 41 
actttggtat cgtggaagga atcatga 
<210> SEQ ID NO 42 
<211> LENGTH: 27 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Target sequence 
<400> SEQUENCE: 42 
actttggtat cgtagaagga ctcatga 
<210> SEQ ID NO 43 
<211> LENGTH: 27 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Target sequence 
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<400> SEQUENCE: 43 
actttggtat cgtagaagga atcatga 
<210> SEQ ID NO 44 
<211> LENGTH: 27 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Target sequence 
<400> SEQUENCE: 44 
actttggtat cgtaaaagga ctcatga 
<210> SEQ ID NO 45 
<211> LENGTH: 78 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Molecular beacon 
<400> SEQUENCE: 45 
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27 
27 
atgactgaat ataaacttgt ggtagttgga gctggtggcg taggcaagag tgccttgacg 60 
atacagctaa ttcagaat 78 
<210> SEQ ID NO 46 
<211> LENGTH: 24 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Donor Beacon 
<400> SEQUENCE: 46 
agtgcgctgt atcgtcaagg cact 
<210> SEQ ID NO 47 
<211> LENGTH: 22 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Acceptor Beacon 
<400> SEQUENCE: 47 
cctacgccat cagctccgta gg 
<210> SEQ ID NO 48 
<211> LENGTH: 22 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Acceptor Beacon 
<400> SEQUENCE: 48 
cctacgccaa cagctccgta gg 
<210> SEQ ID NO 49 
<211> LENGTH: 22 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Acceptor Beacon 
<400> SEQUENCE: 49 
cctacgccac gagctccgta gg 
24 
22 
22 
22 
86 
<210> SEQ ID NO 50 
<211> LENGTH: 22 
<212> TYPE: DNA 
87 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Acceptor Beacon 
<400> SEQUENCE: 50 
cctacgccac aagctccgta gg 
<210> SEQ ID NO 51 
<211> LENGTH: 121 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Molecular Beacon 
<400> SEQUENCE: 51 
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22 
atgggtgccc cgacgttgcc ccctgcctgg cagccctttc tcaaggacca ccgcatctct 60 
acattcaaga actggccctt cttggagggc tgcgcctgca ccccggagcg gatggccgag 120 
g 121 
<210> SEQ ID NO 52 
<211> LENGTH: 23 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Donor Beacon 
<400> SEQUENCE: 52 
ccttgagaaa gggctgccca agg 
<210> SEQ ID NO 53 
<211> LENGTH: 23 
<212> TYPE: DNA 
<213> ORGANISM: Acceptor Beacon 
<400> SEQUENCE: 53 
ccgcattgaa tgtagagatg egg 
<210> SEQ ID NO 54 
<211> LENGTH: 24 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Donor probe 
<400> SEQUENCE: 54 
acctggatgt tgtcctcgtc aggt 
<210> SEQ ID NO 55 
<211> LENGTH: 24 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Acceptor probe 
<400> SEQUENCE: 55 
aagattgaag accttggcga tctt 
<210> SEQ ID NO 56 
<211> LENGTH: 78 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
23 
23 
24 
24 
88 
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<220> FEATURE: 
<223> OTHER INFORMATION: Target Sequence 
<400> SEQUENCE: 56 
atgactgaat ataaacttgt ggtagttgga gctggtggcg taggcaagag tgccttgacg 60 
atacagctaa ttcagaat 78 
<210> SEQ ID NO 57 
<211> LENGTH: 22 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Donor probe 
<400> SEQUENCE: 57 
cctacgccac cagctccgta gg 
<210> SEQ ID NO 58 
<211> LENGTH: 24 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: acceptor probe 
<400> SEQUENCE: 58 
agtgcgctgt atcgtcaagg cact 
<210> SEQ ID NO 59 
<211> LENGTH: 78 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Target Sequence 
<400> SEQUENCE: 59 
22 
24 
atgggtgccc cgacgttgcc ccctgcctgg cagccctttc tcaaggacca ccgcatctct 60 
acattcaaga actggccc 7 8 
<210> SEQ ID NO 60 
<211> LENGTH: 20 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Donor probe 
<400> SEQUENCE: 60 
gagaaagggc tgccattctc 
<210> SEQ ID NO 61 
<211> LENGTH: 21 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Acceptor probe 
<400> SEQUENCE: 61 
accacgtaga gatgcggtgg t 
<210> SEQ ID NO 62 
<211> LENGTH: 26 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Donor probe 
20 
21 
90 
91 
<400> SEQUENCE: 62 
cacgtcgaca agcgcaccga tacgtg 
<210> SEQ ID NO 63 
<211> LENGTH: 26 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Acceptor probe 
<400> SEQUENCE: 63 
acgtgcgaca agcgcaccga tcacgt 
<210> SEQ ID NO 64 
<211> LENGTH: 20 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Primer 
<400> SEQUENCE: 64 
gattcctaca ggaagcaagt 
<210> SEQ ID NO 65 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Primer 
<400> SEQUENCE: 65 
taatggtgaa tatcttc 
<210> SEQ ID NO 66 
<211> LENGTH: 24 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Forward primer 
<400> SEQUENCE: 66 
ccacccatgg caaattccat ggca 
<210> SEQ ID NO 67 
<211> LENGTH: 24 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Reverse primer 
<400> SEQUENCE: 67 
tctagacggc aggtcaggtc cacc 
<210> SEQ ID NO 68 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Linear probe 
<400> SEQUENCE: 68 
cctacgccac cagctcc 
<210> SEQ ID NO 69 
<211> LENGTH: 18 
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<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Control 
<400> SEQUENCE: 69 
aaaaaaaaaa aaaaaaaa 18 
We claim: 
1. A probe set comprising: 
(a) a donor polymer comprising 
(i) a first polynucleotide binding domain complemen-
tary to a first region of a target polynucleotide 
flanked by first and second stem regions which 
hybridize in the absence of the target polynucleotide 
14. The probe set of claim 1, wherein the quantum dot is 
encapsulated in a micelle or polymer coating, or chemically 
15 linked coatings such as silica-based coatings or DHLA (Lipoic Acid) and Mercaptoacetic Acid coatings. 
15. The probe set of claim 14, wherein micelle comprises 
a lipid, phospholipid, or a combination thereof. 
to form a stem-loop or random-coil structure, and 
(ii) a quantum dot; and 
(b) an acceptor polymer comprising 
16. The probe set of claim 14, wherein the polymer 
20 coating comprises polyethylene glycol or derivatives 
thereof. 
(i) a second polynucleotide binding domain comple-
mentary to a second region of the target polynucle-
otide flanked by first and second stem regions which 
25 hybridize in the absence of the target polynucleotide 
to form a stem-loop or random-coil structure, and 
(ii) at least one reporter; 
wherein energy transfer occurs between the donor and the 
at least one reporter when the donor polymer and the 
30 
acceptor polymer hybridize to the target polynucleotide 
and the quantum dot is exposed to an exciting amount 
of energy. 
2. The probe set of claim 1, wherein the reporter does not 
emit a detectable signal when exposed to an exciting amount 
35 
of energy sufficient to cause the donor to emit energy. 
3. The probe set of claim 1, wherein the acceptor probe 
comprises at least two reporters. 
4. The probe set of claim 1, wherein the polymers 
specifically hybridize to the target polynucleotide under 
40 
stringent conditions. 
5. The probe set of claim 1, wherein the polymers 
specifically hybridize to the target polynucleotide in vivo. 
6. The probe set of claim 1, wherein the polymers further 
comprise a protein transduction domain, a targeting signal, 
45 
a fragment thereof or a combination thereof. 
7. The probe set of claim 1, wherein at least one polymer 
comprises a plurality of natural or non-natural nucleotides. 
8. The probe set of claim 1, wherein at least one polymer 
comprises at least one peptide nucleic acid. 
50 9. The probe set of claim 1, wherein at least one polymer 
comprises a plurality of quantum dots. 
10. The probe set of claim 1, wherein at least one linkage 
between subunits of at least one of the polymers is modified 
to resist enzymatic cleavage. 
55 11. The probe set of claim 1, wherein at least one of the 
polymers further comprises at least one quencher. 
12. The probe set of claim 1, wherein the acceptor 
polymer comprises a quencher that quenches the reporter in 
the absence of the target polynucleotide. 
60 13. The probe set of claim 1, wherein the quantum dot 
comprises ZnS, CdS, ZnSe, CdSe, CdTe, CdSexTe1 _x, InAs, 
InP, PbTe, PbSe, PbS, HgS, HgSe, HgTe, CdHgTe, GaAs, or 
combinations thereof. 
17. The probe set of claim 1, wherein the acceptor 
comprises Cy-3, ROX, Texas Red, Red Phycoerythrin 
(RPE), Blue Phycoerythrin (BPE), or Allophycocyanin 
(APC), or a fragment thereof. 
18. The probe set of claim 1, further comprises at least a 
second set of probes specific for a second target polynucle-
otide. 
19. A method for identifying modulators of gene expres-
sion comprising: 
(a) contacting a cell with a test compound; 
(b) contacting the cell of step (a) with the probe set of 
claim 1, wherein each probe is individually, operably 
linked to a protein transduction domain, a targeting 
signal, or a combination thereof; 
(c) irradiating the cell with an exciting amount of radia-
tion; 
( d) detecting electromagnetic emissions from the cell; and 
( e) selecting the test compound that induces a change in 
the electromagnetic emissions of the cell contacted 
with the test compound compared to a control sample. 
20. A method of detecting a target polynucleotide com-
prising: 
(a) delivering at least one probe pair to cell lysates, tissue 
extracts or the interior of a cell, wherein the probe pair 
comprises 
(i) a donor probe comprising a quantum dot and forms 
a stem-loop (or random coil) structure in the absence 
of a target polynucleotide and 
(ii) an acceptor probe comprising at least one reporter 
and forms a stem-loop (or random coil) structure in 
the absence of the target polynucleotide; and 
(b) exposing the quantum dot to an exciting amount of 
energy, wherein energy transfer occurs between the 
quantum dot and the reporter to produce a detectable 
signal when the donor probe and the acceptor probe 
hybridize to the target polynucleotide. 
* * * * * 
